

200 Documents

Publication numbers	Title	Current assignees
WO9926556 A1	Biodegradable intra vaginal devices	INTERAG
WO9740776 A1	Synchronising of animal oestrus and intra vaginal devices useful therein	INTERAG
CA2808276 A1	Intravaginal devices, methods of making, and uses thereof	TEVA WOMENS HEALTH
CA2842550 A1	Intravaginal rings for drug delivery	UNIVERSITY OF UTAH RESEARCH FOUNDATION
CA3016642 A1	Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof	FERRING
WO9963967 A1	Enhanced intra vaginal devices	INTERAG
DE102014004388 A1	Method and system for intravaginal administration of progesterone	KAYSER ANGELA
WO201019226 A1	Intravaginal devices with a rigid support, methods of making, and uses thereof	TEVA WOMENS HEALTH
IE8101229 L	Methods of making intra-vaginal devices and/or intra-vaginal devices	AHI OPERATIONS
WO2017106618 A1	Formulations and methods for controlling the reproductive cycle and ovulation	PROINVET INNOVATIONS
CA2930533 A1	Glycol chitin based thermosensitive hydrogel for vaginal delivery of progesterone	UNIVERSITY OF UTAH RESEARCH FOUNDATION, ...
CA2817713 A1	Intravaginal devices for controlled delivery of lubricants	UNIVERSITY OF UTAH RESEARCH FOUNDATION
WO200994573 A2	Linear order release polymer	UNIVERSITY OF UTAH RESEARCH FOUNDATION
WO9850016 A2	Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors	GALEN, ...
WO201555789 A1	INTRAVAGINAL USE OF 18-METHYL-15 β ,16 β -METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15 β ,16 β -METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION	BAYER PHARMA, ...
WO2011116108 A1	Intra-vaginal device for fecal incontinence	PELVALON
US20170281325 A1	Intra-Vaginal Devices And Methods For Treating Fecal Incontinence	PELVALON
US20140004171 A1	Treatment of endometriosis by intravaginal administration of a low dose of a selective progesterone receptor modulator (SPRM), anti-progestin, or anti-progestational agent	ARSTAT
WO2014127270 A1	Intra-vaginal devices and methods for treating fecal	PELVALON

Publication numbers	Title	Current assignees
	incontinence	
WO200665873 A2	Multicomponent bioactive intravaginal ring	POLY MEDICAL
US5869081 A	Progesterone vaginal ring for treatment of infertility	POPULATION COUNCIL
US5188835 A	Intravaginal devices	KABI PHARMACIA
SE8602666 D0	Intravaginal device and method of preparing the same	KABI PHARMACIA
CA2844292 A1	Devices and methods for intravaginal delivery of drugs and other substances	UNIVERSITY OF UTAH RESEARCH FOUNDATION
WO2012156561 A1	Controlled-release injectable microparticle	IPCVA INSTITUTO DE PROMOCION DE LA CARNE VACUNA ARGENTINA, ...
US20080009662 A1	Resilient device	FIRST QUALITY HYGIENIC
WO2005112862 A1	Methods of packaging intravaginal device	JOHNSON & JOHNSON CONSUMER
US20050277904 A1	Tampon with flexible panels	MCNEIL
WO200808794 A2	Resilient device	FIRST QUALITY HYGIENIC
WO2011163358 A2	Intravaginal devices comprising anticholinergic agents, and methods of making thereof	TEVA WOMENS HEALTH
US20050256484 A1	Method of using an intravaginal device with fluid transport plates	JOHNSON & JOHNSON CONSUMER
WO200256793 A2	Intravaginal device for feminine hygiene	MCNEIL
WO200209631 A1	Vaginal delivery of bisphosphonates	FEMINA PHARMA
WO9856323 A1	Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections	FERRING
US20160235583 A1	Intravaginal device withdrawal assembly	PROCTER & GAMBLE
CA2849734 A1	Intra-vaginal devices and methods for treating fecal incontinence	PELVALON
WO200317974 A1	Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method	PANTARHEI BIOSCIENCE
WO200262415 A1	Geometry retainable devices for body cavities	INTERAG
US20140100417 A1	Intravaginal device withdrawal assembly	PROCTER & GAMBLE
US20120136199 A1	Cushioned resilient intravaginal urinary incontinence device	FIRST QUALITY HYGIENIC
CA2873222 A1	Cervical pessary containing progesterone for prolonged, sustained and continuous release, used to prevent premature birth	LABORATORIOS ANDROMACO
US20110236462 A1	Intravaginal drug delivery device	EVESTRA
CA2270460 A1	Intravaginal set	ADAMED SP Z O O
IL-110972 A	Novel method of progesterone delivery and effect thereof	WATSON LABORATORIES
WO200858145 A2	Therapeutic intra-vaginal device	FEEMSTER STACY LEE, ...
WO200610097 A2	Sustained release compositions containing progesterone	POPULATION COUNCIL, ...

Publication numbers	Title	Current assignees
	receptor modulators	
US20050256486 A1	Fluid management device with fluid transport element for use within a body	JOHNSON & JOHNSON CONSUMER
WO201149948 A2	Progestins for preventing or reducing neurodegeneration or ischemic damage	POPULATION COUNCIL
WO9965497 A1	Vaginal active agent delivery procedures and formulations thereof	INTERAG
BR200600473 A1	Polymeric implant and a process for obtaining a polymeric implant	PHB INDUSTRIAL
WO200355524 A1	Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method	PANTARHEI BIOSCIENCE
WO201713623 A1	Use of intravaginal device to increase weight gain and improve carcass quality in bovine females	BIOGÉNESIS BAGÓ ARGENTINA, ...
US20040265355 A1	Partially absorbable fiber-reinforced composites for controlled drug delivery	POLY MEDICAL
US20120109094 A1	Intravaginal device with fluid transport plates and methods of making	JOHNSON & JOHNSON CONSUMER
WO2012121767 A1	Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent	ARSTAT
US5084277 A	Vaginal progesterone tablet	MORGAN LEE
WO8601998 A1	Intravaginal device.	ROBERT E WILLS
WO200496151 A2	Methods and devices for the sustained release of multiple drugs	MIT - MASSACHUSETTS INSTITUTE OF TECHNOLOGY, ...
WO9833452 A1	Active delivery device and related procedures	INTERAG
WO2012121778 A1	Treatment of endometriosis by intravaginal administration of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent	ARSTAT
CA2986039 A1	Contraceptive compositions and methods for improved efficacy and modulation of side effects	AGILE THERAPEUTICS
US20040043071 A1	Intravaginal mucosal or transmucosal delivery of antimigraine and antinausea drugs	UMD
WO200276426 A2	Intravaginal drug delivery devices for the administration of an antimicrobial agent	PROCTER & GAMBLE PHARMACEUTICALS, ...
US20020143303 A1	Removal string attachment for intravaginal devices	MCNEIL
US20140005157 A1	Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational	ARSTAT
WO200491570 A1	Method of treatment	INTERAG

Publication numbers	Title	Current assignees
EP-887074 A2	Intravaginal drug delivery device	AVENTIS PHARMA
FR2754179 A1	Method of contraception based on a progestative and oestrogen	THERAMEX
WO201249676 A2	An intravaginal support apparatus	CONTIPI MEDICAL
FI200806093 A0	Intravaginal delivery system and process for manufacturing it	BAYER
CA2991017 A1	A drug delivery device	RATHBONE MICHAEL
CA2963034 A1	Platinum-catalyzed silicone drug delivery devices and methods of use thereof	INT PARTNERSHIP FOR MICROBICIDES
US20050256485 A1	Method of using intravaginal device with fluid transport plates	JOHNSON & JOHNSON CONSUMER
WO200365924 A1	Control of a biological function	ADVANCED ANIMAL TECHNOLOGY
MX2009003440 A	Adjustable applicator for urinary incontinence devices	FIRST QUALITY HYGIENIC
WO2007109247 A2	Flexible, compressed intravaginal rings, methods of making and using the same, and apparatus for making the same	TEVA WOMENS HEALTH
DE2657846 A1	Ring shaped vaginal dispensers - contg. contraceptives etc. in containers on dispenser	PROCTER & GAMBLE
WO201329194 A1	Use of non-steroidal anti-inflammatory drugs meloxicam and piroxicam, administered intravaginally, for interruption of a woman's ovulation process	UNIVERSIDAD DE SANTIAGO DE CHILE
US20100130953 A1	Tampon overwrap	JOHNSON & JOHNSON, ...
US4066075 A	U-shape intravaginal device	PROCTER & GAMBLE
US20100330138 A1	Biostable, multipurpose, microbicidal intravaginal devices	POLY MEDICAL
WO2011120925 A1	Parenteral pharmaceutical form which releases aromatase inhibitor and gestagens, for the treatment of endometriosis	BAYER INTELLECTUAL PROPERTY
WO200889488 A2	Biodegradable intravaginal devices for delivery of therapeutics	UNIVERSITY OF UTAH RESEARCH FOUNDATION, ...
EP1535618 A1	Pharmaceutical preparation for continuous hormonal treatment over a period of 21-28 days comprising two ethinylestradio or estradio and drospirenone compositions	BAYER SCHERING PHARMA
WO9321927 A1	Minimizing progestin associated breakthrough bleeding	MEDICAL COLLEGE OF HAMPTON ROADS
US20190091141 A1	Geometrically complex intravaginal rings, systems and methods of making the same	UNIVERSITY OF NORTH CAROLINA
WO201774886 A1	Vaginal ring with visual indication of use	RTI INTERNATIONAL
CA2948287 A1	Formulations and methods for vaginal delivery of antiprogestins	REPROS THERAPEUTICS
WO2011121591 A2	Medical device for treatment of urinary incontinence in females	GYNAMICS WOMENS HEALTH

Publication numbers	Title	Current assignees
WO200605069 A1	Intravaginal device with controlled expansion	MCNEIL
WO9843562 A1	Intravaginal drug delivery system and discharge collection device	ULTRAFEM
US20090137478 A1	Hormone normalization therapy comprising administration of aromatase inhibitor, follicle stimulating hormone, luteinizing hormone, human chorionic gonadotropin, gonadotropin hormone releasing hormone and/or progesterone	BERNSTEIN LORI R, ...
WO2006125159 A2	Intravaginal device with improved rim designs and methods of making same	REPROTECT, ...
WO200377924 A1	Continuous sulfatase inhibiting progestogen hormone replacement therapy	JANSSEN PHARMACEUTICA
US20170014217 A1	Intravaginal incontinence device	PATRUSKY KAREN L
CN105581976 A	Intravaginal drug delivery devices for the delivery of macromolecules and watersoluble drugs	WARNER CHILCOTT
US20130129818 A1	Progesterone formulations	THERAPEUTICSMD
MX2009003437 A	Compact intravaginal device applicator	MCNEIL
WO9940966 A1	Drug delivery system	TELESTA THERAPEUTICS
US4983393 A	Intra-vaginal device and method for sustained drug release	CONTRACT FURNITURE DESIGN, ...
IT7926288 D0	MICROPARTICLES CONTAINING MEDICINAL OR THERAPEUTIC AGENTS AND THEIR USE AS CONTRACEPTIVE	STOLLE RESEARCH & DEVELOPMENT
WO201902486 A1	Intravaginally applicable devices comprising antiviral compounds	AICURIS
WO2014169395 A1	Aromatase inhibitor-releasing intravaginal device	UNIVERSITY OF SASKATCHEWAN
WO2011119194 A1	Novel 19-nor-steroids and their use for treating progesterone-dependent conditions	REPROS THERAPEUTICS
WO201085363 A1	Estrus synchronization preparations and effective cidr-less protocols	HAL WITT, ...
MX2009003438 A	Applicator for intravaginal devices	FIRST QUALITY HYGIENIC
DE10162529 A1	Insertion system for tampons and other intravaginal devices comprises applicator acting with intravaginal device	JOHNSON & JOHNSON
IL-208365 A	Applicator for self-expanding intravaginal urinary incontinence devices	FIRST QUALITY HYGIENIC
WO2007143607 A2	Method of treating atrophic vaginitis	PEAR TREE WOMEN S HEALTH CARE
WO200172293 A2	Antiprogestins with partial agonist activity	US DEPARTMENT OF HEALTH & HUMAN SERVICES

Publication numbers	Title	Current assignees
CA3018148 A1	Geometrically complex intravaginal rings, systems and methods of making the same	UNIVERSITY OF NORTH CAROLINA
GB201616851 D0	Methods and compositions for managing reproduction	OSTARA BIOMEDICAL
GB200120147 D0	Intravaginal administration of an aromatase inhibitor for the treatment of oestrogen-dependent proliferative disorders	ARES TRADING
WO200130357 A1	Hormonal composition based on nomegestrol acetate and an oestrogen and use thereof	THERAMEX
EP1287817 A1	Method of treating uterine leiomyomas and intravaginal drug delivery vehicle for use in such method	PANTARHEI BIOSCIENCE
US6264638 B1	Intravaginal drug delivery system and discharge collection device	BRICKHAVEN II, ...
US20140030313 A1	Treatment of menstrual pain and excessive menstrual blood loss by intravaginal administration of a low dose of antifibrinolytic or hemostatic agent in combination with non-steroidal anti-inflammatory drug	ARSTAT
WO9819681 A1	Use of progesterone for treating or reducing ischemia in menopausal women receiving estrogen	COLUMBIA LAB BERMUDA
US4402695 A	Device for delivering agent in vagina	ALZA
WO9842281 A1	An intra-vaginal device	NIQUOOLA
WO2017161136 A1	Acid salts for vaginal drug delivery	OAK CREST INSTITUTE OF SCIENCE PASADENA
WO2011163356 A2	Methods of treating conditions associated with overactive bladder	TEVA WOMENS HEALTH
CN103784259 A	Tampon overwrap	MCNEIL, ...
US20130165308 A1	Methods of packaging intravaginal devices	JOHNSON & JOHNSON CONSUMER
CA2849335 A1	Methods and systems for identifying and treating anti-progestin sensitive tumors	INVIVIS PHARMACEUTICALS
GB200508010 D0	Intra-vaginal catamenial device with outlet	KEA FLEX MOULDINGS
WO200074684 A1	Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use	MASSACHUSETTS GENERAL HOSPITAL
WO9804220 A1	Intravaginal rings with insertable drug-containing core	POPULATION COUNCIL
WO201984469 A1	Devices, systems, and methods for training pelvic floor muscles	RENOVIA
CA2951532 A1	Intravaginal formulations comprising gnrh	ZOETIS SERVICES
WO2010119029 A1	Method for on-demand contraception	LABORATOIRE HRA PHARMA, ...
EP1541168 A1	Method of synchronising ovulation in cattle	INTERVET INTERNATIONAL
WO200377925 A1	Sulfatase inhibiting continuous progestogen contraceptive regimens	JANSEN PHARMACEUTICA

Publication numbers	Title	Current assignees
IL-116433 A	Intravaginal drug delivery devices for the administration of 17beta-oestradiol precursors	GALEN, ...
US5069906 A	Intra-vaginal device and method	CONTRACT FURNITURE DESIGN, ...
WO2018128956 A1	Contraceptive use of triterpenoids	UNIVERSITY OF CALIFORNIA
CA2944436 A1	Contraceptive and related device	POLY MEDICAL
UY--34554 A	Vaginal ring including meloxicam and an agent for modulating the release of the active principle, which can be used as a continuous-use contraceptive in women	LABORATORIOS ANDROMACO
WO2009128692 A1	Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications	POSI VISIONARY SOLUTIONS
WO2005112856 A1	Intravaginal device with fluid transport plates	JOHNSON & JOHNSON CONSUMER
WO200520880 A2	Methods for the Treatment of Endometriosis	MISCON TRADING
NO8804230 D0	Contraceptive packages containing oestrogen and progestin	JENCAP RESEARCH
WO2012138542 A1	Treatment of menstrual pain and excessive menstrual blood loss by intravaginal administration of a low dose of antifibrinolytic or hemostatic agent in combination with non-steroidal anti-inflammatory drug	ARSTAT
WO200377923 A1	Progesterone oral drug delivery system	WATSON PHARMACEUTICALS
GB200108801 D0	Menstrual fluid collection device	UNIVERSITY OF SALFORD
BE-726454 A	Medicated devices and methods	UPJOHN
US20150136143 A1	Combination therapy intravaginal rings	INTERNATIONAL PARTNERSHIP FOR MICROBICIDES
US20100304426 A1	Analytical methods for measuring synthetic progesterone	TOLMAR
JP2011026206 A	Method for synchronizing estrus of bovine and kit therefor	NATIONAL AGRICULTURE & FOOD RESEARCH ORGANIZATION
WO200504837 A1	Intravaginal drug delivery devices	PROCTER & GAMBLE PHARMACEUTICALS, ...
US4961931 A	Method for the management of hyperplasia	ALZA
US4250611 A	Process for making drug delivery device with reservoir	ALZA
CA2005714 A1	Transdermal estrogen/progestin dosage unit and system.	RUTGERS UNIVERSITY
BE-813298 A	Intravaginal device.	DICKINSON BEN
WO201197571 A2	Methods for the use of progestogen as a glucocorticoid sensitizer	PRAIRIE PHARMACEUTICALS

Publication numbers	Title	Current assignees
WO200903125 A1	Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs	ALLERGAN PHARMACEUTICALS INTERNATIONAL
CA2849228 A1	Slow release estradiol-progesterone formulation	SKENDI FINANCE
DE4335876 A1	Combination of progesterone antagonists and anti-oestrogens with partial agonistic action for use in hormone-replacement therapy for peri- and post-menopausal women	BAYER SCHERING PHARMA
EP-556908 A1	Intrauterine and/or intravaginal device	TECHNOLOGY DEVELOPMENT
WO2018202574 A1	Intravaginal drug delivery system, method for manufacturing such system and its use in gynecological therapies and contraception	BAYER
WO200317971 A1	Drug delivery system	BAYER
US20150157561 A1	Drug delivery system.	MERCK SHARP & DOHME
WO9810771 A1	Prevention of ovarian cancer by administration of progestin products	NEW LIFE PHARMACEUTICALS
DE2657845 A1	Dispenser for retention in vaginal cavity - to release medicaments, contraceptives etc. over prolonged time	PROCTER & GAMBLE
WO9711680 A2	Hormone dispenser for hormone replacement therapy method	BAYER SCHERING PHARMA
WO200937539 A2	Treatment of oestrogen dependant conditions in pre-menopausal women	PREGLEM
WO200137770 A1	Transdermal hormone delivery system: compositions and methods	AGILE THERAPEUTICS
FI9302789 A0	Intravaginal delivery system	LEIRAS
WO8602826 A1	Intravaginal device, particularly for contraception	KNOGLER WOLFGANG, ...
EP2308465 A2	Transmucosal drug delivery device and method including chemical permeation enhancers	PALO ALTO RESEARCH CENTER
EP2062568 A1	Vaginal delivery system	BAYER
WO200785020 A2	Method of treating atrophic vaginitis	PEAR TREE PHARMACEUTICALS
FR2824257 A1	Intravaginal device for prevention of femal urinary incontinence	GUERQUIN BERNARD, ...
WO9942110 A1	Regulation of estrus and ovulation in gilts	THORN BIOSCIENCE
WO9400168 A1	Vaginal discharge collection and drug delivery device	ULTRAFEM
WO9418982 A1	Use of a progesterone receptor antagonist for preventing or inhibiting fertilization	EASTERN VIRGINIA MEDICAL SCHOOL
US4215691 A	Vaginal drug delivery system made from polymer	ALZA
CL0375200800 A1	Progesterone for the prevention of preterm birth	COVENTRY ACQUISITION, ...

Publication numbers	Title	Current assignees
US20050256511 A1	Intravaginal device with fluid transport plates	JOHNSON & JOHNSON CONSUMER
WO200126603 A2	Mesoproggestins (progesterone receptor modulators) as a component of female contraceptives	SCHERING
WO200147490 A1	Devices for the delivery of drugs having antiprogestinic properties	BAYER SCHERING PHARMA
CA2951284 A1	Transdermal cream	THERAPEUTICSMD
US20070238645 A1	Regulators of the non-genomic action of progesterone and methods of use	UNIVERSITY OF CONNECTICUT
US20040220152 A1	Methods of hormornal treatment utilizing extended cycle contraceptive regimens	TEVA WOMENS HEALTH
WO200320210 A2	Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy	FEMINA PHARMA
DE19915073 A1	Monitoring the fertility and pregnancy of cows in a herd including a bull comprises performing an enzyme-linked immunosorbent assay for progesterone in milk, urine or blood 60-100 days after calving	BIOLAB
NO9104900 D0	Low estrogen oral contraceptives	ORGANON
US4927816 A	Formulae and methods for sublingual ingestion of natural progesterone	ESTER GEORGE C
BE-879442 A	Active/passive immunization of the internal female reproductive organs	ALKERMES CONTROLLED THERAPEUTICS
US20130337054 A1	Treatment of excessive menstrual blood loss by intravaginal administration of low doses of antifibrinolytic or hemostatic agent	ARSTAT
US20120097171 A1	Inhibitor of pathogens	MAURICE ROGER POPE, ...
US20120093911 A1	Platinum-catalyzed intravaginal rings	INTERNATIONAL PARTNERSHIP FOR MICROBICIDES
WO200642021 A2	Methods of hormonal treatment utilizing ascending-dose extended cycle regimens	TEVA WOMENS HEALTH
NO9802815 D0	Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy	BARR LABORATORIES, ...
WO9511973 A1	Methods for screening for regulators of intracellular receptor transcription using progesterone receptor a subtype	LIGAND PHARMACEUTICALS
IL-105684 A	Contraception method using competitive progesterone antagonists and novel compounds useful therein	BAYER SCHERING PHARMA
US4900734 A	Novel pharmaceutical composition containing estradiol and progesterone for oral administration	DELK JOE H, ...
WO201390871 A1	Vaginal drug delivery devices and manufacturing methods	VIMAC VENTURES
US20130116222 A1	Dermal delivery compositions and methods	AGILE THERAPEUTICS


Publication numbers	Title	Current assignees
WO201174931 A2	Parenteral pharmaceutical formulation in suspension, having sustained release, in low and ultralow dosage, in hormonal therapy in the climacteric syndrome	TECHSPHERE

Family 1/200 - FAMPAT - ©Questel

Title

(EP1039843)

Biodegradable intra vaginal devices

Images**Publication data including kind & date**

WO9926556	A1	1999-06-03	WO9926556
CA2311311	A1	1999-06-03	CA2311311
AU1696299	A	1999-06-15	AU9916962
EP1039843	A1	2000-10-04	EP1039843
JP2001523515	A	2001-11-27	JP2001523515
AU758858	B2	2003-04-03	AU-758858
EP1039843	A4	2007-12-26	EP1039843
CA2311311	C	2008-05-06	CA2311311

**Abstract**

(EP1039843)

An intra vaginal device for delivering a pharmaceutical agent (e.g. progesterone) into a recipient mammal. The active agent is carried in a matrix of a biodegradable polymer (such as poly epsilon -caprolactone or a starch-like polysaccharide) having an ability to provide (without reliance on a supporting spine) desired retention characteristics of a variable geometry retention device, an appropriate release profile during a finite insertion period and biodegradability upon removal from the mammal.

Inventors

BUNT CRAIG ROBERT

RATHBONE MICHAEL JOHN

BURGGRAAF SHANE

WOODWARD VAUGHAN GRANT

OGLE COLIN ROGER

Latest standardized assignees - inventors removed

INTERAG

EP0902664	A4	2004-10-13	EP-902664
IN0906/MAS/1997	A	2005-03-04	IN1997CH00906
EP0902664	B1	2008-10-08	EP-902664
IN229259	B	2009-03-20	IN-229259
IN2035/CHE/2007	A	2009-09-11	IN2007CH02035

**Abstract**

(EP-902664)

An intra vaginal device which is of a variable geometry kind and which includes a silicone matrix impregnated with progesterone, the confirmation and content of the progesterone impregnated matrix being such as to optimise effectiveness with a lower initial loading of progesterone.

Inventors

RATHBONE MICHAEL JOHN

BUNT CRAIG ROBERT

BURGGRAAF SHANE

Latest standardized assignees - inventors removed


INTERAG

Family 3/200 - FAMPAT - ©Questel

Title

(EP2605795)

Intravaginal devices, methods of making, and uses thereof

Images**Publication data including kind & date**

CA2808276	A1	2012-02-23	CA2808276
WO2012024461	A2	2012-02-23	WO201224461
MX2013002016	A	2013-03-25	MX2013002016
EP2605795	A2	2013-06-26	EP2605795
US20130269706	A1	2013-10-17	US20130269706
WO2012024461	A3	2014-04-10	WO201224461
US8980304	B2	2015-03-17	US8980304
EP2605795	A4	2015-06-10	EP2605795

**Abstract**

(EP2605795)

The present invention relates to annular intravaginal devices comprising an aperture, methods of making, and uses thereof. The annular devices comprise an aperture extending into the device, the aperture having: (a) an interior diameter, and (b)

an exterior entry diameter, wherein the exterior entry diameter of the aperture is less than the interior diameter of the aperture.

Inventors

TSAO JIAXIANG

Latest standardized assignees - inventors removed

TEVA WOMENS HEALTH


Family 4/200 - FAMPAT - ©Questel

Title


(EP2734262)

Intravaginal rings for drug delivery

Images



Dimensions in mm



Dimensions in mm

Publication data including kind & date

CA2842550	A1	2013-01-24	CA2842550				
WO2013013172	A1	2013-01-24	WO201313172				
AU2012283837	A1	2014-02-27	AU2012283837				
CN103796708	A	2014-05-14	CN103796708				
EP2734262	A1	2014-05-28	EP2734262				
KR20140074281	A	2014-06-17	KR20140074281				
US20140209100	A1	2014-07-31	US20140209100				
JP2014520896	A	2014-08-25	JP2014520896				
BR112014001450	A1	2014-08-26	BR112014001450				
MX2014000765	A	2014-09-25	MX2014000765				
EP2734262	A4	2014-12-31	EP2734262				
IN1283/DELNP/2014	A	2015-01-09	IN2014DN01283				
RU2014106067	A	2015-08-27	RU2014106067				
RU2607179	C2	2017-01-10	RU2607179				
AU2012283837	B2	2017-04-27	AU2012283837				
BR112014001450	A2	2017-07-18	BR112014001450				
JP6170044	B2	2017-07-26	JP6170044				
EP2734262	B1	2018-02-28	EP2734262				
MX357598	B	2018-07-16	MX-357598				

Abstract

(EP2734262)

Intravaginal drug delivery devices, including intravaginal rings, are provided herein. The devices include a reservoir of at least one vaginally administrable drug wherein the reservoir is surrounded at least in part by a hydrophilic elastomer. The devices are capable of exhibiting a substantially zero order release profile of drug over extended periods of time. Also disclosed are methods for making the devices and methods of using the devices to prevent or treat a biological condition.

Inventors

SHELKE NAMDEV

RASTOGI RACHNA

KISER PATRICK F

JOHNSON TODD JOSEPH

CLARK JUSTIN THOMAS

Latest standardized assignees - inventors removed

UNIVERSITY OF UTAH RESEARCH FOUNDATION


Family 5/200 - FAMPAT - ©Questel

Title

(EP2359807)

Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof

Images

FIG. 1**Publication data including kind & date**

CA3016642	A1	2009-08-13	CA3016642
WO2009099586	A2	2009-08-13	WO200999586
US20090202612	A1	2009-08-13	US20090202612
CA2713943	A1	2009-08-13	CA2713943
AU2009210779	A1	2009-08-13	AU2009210779
TW200938204	A	2009-09-16	TW200938204
WO2009099586	A3	2010-01-14	WO200999586
AR070561	A1	2010-04-21	AR--70561
IN3272/KOLNP/2010	A	2010-11-12	IN2010KN03272
EP2249757	A2	2010-11-17	EP2249757
MX2010008545	A	2010-12-20	MX2010008545
KR20100133969	A	2010-12-22	KR20100133969
IL207376	A	2010-12-30	IL-207376
JP2011510984	A	2011-04-07	JP2011510984
EA201070919	A1	2011-04-29	EA201070919
CN102098991	A	2011-06-15	CN102098991
EP2249757	A4	2011-07-20	EP2249757
EP2359807	A1	2011-08-24	EP2359807
NZ587758	A	2012-05-25	NZ-587758
IL207376	B	2012-09-24	IL-207376
IL221988	A	2012-11-29	IL-221988
SG187529	A1	2013-02-28	SG-187529
US8580293	B2	2013-11-12	US8580293
US20140030311	A1	2014-01-30	US20140030311
NZ596844	A	2014-03-28	NZ-596844



JP5507467	B2	2014-03-28	JP5507467				
KR20140048321	A	2014-04-23	KR20140048321				
JP2014167001	A	2014-09-11	JP2014167001				
CN102098991	B	2014-10-22	CN102098991B				
CN104146948	A	2014-11-19	CN104146948				
NZ611268	A	2015-03-27	NZ-611268				
IL221988	B	2015-03-31	IL-221988				
EA201491815	A1	2015-03-31	EA201491815				
AU2009210779	B2	2015-04-02	AU2009210779				
BRPI0905946	A2	2015-06-30	BR200905946				
TW201526898	A	2015-07-16	TW201526898				
EA021615	B1	2015-07-30	EA--21615				
MX337634	B	2016-03-14	MX-337634				
KR20160055980	A	2016-05-18	KR20160055980				
SG10201605171Q	A	2016-08-30	SG10201605171Q				
TW201630610	A	2016-09-01	TW201630610				
TWI549681	B	2016-09-21	TWI549681				
US20160279147	A1	2016-09-29	US20160279147				
ZA201307320	B	2017-03-29	ZA201307320				
KR101730517	B1	2017-04-26	KR101730517				
JP6124411	B2	2017-05-10	JP6124411				
EP2359807	B1	2017-07-26	EP2359807				
EP2249757	B1	2017-08-09	EP2249757				
TWI599359	B	2017-09-21	TWI599359				
LT2249757	T	2017-09-25	LT2249757				
ZA201307321	B	2017-09-27	ZA201307321				
DK2359807	T3	2017-10-16	DK2359807T				
DK2249757	T3	2017-10-16	DK2249757T				
HRP20171319	T1	2017-10-20	HRP20171319				
SI2359807	T1	2017-10-30	SI2359807T				
SI2249757	T1	2017-10-30	SI2249757T				
PT2359807	T	2017-11-07	PT2359807T				
PT2249757	T	2017-11-15	PT2249757T				
ES2645630	T3	2017-12-07	ES2645630				
PL2359807	T3	2017-12-29	PL2359807				
PL2249757	T3	2017-12-29	PL2249757				
CN104146948	B	2018-01-02	CN104146948B				
ES2648640	T3	2018-01-04	ES2648640				
HUE035634	T2	2018-05-28	HUE035634				
CA2713943	C	2018-10-23	CA2713943				
EA031017	B1	2018-11-30	EA--31017				
TWI655947	B	2019-04-11	TWI655947				

Abstract

(EP2359807)

The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise a polysiloxane elastomer and a pharmaceutically acceptable oil.

Inventors

AHMED SALAH U

TSAO JIAXIANG

MAHASHABDE ANU

HARRISON DIANE D

Latest standardized assignees - inventors removed


FERRING

Family 6/200 - FAMPAT - ©Questel


Title

(EP1085855)

Enhanced intra vaginal devices

Images**Publication data including kind & date**

WO9963967	A1	1999-12-16	WO9963967
CA2334296	A1	1999-12-16	CA2334296
AU4534599	A	1999-12-30	AU9945345
NZ330596	A	2001-02-23	NZ-330596
EP1085855	A1	2001-03-28	EP1085855
US20010029357	A1	2001-10-11	US20010029357
JP2002517429	A	2002-06-18	JP2002517429
US6776164	B2	2004-08-17	US6776164
AU777673	B2	2004-10-28	AU-777673
EP1085855	A4	2007-12-26	EP1085855

**Abstract**

(EP1085855)

Intra vaginal devices having an improved in vivo performance insofar as release characteristics are concerned. The devices rely on a polymer matrix impregnated not only with the active ingredient (e.g.: progesterone) to be released but also a suitable cyclodextrin. Suitable polymers include poly (epsilon -caprolactone) and starch-like polysaccharides.

Inventors

BUNT CRAIG ROBERT

RATHBONE MICHAEL JOHN

BURGGRAAF SHANE

OGLE COLIN ROGER

Latest standardized assignees - inventors removed

INTERAG

Family 7/200 - FAMPAT - ©Questel

Title

(EP2932961)

Method and system for intravaginal administration of progesterone

Publication data including kind & date[DE102014004388](#) A1 2015-10-01 DE102014004388[EP2932961](#) A1 2015-10-21 EP2932961**Abstract**

(EP2932961)

A method for intra-vaginal administration of progesterone comprises the steps of providing progesterone and vaginal insertion of progesterone, the progesterone on a non-absorbable support member is provided, the non-absorbable support member with the progesterone vaginal is introduced and the non-absorbable support member intravaginal for a predetermined time period is employed. A system for intra-vaginal administration of progesterone with a carrier element, the Vagina of a patient can be inserted, wherein the support element with the drug progesterone-doped, is characterized in, that the support element is not absorbable and active progesterone metered via a predetermined time period provides. As a non-absorbable support member a vaginal ring is used

Inventors

KAYSER ANGELA



Family 8/200 - FAMPAT - ©Questel

Title

(EP2320871)


Intravaginal devices with a rigid support, methods of making, and uses thereof

Images



Publication data including kind & date

WO2010019226	A1	2010-02-18	WO201019226
CA2733727	A1	2010-02-18	CA2733727
AU2009282496	A1	2010-02-18	AU2009282496
US20100040671	A1	2010-02-18	US20100040671
AR074528	A1	2011-01-26	AR--74528
EP2320871	A1	2011-05-18	EP2320871
MX2011001605	A	2011-05-19	MX2011001605
EA201170199	A1	2011-08-30	EA201170199
BRPI0912439	A2	2011-09-06	BR200912439
JP2011530379	A	2011-12-22	JP2011530379
EP2320871	A4	2012-09-19	EP2320871
EA021371	B1	2015-06-30	EA--21371
AU2009282496	B2	2015-08-06	AU2009282496
MX338591	B	2016-04-25	MX-338591
BRPI0912439	A1	2018-02-20	BRPI0912439



Abstract

(EP2320871)

The present invention relates to intravaginal devices having a rigid support, methods of making, and uses thereof. The devices comprise (a) a rigid support having a Shore A Hardness of at least about 20 and a tensile strength of at least about 1 MPa, (b) a matrix, and (c) an active agent dispersed in the matrix, wherein the support and the matrix are adjacent and wherein the device is annular.

Inventors

DE3122506

C2 1990-08-16 DE3122506

Abstract

(US4449980)

An intra-vaginal device for supplying minerals, hormones or medicaments to an animal is formed as an injection moulded polymeric body having a skin in which adjacent at least part of the surface thereof at least one active ingredient is incorporated. The body is preferably separately moulded before the skin is applied and the skin is preferably of a two part silicone rubber or a polymer such as ethylene vinyl acetate or a polymer substance and the active ingredient is selected from one or more of progesterone oestrogen testosterone, mineral trace elements such as selenium cobalt copper and boron and anthelmintics.

Inventors

MILLAR THOMAS D

MILLER DAVID M

Latest standardized assignees - inventors removed


AHI OPERATIONS

Family 10/200 - FAMPAT - ©Questel

Title

(EP3389690)

Formulations and methods for controlling the reproductive cycle and ovulation

Images*FIG. 1***Publication data including kind & date**

WO2017106618 A1 2017-06-22 WO2017106618

WO2017105512 A1 2017-06-22 WO2017105512



UY37033	A	2017-07-31	UY--37033				
BR112017018319	A1	2017-09-05	BR112017018319				
AR107067	A1	2018-03-14	AR-107067				
BR112017018319	A2	2018-04-17	BR112017018319				
AU2016369500	A1	2018-06-07	AU2016369500				
CO2018006041	A2	2018-07-10	CO2018006041				
CN108367046	A	2018-08-03	CN108367046				
PE12902018	A1	2018-08-07	PE201801290				
CL2018001635	A1	2018-08-17	CL1635201800				
US20180289614	A1	2018-10-11	US20180289614				
EP3389690	A1	2018-10-24	EP3389690				
MX2018007354	A	2018-11-09	MX2018007354				

Abstract

(EP3389690)

Hormone formulations, dosage units including the hormone formulations, and methods of use relate to a controlled release formulation, which includes hormones, e.g., progesterone. Formulations and methods are for controlling the reproductive cycle and/or ovulation of a female mammal, for example, to promote ovulation in a female mammal or synchronizing the ovulation or heat/estrus of a group of female mammals. In addition, formulations are for increasing the likelihood that a female mammal becomes pregnant, for example, after insemination or embryo transference. In addition, formulations are for reducing the anestrous period in a female mammal.

Inventors

COLMAN JUAN ANDRES

SAMMARTINO DANIEL ROBERTO

Latest standardized assignees - inventors removed

PROINVET INNOVATIONS

Family 11/200 - FAMPAT - ©Questel

Title

(EP3068223)

Glycol chitin based thermosensitive hydrogel for vaginal delivery of progesterone

Images




FIG. 1

Publication data including kind & date

CA2930533	A1	2015-05-21	CA2930533
WO2015073066	A1	2015-05-21	WO201573066
EP3068223	A1	2016-09-21	EP3068223
US20160287710	A1	2016-10-06	US20160287710
EP3068223	A4	2017-06-21	EP3068223

**Abstract**

(EP3068223)

Compositions, methods, and kits for vaginal administration of progesterone are described.

Inventors

JANAT-AMSBURY MARGIT MARIA

HUH KANG MOO


PETERSON CHARLES MATTHEW

Latest standardized assignees - inventors removed

UNIVERSITY OF UTAH RESEARCH FOUNDATION

INDUSTRY & ACAD COOP CHUNGNAM NATIONAL UNIVERSITY

Images



CA2817713	A1	2012-05-18	CA2817713
WO2012065073	A2	2012-05-18	WO201265073
WO2012065073	A3	2012-07-19	WO201265073
AU2011325975	A1	2013-06-06	AU2011325975
IL226298	A	2013-07-31	IL-226298
CN103298519	A	2013-09-11	CN103298519
EP2637730	A2	2013-09-18	EP2637730
JP2013543763	A	2013-12-09	JP2013543763
MX2013005354	A	2014-02-03	MX2013005354
US20140074067	A1	2014-03-13	US20140074067
KR20140091647	A	2014-07-22	KR20140091647
IN4656/DELNP/2013	A	2014-11-28	IN2013DN04656
BR112013011744	A1	2014-12-02	BR112013011744



RU2013126633	A	2014-12-20	RU2013126633				
US9078813	B2	2015-07-14	US9078813				
US20150238415	A1	2015-08-27	US20150238415				
AU2011325975	B2	2015-11-26	AU2011325975				
US9226894	B2	2016-01-05	US9226894				
US20160113866	A1	2016-04-28	US20160113866				
MX339735	B	2016-06-07	MX-339735				
RU2591786	C2	2016-07-20	RU2591786				
EP2637730	A4	2016-07-20	EP2637730				
BR112013011744	A2	2016-08-09	BR112013011744				
CN103298519	B	2016-09-14	CN103298519B				
US9642795	B2	2017-05-09	US9642795				
JP6139408	B2	2017-05-31	JP6139408				
IL226298	B	2017-06-29	IL-226298				
US20170273899	A1	2017-09-28	US20170273899				
US20180104182	A1	2018-04-19	US20180104182				
BR112013011744	A8	2018-07-03	BR112013011744				
CA2817713	C	2018-12-04	CA2817713				
BR112013011744	A8	2018-12-18	BR112013011744				

Abstract

(EP2637730)

The present technology provides intravaginal devices designed to deliver lubricants to the vagina for a sustained period of time. The intravaginal devices include a first segment comprising an outer surface and a lumen containing a lubricant, wherein the first segment is configured to deliver the contents of the lumen to the outer surface, and the first segment comprises a polymer selected from the group consisting of a hydrophilic, semi-permeable elastomer and a hydrophobic elastomer. The lubricant may be an aqueous lubricant. The present technology further provides an intravaginal device including a solid first segment that includes a hydrophilic semi-permeable elastomer, an outer surface and an aqueous lubricant, wherein the first segment is configured to deliver the aqueous lubricant to the outer surface.

Inventors

KISER PATRICK F

MCCABE R TYLER

KISER MARGARET N

ALBRIGHT THEODORE HENRY

Latest standardized assignees - inventors removed

UNIVERSITY OF UTAH RESEARCH FOUNDATION

Family 13/200 - FAMPAT - ©Questel

Title

(EP2244782)

Linear order release polymer

Images

urethane composition and a pharmaceutically effective amount of at least one vaginally administrable drug homogeneously distributed throughout the polyether urethane. The devices are capable of exhibiting a substantially zero order release profile of drug over extended periods of time. Also disclosed are methods for making the devices and methods of using the devices to prevent or treat a biological condition.

Inventors

KISER PATRICK F

GUPTA KAVITA

Latest standardized assignees - inventors removed

UNIVERSITY OF UTAH RESEARCH FOUNDATION


Family 14/200 - FAMPAT - ©Questel

Title

(EP-981327)

Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors

Images



Publication data including kind & date

WO9850016	A2	1998-11-12	WO9850016
CA2288046	A1	1998-11-12	CA2288046
AU7446998	A	1998-11-27	AU9874469
WO9850016	A3	1999-02-04	WO9850016
NO995419	D0	1999-11-05	NO9905419
NO995419	A	2000-01-07	NO9905419
NO995419	L	2000-01-07	NO-995419
EP0981327	A2	2000-03-01	EP-981327
CN1255056	A	2000-05-31	CN1255056
IL132702	A	2001-03-19	IL-132702



JP2001524124	A	2001-11-27	JP2001524124				
AU741482	B2	2001-11-29	AU-741482				
NZ501236	A	2002-02-01	NZ-501236				
US6416780	B1	2002-07-09	US6416780				
EP0981327	B1	2002-11-06	EP-981327				
AT227120	T	2002-11-15	ATE227120				
DE69809222	D1	2002-12-12	DE69809222				
PT981327	E	2003-02-28	PT-981327				
DK981327	T3	2003-03-10	DK-981327T				
ES2187024	T3	2003-05-16	ES2187024				
DE69809222	T2	2003-08-14	DE69809222				
IL132702	B	2004-11-10	IL-132702				
CN1184957	C	2005-01-19	CN1184957C				
CA2288046	C	2006-10-03	CA2288046				

Abstract

(EP-981327)

The invention relates to an intravaginal shell or core drug delivery device suitable for administration to the human or animal female. The device comprises testosterone or a testosterone precursor in a polymer matrix, surrounded by a sheath, and is capable of releasing the testosterone or testosterone precursor in a substantially zero order pattern on a daily basis for at least three weeks. The device is intended to restore circulating testosterone levels to normal physiological range or to induce suprathreshold testosterone levels.

Inventors

PASSMORE CLARE

GILLIGAN CLAIRE

Latest standardized assignees - inventors removed

GALEN

PROCTER & GAMBLE PHARMACEUTICALS

WARNER CHILCOTT PHARMACEUTICALS

ALLERGAN PHARMACEUTICALS INTERNATIONAL


Family 15/200 - FAMPAT - ©Questel

Title

(WO201555789)

INTRAVAGINAL USE OF 18-METHYL-15 β ,16 β -METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15 β ,16 β -METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION

Images

**Publication data including kind & date**

WO2015055789	A1	2015-04-23	WO201555789
UY35789	A	2015-05-29	UY--35789
TW201605457	A	2016-02-16	TW201605457
AR098059	A1	2016-04-27	AR--98059

**Abstract**

(WO201555789)

The present invention relates to intravaginal use of 18-methyl-15 β ,16 β -methylene-19-nor-20-spirox-4-en-3-ones of the general formula (I), to an intravaginal ring comprising 18-methyl-15 β ,16 β -methylene-19-nor-20-spirox-4-en-3-ones of the general formula (I) and its use in contraception.

Inventors

MUHN HANS-PETER
 LINDENTHAL BERNHARD
 FUHRMANN ULRIKE
 HOFMANN BIRTE MARIA
 FELS LÜDER M
 PRELLE KATJA
 NUBBEMEYER REINHARD
 RÖSE LARS
 SCHMEES NORBERT
 JUKARAINEN HARRI
 VALO TUULA
 PIHLAJA JYRKI
 HOLMBERG SVANTE

Latest standardized assignees - inventors removed


BAYER PHARMA
 BAYER

Title

(EP2547284)

Intra-vaginal device for fecal incontinence

Images



Publication data including kind & date

WO2011116108	A1	2011-09-22	WO2011116108
CA2793488	A1	2011-09-22	CA2793488
AU2011227265	A1	2012-10-11	AU2011227265
US20130012764	A1	2013-01-10	US20130012764
EP2547284	A1	2013-01-23	EP2547284
US20130138135	A1	2013-05-30	US20130138135
US20130144112	A1	2013-06-06	US20130144112
US20130150661	A1	2013-06-13	US20130150661
JP2013521947	A	2013-06-13	JP2013521947
US8740767	B2	2014-06-03	US8740767
US8740766	B2	2014-06-03	US8740766
US20140275746	A1	2014-09-18	US20140275746
US9072578	B2	2015-07-07	US9072578
JP5778242	B2	2015-07-17	JP5778242
JP2015165977	A	2015-09-24	JP2015165977
US20160000545	A1	2016-01-07	US20160000545



US9289278	B2	2016-03-22	US9289278				
AU2011227265	B2	2016-03-31	AU2011227265				
JP5960327	B2	2016-07-01	JP5960327				
EP2547284	A4	2017-07-05	EP2547284				
US9707067	B2	2017-07-18	US9707067				
CA2793488	C	2018-06-19	CA2793488				

Abstract

(EP2547284)

An intra-vaginal device for the control of stool passage, including a body mechanism for securing the device around the area of the pubic notch and in the area of the posterior fornix, the body mechanism including a force applying mechanism for reversibly applying a force to a posterior portion of the vagina to occlude the rectum. A method of controlling the passage of stool in a patient, by inserting an intra-vaginal device into the patient's vagina such that an anterior end rests around the pubic notch and a posterior end rests in the posterior fornix, exerting a force towards the posterior side of the vagina, moving an anterior wall of the patient's rectum towards the posterior wall of the rectum with the force applying portion, impeding the passage of stool, and removing the force, allowing stool to pass.

Inventors

HERBOWY STEVEN LAWRENCE

ROSEN MILES HARRIS

BRENNER JACOB SAMUEL

Latest standardized assignees - inventors removed


PELVALON

Family 17/200 - FAMPAT - ©Questel

Title

(US20170281325)

Intra-Vaginal Devices And Methods For Treating Fecal Incontinence

Images

Publication data including kind & date

[US20170281325](#) A1 2017-10-05 US20170281325

**Abstract**

(US20170281325)

Devices and methods for intra-vaginal bowel control.

Inventors

ROSEN MILES HARRIS

HERBOWY STEVEN LAWRENCE

BRENNER JACOB SAMUEL

Latest standardized assignees - inventors removed

PELVALON

Family 18/200 - FAMPAT - ©Questel

Title

(US10251836)

Treatment of endometriosis by intravaginal administration of a low dose of a selective progesterone receptor modulator (SPRM), anti-progestin, or anti-progestational agent

Publication data including kind & date

[US20140004171](#) A1 2014-01-02 US20140004171

[US10251836](#) B2 2019-04-09 US10251836

**Abstract**

(US10251836)

A method and intravaginal drug delivery device for reducing size of endometrial implants in a female in need thereof are provided. The method includes administering intravaginally to the female a therapeutically effective amount of an active agent, wherein the agent is delivered on a delivery device directly to the endometrial implants, wherein said amount is able to significantly reduce the size of endometrial implants, wherein the active agent is any one of selective progesterone receptor modulator (SPRM), an anti-progestin agent, and an anti-progestational agent.

Inventors

RUBIN ARKADY

Latest standardized assignees - inventors removed

ARSTAT


Family 19/200 - FAMPAT - ©Questel

Title

(WO2014127295)

Intra-vaginal devices and methods for treating fecal incontinence

Images



Publication data including kind & date

WO2014127270	A1	2014-08-21	WO2014127270
WO2014127295	A1	2014-08-21	WO2014127295
US20140275744	A1	2014-09-18	US20140275744
US20140275743	A1	2014-09-18	US20140275743
US9974635	B2	2018-05-22	US9974635
US9999490	B2	2018-06-19	US9999490
US20190091002	A1	2019-03-28	US20190091002



Abstract

(WO2014127295)

An intravaginal device for the control of stool passage is provided. The intravaginal device comprising a collapsible stabilizing body including a plurality of segments interconnected by joints and configured to modulate between an open state and collapsed state by movement of the segments about the joints, an occluding portion, and a locking mechanism configured to maintain the collapsible stabilizing body in the open state upon engagement of the locking mechanism and permit the collapsible stabilizing body to collapse upon disengagement of the locking mechanism.

Inventors

ROSEN MILES HARRIS

HERBOWY STEVEN LAWRENCE

GOOR JARED

BROOKS NARVEL MILTON III

Latest standardized assignees - inventors removed

PELVALON

Family 20/200 - FAMPAT - ©Questel

Title

(EP2424505)

Multicomponent bioactive intravaginal ring

Publication data including kind & date

WO2006065873	A2	2006-06-22	WO200665873			
WO2006065873	A3	2006-08-10	WO200665873			
EP1827328	A2	2007-09-05	EP1827328			
US20080069850	A1	2008-03-20	US20080069850			
WO2009048594	A2	2009-04-16	WO200948594			
WO2009048594	A3	2009-07-30	WO200948594			
EP1827328	A4	2009-10-14	EP1827328			
US20100062039	A1	2010-03-11	US20100062039			
EP1827328	B1	2011-08-17	EP1827328			
US8057817	B2	2011-11-15	US8057817			
US8062658	B2	2011-11-22	US8062658			
ES2371554	T3	2012-01-05	ES2371554			
US20120024472	A1	2012-02-02	US20120024472			
EP2424505	A2	2012-03-07	EP2424505			
US8506988	B2	2013-08-13	US8506988			
EP2424505	A4	2013-10-23	EP2424505			
EP2424505	B1	2018-05-09	EP2424505			
DK2424505	T3	2018-07-30	DK2424505T			
HRP20181108	T1	2018-09-07	HRP20181108			
LT2424505	T	2018-09-10	LT2424505			
ES2682111	T3	2018-09-18	ES2682111			
SI2424505	T1	2018-09-28	SI2424505T			
PL2424505	T3	2018-10-31	PL2424505			
HUE038934	T2	2018-12-28	HUE038934			

Abstract

(EP2424505)

Intravaginal ring devices have multicomponent drug releasing substrates loaded with at least one bioactive agent and designed to effect contraception and/or provide means to treat and/or prevent diseases caused by infectious bacteria, fungi, virus, and retroviruses, without compromising the primary function of normally occurring, useful vaginal microflora in female patients.

Inventors

SHALABY SHALABY W

HILAS GEORGIOS T

Latest standardized assignees - inventors removed

POLY MEDICAL

Family 21/200 - FAMPAT - ©Questel


Title

(US5869081)

Progesterone vaginal ring for treatment of infertility

Images

FIG. 1

**Publication data including kind & date**[US5869081](#)

A 1999-02-09 US5869081

**Abstract**

(US5869081)

The present invention relates to a method of administering progesterone to a normogonadal or a functionally agonadal human female undergoing an assisted reproduction technique. The invention further provides a method of hormone replacement for a human female. In a preferred embodiment of the present invention, progesterone is provided by intravaginal administration of a progesterone-containing polysiloxane ring.

Inventors

JACKANICZ THEODORE

CROXATTO AVONI HORACIO B

DREXLER LEOPOLDO GLASSER

ZEGERS-HOCHSCHILD FERNANDO

Latest standardized assignees - inventors removed

POPULATION COUNCIL

Family 22/200 - FAMPAT - ©Questel

Title

(US5188835)

Intravaginal devices

Publication data including kind & date

[US5188835](#) A 1993-02-23 US5188835



Abstract

(US5188835)

The invention concerns an intravaginal device comprising a combination of 17.beta.-estradiol and a supporting matrix for treating hypoestrogenic women. The device releases continuously 17.beta.-estradiol at a rate of about 0.5 to about 25 .mu.g/24 h. The invention also comprises a method of preparing the device and a method of treating hypoestrogenic women by using the device.

Inventors

LINDSKOG INGA M

SJOEGREN BENGT C H

ANDERSSON SVEN-BOERJE

Latest standardized assignees - inventors removed

KABI PHARMACIA

Family 23/200 - FAMPAT - ©Questel

Title

(EP-253109)

Intravaginal device and method of preparing the same

Images

体外IVR的 E_2 释放量(0.9%盐水)。
(3套阴道环的平均值。)

时间， 日	E ₂ 释放量，微克/24 小时	
	A	B
5	24	9
10	23	9
15	23	9
20	22	9
25	21	8
30	21	8
35	20	8
40	20	8
45	20	8
50	20	8
60	19	7
70	18	7
80	18	7
90	17	7
100	16	7
110	15	7
120	14	7
140	14	7

D0 1987-06-15 DK8703034



PT85082	A	1987-07-01	PT--85082				
ZA8704174	B	1987-12-11	ZA8704174				
IE871377	L	1987-12-16	IE8701377				
NO872489	L	1987-12-17	NO-872489				
DK303487	A	1987-12-17	DK8703034				
AU7422287	A	1987-12-17	AU8774222				
FI872629	A	1987-12-17	FI8702629				
IL82769	A	1987-12-20	IL--82769				
JPS62298532	A	1987-12-25	JP62298532				
CN87104229	A	1987-12-30	CN87104229				
EP0253109	A1	1988-01-20	EP-253109				
KR19880000114	A	1988-03-23	KR19880000114				
HUT44931	A	1988-05-30	HU-T44931				
US4871543	A	1989-10-03	US4871543				
PT85082	B	1990-03-08	PT--85082				
AU599988	B2	1990-08-02	AU-599988				
NZ220616	A	1990-09-26	NZ-220616				
IL82769	B	1991-07-18	IL--82769				
EP0253109	B1	1991-10-09	EP-253109				
AT68097	T	1991-10-15	ATE068097				
DE3773557	D1	1991-11-14	DE3773557				
HU205014	B	1992-03-30	HU-205014				
ES2026481	T3	1992-05-01	ES2026481				
KR920005824	B1	1992-07-20	KR920005824				
PH26981	A	1992-12-28	PH--26981				
GR3003551	T3	1993-03-16	GR3003551				
CA1314482	C	1993-03-16	CA1314482				
NO172784	B	1993-06-01	NO-172784				
NO172784	C	1993-09-08	NO-172784				
FI91709	B	1994-04-29	FI--91709				
FI91709	C	1994-08-10	FI--91709				
IE60654	B1	1994-08-10	IE--60654				
CN1034391	C	1997-04-02	CN1034391C				
JP2671953	B2	1997-11-05	JP2671953				
DK175529	B1	2004-11-22	DK-175529				

Abstract

(EP-253109)

The invention concerns an intravaginal device comprising a combination of 17 beta -estradiol and a supporting matrix for treating hypoestrogenic women. The device releases continuously 17 beta -estradiol at a rate of about 0.5 to about 25 mu g/24 h. The invention also comprises a method of preparing the device and a method of treating hypoestrogenic women by using the device.

Inventors

LINDSKOG, INGA MARIANNE

SJOEGREN, BENGT CHRISTER HANS

ANDERSSON, SVEN-BOERJE

Latest standardized assignees - inventors removed

KABI PHARMACIA

Inventors

KISER PATRICK F

O'MEL VLAD G

PRATHER LELAND J

DAMIAN FESTO

Latest standardized assignees - inventors removed

UNIVERSITY OF UTAH RESEARCH FOUNDATION

Family 25/200 - FAMPAT - ©Questel

Title

(WO2012156561)

Controlled-release injectable microparticle

Publication data including kind & date

WO2012156561	A1	2012-11-22	WO2012156561			
AR082266	A1	2012-11-28	AR--82266			
UY34071	A	2013-01-03	UY--34071			
AU2012258122	A1	2014-01-09	AU2012258122			
BR112013029316	A1	2014-05-13	BR112013029316			
US20140335193	A1	2014-11-13	US20140335193			
BR112013029316	A2	2017-04-18	BR112013029316			
AU2012258122	B2	2017-07-06	AU2012258122			

Abstract

(WO2012156561)

The invention relates to a controlled-release injectable microparticle comprising a polyvinyl alcohol polymer and one or more hormones, in particular progesterone. Said microparticle induces estrus in female mammals after a single application. The invention also relates to a method for obtaining the microparticle.

Inventors

RINTOUL IGNACIO

BADANO JUAN MANUEL

GRAU RICARDO

Latest standardized assignees - inventors removed

IPCVA INSTITUTO DE PROMOCION DE LA CARNE VACUNA ARGENTINA

UNL UNIVERSIDAD NACIONAL DEL LITORAL

CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS & TECNICAS CONICET


Family 26/200 - FAMPAT - ©Questel

Title

(US9050183)

Resilient device

Images



Publication data including kind & date

US20080009662	A1	2008-01-10	US20080009662
US20100218359	A1	2010-09-02	US20100218359
US20130165742	A1	2013-06-27	US20130165742
US8608639	B2	2013-12-17	US8608639
US8613698	B2	2013-12-24	US8613698
US9050183	B2	2015-06-09	US9050183



Abstract

(US9050183)

An intravaginal device has a working portion (e.g., intravaginal urinary incontinence device suppository, tampon) and an anchoring portion comprising at least one member extending beyond at least one end of the working portion to maintain the working portion in place during use.

Inventors

BARTNING MICHELLE
 GIRONDA KEVIN F
 HOU MARI
 LUCHINO THOMAS P
 LUEHRS KIRSTEN FREISLINGER
 MAVINKURVE PRAMOD
 ROSENFELD LEONARD
 HULL JR RAYMOND J
 CHASE DAVID J

Latest standardized assignees - inventors removed


FIRST QUALITY HYGIENIC

Family 27/200 - FAMPAT - ©Questel


Title

(EP2347742)

Methods of packaging intravaginal device

Images**Publication data including kind & date**

WO2005112862	A1	2005-12-01	WO2005112862
CA2566692	A1	2005-12-01	CA2566692
AU2005245015	A1	2005-12-01	AU2005245015
NO20065645	L	2007-02-09	NO20065645
EP1755516	A1	2007-02-28	EP1755516
IL179266	A	2007-03-08	IL-179266
CN1980621	A	2007-06-13	CN1980621
BRPI0510015	A	2007-09-18	BR200510015
BRPI0510015	A1	2007-09-18	BRPI0510015
JP2007537797	A	2007-12-27	JP2007537797
US20090260205	A1	2009-10-22	US20090260205
CN1980621	B	2010-11-10	CN1980621B
AU2005245015	B2	2011-06-16	AU2005245015
JP4772785	B2	2011-07-01	JP4772785
EP2347742	A1	2011-07-27	EP2347742
EP2347742	B1	2012-06-20	EP2347742
CA2566692	C	2012-08-21	CA2566692
PL2347742	T3	2012-11-30	PL2347742
EP1755516	B1	2014-03-12	EP1755516
US8864640	B2	2014-10-21	US8864640
EP2347742	B2	2015-08-19	EP2347742
BRPI0510015	A8	2016-07-19	BR200510015
BRPI0510015	A8	2017-06-20	BRPI0510015
BRPI0510015	B1	2017-08-29	BRPI0510015

**Abstract**

(EP2347742)

A method of folding a plurality of flexible elements about a central fluid storage element comprising the steps of urging an intravaginal device into a folding device; imparting relative rotation between at least a portion of the folding device and the intravaginal device; and contacting the plurality of flexible extensions with the folding device. Wherein the intravaginal device includes a fluid storage element and a plurality of flexible extensions extending therefrom, and the flexible extensions are folded about the fluid storage element in a uniform direction. Alternatively, in place of relative rotation, the flexible extensions are folded by means of guide rails of the folding device, the guide rails folding the flexible extensions about the fluid storage element. Several apparatus may be employed in this and related methods.

Inventors

BINNER CURT

CARASSO SAMUEL C

CHASE DAVID J

DANYI ERIN

GLASGOW TARA

KIMBALL DAVID L

KOZOROVITSKY JULIA

NG TONY C

Latest standardized assignees - inventors removed


JOHNSON & JOHNSON CONSUMER

Family 28/200 - FAMPAT - ©Questel

Title

(EP1773270)

Tampon with flexible panels

Images**Publication data including kind & date**

US20050277904	A1	2005-12-15	US20050277904
WO2006016933	A1	2006-02-16	WO200616933
CA2566790	A1	2006-02-16	CA2566790



AU2005272194	A1	2006-02-16	AU2005272194				
AR048791	A1	2006-05-24	AR--48791				
NO20065631	L	2007-02-06	NO20065631				
IL179271	A	2007-03-08	IL-179271				
EP1773270	A1	2007-04-18	EP1773270				
CN101018520	A	2007-08-15	CN101018520				
BRPI0510025	A	2007-09-25	BR200510025				
BRPI0510025	A1	2007-09-25	BRPI0510025				
JP2007537022	A	2007-12-20	JP2007537022				
US20080255495	A1	2008-10-16	US20080255495				
AU2005272194	B2	2012-01-19	AU2005272194				
US20130165894	A1	2013-06-27	US20130165894				
US20130165893	A1	2013-06-27	US20130165893				
BRPI0510025	A8	2016-04-19	BR200510025				
BRPI0510025	A8	2017-07-11	BRPI0510025				

Abstract

(EP1773270)

An intravaginal device has a fluid storage element having a longitudinal axis and is in fluid communication with at least one flexible panel.

Inventors

CHASE DAVID J

DANYI ERIN

GLASGOW TARA

Latest standardized assignees - inventors removed

MCNEIL


Family 29/200 - FAMPAT - ©Questel

Title

(EP2043570)

Resilient device

Images



Publication data including kind & date

WO2008008794	A2	2008-01-17	WO2008008794
CA2657138	A1	2008-01-17	CA2657138
AU2007272601	A1	2008-01-17	AU2007272601
US20080033230	A1	2008-02-07	US20080033230
WO2008008794	A3	2008-03-06	WO2008008794
EP2043570	A2	2009-04-08	EP2043570
CN101522140	A	2009-09-02	CN101522140
JP2009543606	A	2009-12-10	JP2009543606
RU2009104309	A	2010-08-20	RU2009104309
RU2432927	C2	2011-11-10	RU2432927
BRPI0714288	A2	2013-03-05	BR200714288
US20130160272	A1	2013-06-27	US20130160272
AU2007272601	B2	2014-01-16	AU2007272601
JP5490533	B2	2014-03-07	JP5490533
US8753258	B2	2014-06-17	US8753258
JP2014121638	A	2014-07-03	JP2014121638



CA2657138	C	2014-08-26	CA2657138				
CN101522140	B	2014-10-22	CN101522140B				
CN104257450	A	2015-01-07	CN104257450				
US9173768	B2	2015-11-03	US9173768				
JP5960177	B2	2016-07-01	JP5960177				
JP2016165616	A	2016-09-15	JP2016165616				
CN104257450	B	2017-05-10	CN104257450B				
BRPI0714288	B1	2018-06-26	BR200714288				
JP6373903	B2	2018-08-15	JP6373903				
EP2043570	B1	2018-10-31	EP2043570				

Abstract

(EP2043570)

An intravaginal device has a working portion (1) (e.g., intravaginal urinary- incontinence device suppository, tampon) and an anchoring portion (4) comprising at least one member extending beyond at least one end of the working portion to maintain the working portion in place during use.

Inventors

BARTNING MICHELLE

GIRONDA KEVIN F

HOU MARI

LUCHINO THOMAS P

FREISLINGER LUEHRS KIRSTEN

MAVINKURVE PRAMOD

ROSENFELD LEONARD

HULL JR RAYMOND J

CHASE DAVID J

Latest standardized assignees - inventors removed

FIRST QUALITY HYGIENIC

Family 30/200 - FAMPAT - ©Questel

Title

(EP2585011)

Intravaginal devices comprising anticholinergic agents, and methods of making thereof

Images

The present invention is directed to an intravaginal device comprising: (a) an annular first matrix comprising a pocket and a pocket wall, wherein the pocket wall has a uniform thickness, and wherein the pocket wall encompasses the pocket; and (b) a second matrix comprising an anticholinergic agent, wherein the second matrix is located in the pocket. The present invention is also directed to a method of making an intravaginal device, the method comprising: (a) placing a first matrix into a mold, the mold, being shaped so as to form an annular intravaginal device comprising a pocket and a pocket wall, wherein the pocket wall has a uniform thickness, and wherein the pocket wall encompasses the pocket; (b) curing the first matrix; (c) placing a second matrix comprising an anticholinergic agent in the pocket; and (d) curing the second matrix.

Inventors

TEVA WOMEN S HEALTH INC

Latest standardized assignees - inventors removed


TEVA WOMENS HEALTH

Family 31/200 - FAMPAT - ©Questel

Title

(EP1755513)

Method of using an intravaginal device with fluid transport plates

Images

Publication data including kind & date

US20050256484	A1	2005-11-17	US20050256484				
WO2005112859	A1	2005-12-01	WO2005112859				
CA2566682	A1	2005-12-01	CA2566682				
AU2005244896	A1	2005-12-01	AU2005244896				
AR048845	A1	2006-05-31	AR--48845				
US20060217677	A1	2006-09-28	US20060217677				
NO20065633	L	2007-02-07	NO20065633				
EP1755513	A1	2007-02-28	EP1755513				
IL179270	A	2007-03-08	IL-179270				
CN1988867	A	2007-06-27	CN1988867				
BRPI0511131	A	2007-11-27	BR200511131				
BRPI0511131	A1	2007-11-27	BRPI0511131				
JP2007537021	A	2007-12-20	JP2007537021				
AU2005244896	B2	2010-09-23	AU2005244896				
US8057453	B2	2011-11-15	US8057453				
US20110301562	A1	2011-12-08	US20110301562				
CA2566682	C	2013-07-09	CA2566682				
US8535285	B2	2013-09-17	US8535285				
BRPI0511131	A8	2016-12-06	BR200511131				
BRPI0511131	A8	2017-09-26	BRPI0511131				

Abstract

(EP1755513)

A method of capturing bodily fluid intravaginally providing an intravaginal device that has a fluid storage element having a longitudinal axis and is in fluid communication with at least one fluid transport element. The method involves providing at least one fluid transport element that is bendable about an axis substantially parallel to the longitudinal axis of the fluid storage element and positioned within a human vagina.

Inventors

CHASE DAVID J

DANYI ERIN

HOU MARI

Latest standardized assignees - inventors removed

JOHNSON & JOHNSON CONSUMER

Family 32/200 - FAMPAT - ©Questel

Title

(EP1381330)

Intravaginal device for feminine hygiene

Images




Fig. 1

Publication data including kind & date

WO02056793	A2	2002-07-25	WO200256793
CA2432795	A1	2002-07-25	CA2432795
US20020120243	A1	2002-08-29	US20020120243
WO02056793	A3	2003-10-30	WO200256793
EP1381330	A2	2004-01-21	EP1381330
CN1551749	A	2004-12-01	CN1551749
RU2003118447	A	2004-12-10	RU2003118447
MXPA03005773	A	2005-01-25	MX2003PA005773
IN0809/KOLNP/2003	A	2005-02-04	IN2003KN00809



Abstract

(EP1381330)

The invention relates to an intravaginal device for feminine hygiene that comprises a core which is completely surrounded by a sheathing that is impermeable to liquid water.


Inventors

KRAEMER ROBERT
BUZOT HERVE
Latest standardized assignees - inventors removed
MCNEIL

Family 33/200 - FAMPAT - ©Questel

Title
(EP1311213)
Vaginal delivery of bisphosphonates

Images



Publication data including kind & date

WO200209631	A1	2002-02-07	WO200209631
CA2416122	A1	2002-02-07	CA2416122
AU7892001	A	2002-02-13	AU200178920
NO20030422	D0	2003-01-27	NO200300422
NO20030422	A	2003-03-11	NO200300422
NO20030422	L	2003-03-11	NO20030422
EP1311213	A1	2003-05-21	EP1311213
US6572874	B1	2003-06-03	US6572874
MXPA03000803	A	2003-06-04	MX2003PA000803
IL154134	A	2003-07-31	IL-154134
CZ2003494	A3	2003-08-13	CZ200300494
CN1461207	A	2003-12-10	CN1461207
HU0303189	A2	2003-12-29	HU200303189
BR0113134	A	2004-06-22	BR200113134
BRPI0113134	A1	2004-06-22	BRPI0113134
JP2004519420	A	2004-07-02	JP2004519420
PL365884	A1	2005-01-10	PL2001365884
CN1201749	C	2005-05-18	CN1201749C
AU2001278920	B2	2006-03-02	AU2001278920



NZ524069	A	2007-02-23	NZ-524069
IL154134	B	2008-11-26	IL-154134
BRPI0113134	A2	2010-06-29	BR200113134

**Abstract**

(EP1311213)

Devices, methods, and compositions for vaginal delivery of bisphosphonates. A targeted site delivery of bisphosphonates to the vagina using a medicated intravaginal device comprising a bisphosphonate composition formulated for transvaginal delivery. A method for treatment of osteoporosis and related bone and skeleton diseases, for prevention of bone breakdown and loss of bone mass and strength by intravaginal administration of bisphosphonates to the vagina and transvaginal delivery of bisphosphonates to the general circulation.

Inventors

HARRISON DONALD C

LIU JAMES H

RITSCHER WOLFGANG

PAULETTI GIOVANNI

Latest standardized assignees - inventors removed

FEMINA PHARMA


Family 34/200 - FAMPAT - ©Questel

Title

(EP1301150)

Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections

Images



Publication data including kind & date

WO9856323	A1	1998-12-17	WO9856323
CA2293346	A1	1998-12-17	CA2293346
AU7697698	A	1998-12-30	AU9876976
EP0988009	A1	2000-03-29	EP-988009
US6086909	A	2000-07-11	US6086909
BR9810089	A	2000-08-08	BR9810089
BRPI9810089	A1	2000-08-08	BRPI9810089
CN1263454	A	2000-08-16	CN1263454
US6197327	B1	2001-03-06	US6197327
IL133431	A	2001-04-30	IL-133431



AU735407	B2	2001-07-05	AU-735407				
WO200203896	A1	2002-01-17	WO200203896				
CA2416050	A1	2002-01-17	CA2416050				
AU8128701	A	2002-01-21	AU200181287				
NZ502120	A	2002-04-26	NZ-502120				
JP2002515069	A	2002-05-21	JP2002515069				
US6416779	B1	2002-07-09	US6416779				
EP1301150	A1	2003-04-16	EP1301150				
BR0112571	A	2003-05-27	BR200112571				
BRPI0112571	A1	2003-05-27	BRPI0112571				
IL153719	A	2003-07-06	IL-153719				
MXPA02012819	A	2003-09-22	MX2002PA012819				
JP2004508296	A	2004-03-18	JP2004508296				
EP1301150	A4	2004-08-11	EP1301150				
CN1592600	A	2005-03-09	CN1592600				
CN1199621	C	2005-05-04	CN1199621C				
NZ524047	A	2005-08-26	NZ-524047				
HK1029914	A1	2006-02-24	HK1029914				
EP0988009	A4	2006-04-19	EP-988009				
AU2001281287	B2	2006-10-19	AU2001281287				
AU2001281287	B8	2006-12-07	AU2001281287				
CN1306919	C	2007-03-28	CN1306919C				
CA2293346	C	2008-10-21	CA2293346				
IL133431	B	2008-12-29	IL-133431				
IL153719	B	2009-12-24	IL-153719				
BRPI0112571	A2	2010-08-24	BR200112571				
BRPI9810089	A2	2013-03-12	BR9810089				

Abstract

(EP1301150)

Devices, methods, and compositions for treating vaginal fungal, bacterial, viral and parasitic infections by intravaginal or transvaginal administration of therapeutic and/or palliative antifungal, antibacterial, antiviral or parasitocidal drugs to the vagina or to the uterus.

Inventors

D AUGUSTINE MERIDA A

LIU JAMES H

HARRISON DONALD C

Latest standardized assignees - inventors removed

FERRING


Family 35/200 - FAMPAT - ©Questel

Title

(US20160235583)

Intravaginal device withdrawal assembly

Images

**Publication data including kind & date**[US20160235583](#)

A1 2016-08-18

US20160235583

**Abstract**

(US20160235583)

An intravaginal device having an aperture and a withdrawal assembly. The withdrawal assembly has a withdrawal member

and an obstruction.

Inventors

DURLING EVAN JOSEPH

STRONG KEVIN CHARLES

AVERY JR ROBERT CLARK

KNUTH HINRICH

JONES DANIEL CHRISTY

Latest standardized assignees - inventors removed

PROCTER & GAMBLE

Family 36/200 - FAMPAT - ©Questel

Title

(EP2757987)

Intra-vaginal devices and methods for treating fecal incontinence

Images

ROSEN MILES HARRIS

HERBOWY STEVEN LAWRENCE

BRENNER JACOB SAMUEL

Latest standardized assignees - inventors removed

PELVALON

Family 37/200 - FAMPAT - ©Questel

Title

(WO200317974)

Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method

Publication data including kind & date[WO03017973](#)

A1 2003-03-06 WO200317973

[WO03017974](#)

A1 2003-03-06 WO200317974

**Abstract**

(WO200317974)

The present invention relates to a method of treating a benign gynaecological disorder in a female mammal, said method comprising intravaginal administration of anti-estrogen to a female mammal suffering from such a disorder in a therapeutically effective dosage to prevent or reduce symptoms of said benign gynaecological disorder. The intravaginal administration of anti-estrogen, in comparison to other routes of administration, achieves the desired clinical levels. The present method is particularly suitable for treating a benign gynaecological disorder selected from the group consisting of uterine leiomyomas, endometriosis, adenomyosis, dysmenorrhea, and functional menorrhagia and metrorrhagia. Another aspect of the invention is concerned with a drug delivery vehicle for intravaginal use, which drug delivery vehicle contains at least 10 µg of an anti-estrogen and a plurality of oral dosage units containing one or more estrogens in an amount equivalent to a daily oral dosage of at least 1 µg ethinyl estradiol.

Inventors

COELINGH BENNINK HERMAN JAN TI

THIJSSSEN JOSEPH HELENUS HUBERT

Latest standardized assignees - inventors removed

PANTARHEI BIOSCIENCE

Family 38/200 - FAMPAT - ©Questel

Title

(EP1363696)

Geometry retainable devices for body cavities

Images




FIGURE 1

Publication data including kind & date

WO02062415	A1	2002-08-15	WO200262415
CA2438127	A1	2002-08-15	CA2438127
NZ509894	A	2002-11-26	NZ-509894
KR20030083712	A	2003-10-30	KR20030083712
EP1363696	A1	2003-11-26	EP1363696
BR0207497	A	2004-03-09	BR200207497
BRPI0207497	A1	2004-03-09	BRPI0207497
US20040142012	A1	2004-07-22	US20040142012
JP2004522528	A	2004-07-29	JP2004522528
ZA200306042	B	2004-11-05	ZA200306042
AU2002235050	B2	2007-02-15	AU2002235050
BRPI0207497	A2	2011-03-09	BR200207497



Abstract

(EP1363696)

A passive or active release device for a medicament or other substance for a target species mammal. The device is of a kind capable of being inserted into a body cavity of a target species mammal and deploying resiliently to one or more retention condition(s). The device is wholly or in part moulded from poly (ε-caprolactone) (optionally impregnated with at least a physiologically effective agent to be released therefrom or optionally to carry some device or material to be body cavity retained at least for a period). The device is preferably of substantially a "T" or "Y" shape.

Inventors

BUNT CRAIG ROBERT

RATHBONE MICHAEL JOHN

OGLE COLIN ROGER

WYLLIE MARK ANDREW

Latest standardized assignees - inventors removed

INTERAG


Family 39/200 - FAMPAT - ©Questel

Title

(EP2906142)

Intravaginal device withdrawal assembly

Images



Publication data including kind & date

US20120136199	A1	2012-05-31	US20120136199				
CA2818863	A1	2012-06-07	CA2818863				
WO2012074779	A1	2012-06-07	WO201274779				
AU2011336967	A1	2013-06-13	AU2011336967				
EP2645960	A1	2013-10-09	EP2645960				
CN103354737	A	2013-10-16	CN103354737				
JP2014507170	A	2014-03-27	JP2014507170				
RU2013129826	A	2015-01-10	RU2013129826				
BR112013013439	A1	2015-03-24	BR112013013439				
EP2645960	B1	2015-07-08	EP2645960				
AU2011336967	B2	2015-08-13	AU2011336967				
ES2549044	T3	2015-10-22	ES2549044				
RU2570772	C2	2015-12-10	RU2570772				
JP5902191	B2	2016-03-18	JP5902191				
CN103354737	B	2016-05-18	CN103354737B				
CA2818863	C	2018-02-20	CA2818863				

Abstract

(EP2645960)

An intravaginal device has a first structural material formed into a device frame and a second cushioning material having a thickness surrounding portions of the device frame. The first structural material includes a working portion and an anchoring portion extending therefrom. The device frame includes interconnected elongate elements having a maximum cross-section of less than about 5 mm and a longitudinal axis. The device frame has a plurality of primary bearing surfaces arranged and configured to bear on vaginal tissue during insertion and use, and the thickness of the cushioning material on the device frame is greater on the primary bearing surfaces than on surfaces of the device frame disposed toward the device interior. Preferably, the first structural material is a high modulus polymer and the second material is a thermoplastic elastomer. The intravaginal device may be included in a device delivery system including a delivery applicator.

Inventors

MAVINKURVE PRAMOD

HOU MARI

HULL RAYMOND J JR

ROSENFELD LEONARD

Latest standardized assignees - inventors removed

FIRST QUALITY HYGIENIC


Family 41/200 - FAMPAT - ©Questel

Title

(EP2982352)

Cervical pessary containing progesterone for prolonged, sustained and continuous release, used to prevent premature birth


Images



A



B



C

Publication data including kind & date

CA2873222	A1	2015-12-28	CA2873222				
WO2015198104	A1	2015-12-30	WO2015198104				
EP2982352	A1	2016-02-10	EP2982352				
BR112014030232	A1	2016-03-01	BR112014030232				
CN105392454	A	2016-03-09	CN105392454				
MX2014014769	A	2016-03-30	MX2014014769				
AR098604	A1	2016-06-01	AR--98604				
IN8757/CHENP/2014	A	2016-08-31	IN2014CN08757				
US20160250229	A1	2016-09-01	US20160250229				
KR20170021929	A	2017-03-02	KR20170021929				
CR20160604	A	2017-03-10	CR20160604				
EP2982352	A4	2017-06-14	EP2982352				
BR112014030232	A2	2017-06-27	BR112014030232				
JP2017524030	A	2017-08-24	JP2017524030				
US9820994	B2	2017-11-21	US9820994				
CN105392454	B	2018-05-08	CN105392454B				
EP2982352	B1	2018-10-03	EP2982352				
LT2982352	T	2018-11-12	LT2982352				
DK2982352	T3	2018-11-26	DK2982352T				
HRP20181794	T1	2018-12-28	HRP20181794				
SI2982352	T1	2018-12-31	SI2982352T				
PL2982352	T3	2019-01-31	PL2982352				
ES2699003	T3	2019-02-06	ES2699003				
HUE040176	T2	2019-02-28	HUE040176				

Abstract

(EP2982352)

Cerclage pessary containing progesterone homogeneously distributed in the pessary body providing a prolonged, sustained and continuous release for a period of at least 6 months, wherein the pessary consists of dimethylsiloxane elastomer with RTV (Room Temperature Vulcanization) mechanism, the progesterone amount is from 20% to 30% w/w, relative to pessary weight and the ratios of the polymers forming the matrix is from 6:1 to 14 1. The cerclage pessary is useful for the prevention of preterm birth. Progesterone diffuses through the polymer continuously, without altering the shape and integrity of the pessary, since the elastomer forming the polymeric matrix used herein is not biodegradable. This guarantees that the form of pessary remains intact until the end of treatment

Inventors

CAMPOS PÉREZ GERMÁN ARZOBINDO

CHEN SHU-CHEN

Latest standardized assignees - inventors removed

LABORATORIOS ANDROMACO

Family 42/200 - FAMPAT - ©Questel

Title

(EP2552426)

Intravaginal drug delivery device

Images




FIG. 1




FIG. 2




FIG. 3

Publication data including kind & date

US20110236462	A1	2011-09-29	US20110236462
WO2011126810	A2	2011-10-13	WO2011126810
CA2798034	A1	2011-10-13	CA2798034
WO2011126810	A3	2012-02-23	WO2011126810
EP2552426	A2	2013-02-06	EP2552426
CN103025320	A	2013-04-03	CN103025320
JP2013523745	A	2013-06-17	JP2013523745
KR20130067259	A	2013-06-21	KR20130067259
ZA201208185	B	2014-03-26	ZA201208185
RU2012146080	A	2014-05-10	RU2012146080
EP2552426	A4	2014-12-17	EP2552426
AU2011238710			



	B2	2015-08-20	AU2011238710				
JP5813093	B2	2015-10-02	JP5813093				
US20170319833	A1	2017-11-09	US20170319833				
KR101828619	B1	2018-02-12	KR101828619				
RU2648827	C2	2018-03-28	RU2648827				

Abstract

(EP2552426)

Described herein is an intravaginal drug delivery system. In an embodiment the intravaginal drug delivery system includes a progestin and estrogen compound, and releases the active ingredients in a fixed physiological ratio over a prolonged period of time to produce a contraceptive state in a female.

Inventors

SHAKED ZE EV

NICKISCH KLAUS

DINUNZIO JIM

ZHANG FENG

OMELCZUK MARCELO

Latest standardized assignees - inventors removed

EVESTRA


Family 43/200 - FAMPAT - ©Questel

Title

(EP1588680)

Intravaginal set

Images



CA2270460	A1	1999-11-04	CA2270460
PL326141	A1	1999-11-08	PL98326141
EP0955024	A2	1999-11-10	EP-955024
CN1238170	A	1999-12-15	CN1238170
EP0955024	A3	2002-02-06	EP-955024
US6530879	B1	2003-03-11	US6530879
PL186960	B1	2004-04-30	PL-186960
EP0955024	B1	2005-09-07	EP-955024
AT303775	T	2005-09-15	ATE303775
DE69927085	D1	2005-10-13	DE69927085
DK0955024	T3	2005-10-17	DK-955024T
EP1588680	A1	2005-10-26	EP1588680
PT955024	E	2005-11-30	PT-955024
ES2247756	T3	2006-03-01	ES2247756
DE69927085	T2	2006-06-29	DE69927085
CN1264484	C	2006-07-19	CN1264484C
CA2270460	C	2006-11-28	CA2270460
HK1024160	A1	2007-02-09	HK1024160
EP1588680	B1	2007-11-28	EP1588680
PT1588680	E	2007-12-18	PT1588680
DE69937654	D1	2008-01-10	DE69937654
DK1588680	T3	2008-01-28	DK1588680T



ES2297564

T3 2008-05-01 ES2297564

DE69937654

T2 2008-10-30 DE69937654

**Abstract**

(EP1588680)

An intravaginal set for treatment of prolapse of urogenital organs and urinary stress incontinence or in the period of intervals in women when the intravaginal therapeutic insert for treatment of static disorders of the urogenital organs and urinary stress incontinence is not currently inserted, said method being realised by means of an intravaginal set of inserts, that permits selecting the appropriate size of corrective insert from a subset of intravaginal corrective inserts, consisting of at least two balls with step increase in diameter, ranging between the minimal and maximal woman vaginal diameter, each ball being preferably hollow, each ball has the loosely hanging string and each ball is made preferably of medical material, such as polycarbonate or methyl methacrylate, said selecting being realised by means of an intravaginal measuring subset comprising at least two metal or plastic balls having graduated diameters corresponding to graduated diameters of the balls from the subset of the intravaginal corrective inserts, which balls instead of the loosely hanging string have a rigidly mounted linearly scaled slat for measurement of optimal diameter and depth of localization of the corrective insert in the vagina, depending an actual and individual anatomical conditions of urogenital organ of the woman being treated, by the selection of appropriate optimal diameter and depth of localization of the corrective insert in vagina by approximations with using the balls from the measuring subset, so that contraction of the levator ani muscle will cause the elevation of the insert and the elevation of the insert will cause the elevation of the uterus and/or correction of the cysto-urethral angle.

Inventors

ADAMKIEWICZ MARIAN

Latest standardized assignees - inventors removed


ADAMED SP Z O O

Family 44/200 - FAMPAT - ©Questel


Title

(EP-719146)

Novel method of progesterone delivery and effect thereof

Images**Publication data including kind & date**

IL110972	A	1994-11-28	IL-110972
WO9507699	A1	1995-03-23	WO9507699
CA2171939	A1	1995-03-23	CA2171939
MA23329	A1	1995-04-01	MA--23329
AU7726194	A	1995-04-03	AU9477261
ZA9407073	B	1995-05-02	ZA9407073
PE50795	A1	1996-01-19	PE9500507
NO961044	D0	1996-03-14	NO9601044
FI961221	A0	1996-03-15	FI9601221



CO4290332	A1	1996-04-17	CO4290332A1				
FI961221	A	1996-05-14	FI9601221				
NO961044	L	1996-05-14	NO-961044				
HU9600669	D0	1996-05-28	HU9600669				
EP0719146	A1	1996-07-03	EP-719146				
LT96027	A	1996-07-25	LT9600027				
US5543150	A	1996-08-06	US5543150				
KR19967004554	A	1996-10-09	KR19967004554				
LV11527	A	1996-10-20	LV--11527				
BR9407475	A	1996-11-12	BR9407475				
BRPI9407475	A1	1996-11-12	BRPI9407475				
LT4072	B	1996-11-25	LT---4072				
LV11527	B	1997-02-20	LV--11527				
JPH09502724	A	1997-03-18	JP09502724				
PH30813	A	1997-10-17	PH--30813				
HUT76824	A	1997-11-28	HU-T76824				
IL110972	B	1998-03-10	IL-110972				
AU689133	B2	1998-03-26	AU-689133				
EP0719146	B1	1998-12-23	EP-719146				
AT174796	T	1999-01-15	ATE174796				
DE69415543	D1	1999-02-04	DE69415543				
ES2126783	T3	1999-04-01	ES2126783				
GR3029314	T3	1999-05-28	GR3029314				
DE69415543	T2	1999-06-17	DE69415543				
DK0719146	T3	1999-08-23	DK-719146T				
RU2148393	C1	2000-05-10	RU2148393				
NO308585	B1	2000-10-02	NO-308585				
KR100278553	B1	2001-01-15	KR100278553				
JP3143474	B2	2001-03-07	JP3143474				
CA2171939	C	2002-01-01	CA2171939				
HU221583	B	2002-11-28	HU-221583				
FI115444	B	2005-05-13	FI-115444				
NZ273816	A	2007-09-28	NZ-273816				

Abstract

(EP-719146)

The present invention teaches that relatively low levels of serum progesterone, 1 to 6 ng/ml, may be used to prevent endometrial cancer. The vaginal delivery of progesterone using a cross-linked polycarboxylic polymer produces this low serum progesterone level while also providing the full secretory transformation of the endometrium, indicating the efficacy of the progesterone. Such low levels of serum progesterone will decrease the risk of breast cancer experienced by women undergoing hormone replacement therapy ("HRT") and minimize the potential of other undesirable progesterone associated side effects.

Inventors

BOLOGNA WILLIAM JOSEPH

LEVINE HOWARD LESLIE


Latest standardized assignees - inventors removed

WATSON LABORATORIES

Family 45/200 - FAMPAT - ©Questel

Title

Images



WO2008058145	A2	2008-05-15	WO200858145
US20080125692	A1	2008-05-29	US20080125692
WO2008058145	A3	2008-10-23	WO200858145
EP2083774	A2	2009-08-05	EP2083774
CN101583328	A	2009-11-18	CN101583328
IN2583/CHENP/2009	A	2010-06-25	IN2009CN02583
EP2083774	A4	2012-02-08	EP2083774
CN101583328	B	2013-05-29	CN101583328B
US8728140	B2	2014-05-20	US8728140
EP2083774	B1	2014-05-28	EP2083774
US20140222122	A1	2014-08-07	US20140222122
DK2083774	T3	2014-08-25	DK2083774T
ES2492646	T3	2014-09-10	ES2492646
IN302244	B	2018-10-16	IN-302244



Abstract

(EP2083774)

Intra-vaginal devices and methods are disclosed for a broad range of applications in the women's health field. The devices and methods provide for placement in the cervical region, and for transferring heat to a cervical region, a barrier contraception method, collection of menstrual fluid, and release of drugs and/or hormones intra- vaginally. The device also can address multiple women's health issues.

Inventors

FEEMSTER STACY

ALSBERG TERRY

Latest standardized assignees - inventors removed

FEEMSTER STACY LEE





ALSBERG TERRY WAYNE

Family 46/200 - FAMPAT - ©Questel

Title

(EP1768625)

Sustained release compositions containing progesterone receptor modulators

Images

Publication data including kind & date

WO2006010097	A2	2006-01-26	WO200610097				
CA2573266	A1	2006-01-26	CA2573266				
AU2005265357	A1	2006-01-26	AU2005265357				
WO2006010097	A3	2006-08-10	WO200610097				
EP1768625	A2	2007-04-04	EP1768625				
KR20070044005	A	2007-04-26	KR20070044005				
MX2007000273	A	2007-05-21	MX2007000273				
IN0318/KOLNP/2007	A	2007-07-06	IN2007KN00318				
CN101080205	A	2007-11-28	CN101080205				
JP2008505718	A	2008-02-28	JP2008505718				
BRPI0513141	A	2008-04-29	BR200513141				
BRPI0513141	A1	2008-04-29	BRPI0513141				
EP1768625	A4	2008-07-09	EP1768625				
US20080199511	A1	2008-08-21	US20080199511				
NZ552720	A	2010-02-26	NZ-552720				
IN245805	B	2011-02-04	IN-245805				
EP1768625	B1	2011-02-09	EP1768625				
AT497745	T	2011-02-15	ATE497745				
DE602005026290	D1	2011-03-24	DE602005026290				
AU2005265357	B2	2011-04-07	AU2005265357				
PT1768625	E	2011-04-18	PT1768625				
DK1768625	T3	2011-05-09	DK1768625T				
ES2360806	T3	2011-06-09	ES2360806				
CN101080205	B	2011-10-12	CN101080205B				
CA2573266	C	2011-11-08	CA2573266				
JP2012040400	A	2012-03-01	JP2012040400				
JP5017109	B2	2012-06-15	JP5017109				
KR101229701	B1	2013-02-05	KR101229701				
VN0011555	B	2013-08-26	VN--11555B				
US8865200	B2	2014-10-21	US8865200				
BRPI0513141	A2	2019-04-09	BRPI0513141				

Abstract

(EP1768625)

Disclosed are sustained release compositions for vaginal or transdermal administration that contain a progesterone receptor modulator such as CDB-2914 (also referred to as VA-2914), and methods of using them for long term contraception or therapeutic purposes. Also disclosed are methods for making the compositions.

Inventors

SITRUK-WARE REGINE

TSONG YUN-YEN

Latest standardized assignees - inventors removed

POPULATION COUNCIL

HRA PHARMA LAB

Family 47/200 - FAMPAT - ©Questel

Title

(EP2347743)

Fluid management device with fluid transport element for use within a body

BRPI0510026	A1	2007-09-25	BRPI0510026				
BRPI0511121	A	2007-11-27	BR200511121				
BRPI0511121	A1	2007-11-27	BRPI0511121				
BRPI0511117	A	2007-11-27	BR200511117				
BRPI0511117	A1	2007-11-27	BRPI0511117				
JP2007537020	A	2007-12-20	JP2007537020				
JP2007537024	A	2007-12-20	JP2007537024				
JP2007537796	A	2007-12-27	JP2007537796				
US20090171310	A1	2009-07-02	US20090171310				
CN100553598	C	2009-10-28	CN100553598C				
US7618403	B2	2009-11-17	US7618403				
US20100069866	A1	2010-03-18	US20100069866				
US20100170069	A1	2010-07-08	US20100170069				
CN101779997	A	2010-07-21	CN101779997				
EP1755514	B1	2010-12-01	EP1755514				
US7845380	B2	2010-12-07	US7845380				
AT489928	T	2010-12-15	ATE489928				
US7861494	B2	2011-01-04	US7861494				
DE602005025113	D1	2011-01-13	DE602005025113				
CN1980620	B	2011-01-19	CN1980620B				
ES2354821	T3	2011-03-18	ES2354821				
CN1980622	B	2011-04-20	CN1980622B				
AU2005245014	B2	2011-07-21	AU2005245014				
EP2347743	A1	2011-07-27	EP2347743				
AU2005244897	B2	2011-07-28	AU2005244897				
AU2005244895	B2	2011-07-28	AU2005244895				
US8028500	B2	2011-10-04	US8028500				
JP4902531	B2	2012-01-13	JP4902531				
JP2012024641	A	2012-02-09	JP2012024641				
JP4943323	B2	2012-03-09	JP4943323				
US20120197223	A1	2012-08-02	US20120197223				
US8247642	B2	2012-08-21	US8247642				
CA2566690	C	2012-10-09	CA2566690				
CA2566990	C	2012-10-16	CA2566990				
CA2566683	C	2013-03-05	CA2566683				
CN101779997	B	2013-05-15	CN101779997B				
US20130165892	A1	2013-06-27	US20130165892				
US20130172845	A1	2013-07-04	US20130172845				
US8480833	B2	2013-07-09	US8480833				
JP5410495	B2	2013-11-15	JP5410495				
US20140052090	A1	2014-02-20	US20140052090				
EP1765242	B1	2014-11-19	EP1765242				
EP1758537	B1	2014-11-26	EP1758537				
US9035126	B2	2015-05-19	US9035126				
US9035124	B2	2015-05-19	US9035124				
US9044354	B2	2015-06-02	US9044354				
BRPI0511121	A8	2016-12-06	BR200511121				
BRPI0511117	A2	2016-12-06	BR200511117				

BRPI0511121	A8	2017-05-09	BRPI0511121
BRPI0510026	A8	2017-12-19	BRPI0510026
BRPI0511117	B1	2018-02-06	BR200511117
BRPI0511121	B1	2018-03-13	BR200511121

**Abstract**

(EP2347743)

A fluid management device for use in a mammalian body, the device comprising a convolutedly wound plate having a first surface and a second surface wherein the first surface of the plate in one winding of the device is disposed and maintained in facing relationship with the second surface and is capable of separating from the second surface sufficiently to provide inter-plate capillary action.

Inventors

BIGGS JEANN

CARASSO SAMUEL C

CHASE DAVID J

DANYI ERIN

HOU MARI

GLASGOW TARA

KOZOROVITSKY JULIA

MOSCHEROSCH H MICHAEL

STURGEON JENNIFER

ULMAN JOHN

Latest standardized assignees - inventors removed

JOHNSON & JOHNSON CONSUMER

Family 48/200 - FAMPAT - ©Questel


Title

(EP2745847)

Progestins for preventing or reducing neurodegeneration or ischemic damage


Images

FIG. 1
NESTORONE PROMOTES MYELINATION IN
ORGANOTYPIC CEREBELLAR SLICE CULTURES



Publication data including kind & date

WO2011049948	A2	2011-04-28	WO201149948
CA2777551	A1	2011-04-28	CA2777551
WO2011049948	A3	2011-06-16	WO201149948
WO2011049948	A4	2011-08-04	WO201149948
AU2010308308	A1	2012-06-07	AU2010308308
EP2490680	A2	2012-08-29	EP2490680
US20120231052	A1	2012-09-13	US20120231052
MX2012004542	A	2012-11-29	MX2012004542
JP2013508379	A	2013-03-07	JP2013508379
US20130116217	A1	2013-05-09	US20130116217
BR112012009306	A1	2013-06-11	BR112012009306
AU2010308308	B2	2013-11-28	AU2010308308
CA2836388	A1	2014-06-21	CA2836388
EP2745847	A1	2014-06-25	EP2745847
MX2013015310	A	2014-11-04	MX2013015310



JP2015083557	A	2015-04-30	JP2015083557				
CA2777551	C	2015-12-22	CA2777551				
JP5871807	B2	2016-01-22	JP5871807				
BR112012009306	A2	2016-06-07	BR112012009306				
US9446051	B2	2016-09-20	US9446051				
MX347890	B	2017-05-18	MX-347890				
EP2490680	B1	2018-04-04	EP2490680				
ES2669694	T3	2018-05-28	ES2669694				
US10052335	B2	2018-08-21	US10052335				

Abstract

(EP2745847)

Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17 $\pm$ -acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration, and include effects on stroke and TBI.

Inventors

SITRUK-WARE REGINE

SCHUMACHER MICHAEL MARIA HELMUT

BRINTON ROBERTA

EL-ETR MARTINE

GHOUMARI ABDELMOUMAN

GUENNOUN RACHIDA

Latest standardized assignees - inventors removed

POPULATION COUNCIL

Family 49/200 - FAMPAT - ©Questel

Title

(EP1087773)

Vaginal active agent delivery procedures and formulations thereof

Images




FIGURE 1

Publication data including kind & date

WO9965497	A1	1999-12-23	WO9965497
CA2335255	A1	1999-12-23	CA2335255
AU4535899	A	2000-01-05	AU9945358
NZ330726	A	2000-10-27	NZ-330726
EP1087773	A1	2001-04-04	EP1087773
US20020028788	A1	2002-03-07	US20020028788
EP1087773	A4	2002-03-13	EP1087773
AU746524	B2	2002-05-02	AU-746524
US20030007994	A1	2003-01-09	US20030007994
JP2003522104	A	2003-07-22	JP2003522104
EP1087773	B1	2005-01-12	EP1087773
ATE286733	T	2005-01-15	ATE286733
DE69923177	D1	2005-02-17	DE69923177
DE69923177	T2	2005-12-29	DE69923177



Abstract

(EP1087773)

Intra-vaginal delivery procedures including compositions and units therefor whereby an effective releasable amount of oestradiol 17 beta is released to achieve an efficacious effect insofar as oestrus expression is concerned. Preferably a cyclodextrin is utilised to enhance absorption.

Inventors

BUNT CRAIG ROBERT
RATHBONE MICHAEL JOHN
BURGGRAAF SHANE

Latest standardized assignees - inventors removed


INTERAG

Family 50/200 - FAMPAT - ©Questel

Title

(EP1981486)

Polymeric implant and a process for obtaining a polymeric implant

Images**Publication data including kind & date**

BRPI0600473	A1	2006-04-11	BR200600473				
WO2007090255	A2	2007-08-16	WO200790255				
CA2641043	A1	2007-08-16	CA2641043				
AU2007214274	A1	2007-08-16	AU2007214274				
DOP2007000026	A	2007-08-31	DO200700026				
BRPI0600473	A	2007-10-23	BR200600473				
WO2007090255	A3	2007-11-29	WO200790255				
EP1981486	A2	2008-10-22	EP1981486				
KR20080094805	A	2008-10-24	KR20080094805				
CN101378733	A	2009-03-04	CN101378733				
JP2009526093	A	2009-07-16	JP2009526093				
US20090291119	A1	2009-11-26	US20090291119				
CN101378733	B	2013-03-06	CN101378733B				
BRPI0600473	A2	2017-12-05	BRPI0600473				

Abstract

(EP1981486)

The polymeric implant is obtained from a renewable source, comprising a body (10) formed by at least one biodegradable polymer selected from the group consisting of polyhydroxyalcanoates (PHAs) and copolymers thereof, said body (10) incorporating, in its micro-structure, an active ingredient in a sufficient quantity to control at least one oestrus cycle of mammal animals. The invention further refers to a process for obtaining a polymeric implant comprising the steps of: mixing progesterone or progestogen, at least one polymer of the group of PHAs, one polymeric additive defined by poly(ϵ -caprolactone), and at least one dispersant additive and/or solvent, to obtain a colloidal solution; evaporating the solvent of the colloidal solution, and forming a paste with the components dispersed therein; drying the paste to remove the residual

solvents and control the granulometry of the polymer composite; extruding the polymeric composite and moulding the latter in an implant body (10).

Inventors

NASCIMENTO JEFTER FERNANDES

PACHEKOSKI WAGNER MAURICIO

Latest standardized assignees - inventors removed

PHB INDUSTIAL

Family 51/200 - FAMPAT - ©Questel

Title

(EP1862182)

Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Publication data including kind & date

WO03055524	A1	2003-07-10	WO200355524			
CA2471388	A1	2003-07-10	CA2471388			
AU2002358346	A1	2003-07-15	AU2002358346			
EP1455831	A1	2004-09-15	EP1455831			
US20060217315	A1	2006-09-28	US20060217315			
EP1455831	B1	2007-10-31	EP1455831			
AT376839	T	2007-11-15	ATE376839			
EP1862182	A2	2007-12-05	EP1862182			
DE60223284	D1	2007-12-13	DE60223284			
DE60223284	T2	2008-07-31	DE60223284			

Abstract

(EP1862182)

One aspect of the present invention relates to a method of controlled ovarian hyperstimulation in a mammalian female, said method comprising administration to said female of a substance having follicle stimulating hormone activity (FSH substance) in an amount effective to stimulate follicular development and of anti-P in an effective amount to prevent a premature endogenous LH-surge, followed by the administration of a meiosis and luteinisation inducing substance (ML substance) in an amount effective to stimulate resumption of meiosis and luteinisation, and of a progestogen and/or a precursor thereof in an amount effective to prevent or suppress symptoms of progesterone antagonism and/or deficiency, wherein the progestogen and/or the precursor thereof is administered within 24 hours of the first administration of the ML substance. Another aspect of the present invention relates to a pharmaceutical kit for use in a method of controlled ovarian hyperstimulation in mammalian females, said kit comprising a parenteral dosage unit containing a FSH substance, a parenteral or oral dosage unit containing an anti-P and a parenteral or oral dosage unit containing a progestogen and/or a precursor thereof.

Inventors

COELINGH BENNINK HERMAN JAN TI

BUNSCHOTEN EVERT JOHANNES

Latest standardized assignees - inventors removed

PANTARHEI BIOSCIENCE

Family 52/200 - FAMPAT - ©Questel


Title

(WO201713623)

Use of intravaginal device to increase weight gain and improve carcass quality in bovine females

Images

Figure 1A

**Publication data including kind & date**

WO2017013623	A1	2017-01-26	WO201713623
UY36813	A	2017-01-31	UY--36813
AR105311	A1	2017-09-27	AR-105311
BR112017028303	A1	2018-04-03	BR112017028303
BR112017028303	A2	2018-09-04	BR112017028303

**Abstract**

(WO201713623)

A method for increasing meat quantity and improving meat quality of female bovines, wherein the method comprises administering high concentrations of progesterone via an intravaginal device for prolonged periods of time.

Inventors

TURIC CARLOS ESTEBAN
MARTINEZ MARISA ANDREA

Latest standardized assignees - inventors removed

BIOGÉNESIS BAGÓ ARGENTINA
BIOGÉNESIS BAGÓ HONG KONG

Family 53/200 - FAMPAT - ©Questel

Title

(EP1786356)

Partially absorbable fiber-reinforced composites for controlled drug delivery

Images

**Publication data including kind & date**

US20040265355	A1	2004-12-30	US20040265355				
WO2005002471	A1	2005-01-13	WO200502471				
US20050053639	A1	2005-03-10	US20050053639				
WO2006028475	A1	2006-03-16	WO200628475				
EP1648338	A1	2006-04-26	EP1648338				
EP1786356	A1	2007-05-23	EP1786356				
EP1786356	A4	2011-11-30	EP1786356				
EP1648338	A4	2011-11-30	EP1648338				
US8399013	B2	2013-03-19	US8399013				
US8404272	B2	2013-03-26	US8404272				
EP1786356	B1	2013-07-03	EP1786356				
US20130197099	A1	2013-08-01	US20130197099				
ES2434391	T3	2013-12-16	ES2434391				
EP1648338	B1	2014-01-08	EP1648338				
US20140044769	A1	2014-02-13	US20140044769				
ES2455272	T3	2014-04-15	ES2455272				
US8992968	B2	2015-03-31	US8992968				
US20150196647	A1	2015-07-16	US20150196647				
US9084717	B2	2015-07-21	US9084717				
US20150238419	A1	2015-08-27	US20150238419				
US9308168	B2	2016-04-12	US9308168				
US9370574	B2	2016-06-21	US9370574				
US20160184493	A1	2016-06-30	US20160184493				

Abstract

(EP1786356)

This invention describes a partially absorbable, fiber-reinforced composite in the form of a ring, or a suture-like thread, with modified terminals for use as a controlled delivery system of at least one bioactive agent, wherein said composite comprising an absorbable fiber construct capable of providing time-dependent mechanical properties of a biostable elastomeric matrix containing an absorbable microparticulate ion-exchanger to modulate the release of the bioactive agent(s) for a desired period(s) of time at a specific biological site; this can be a vaginal canal, peritoneal cavity, scrotum, prostate gland, an ear loop or subcutaneous tissue. Such drug delivery systems can be used for the local administration of at least one bioactive agent, including those used as contraceptive, antimicrobial, anti-inflammatory and/or antiviral agents as well as for cancer treatment.

Inventors

SHALABY SHALABY W

Latest standardized assignees - inventors removed

POLY MEDICAL


Family 54/200 - FAMPAT - ©Questel

Title

(US20120109094)

Intravaginal device with fluid transport plates and methods of making

Images



Publication data including kind & date

US20120103529	A1	2012-05-03	US20120103529
US20120109094	A1	2012-05-03	US20120109094



Abstract

(US20120109094)

An intravaginal device has a fluid storage element and at least one fluid transport element in fluid communication with the fluid storage element. The at least one fluid transport element has a first plate a second plate coupled to the first plate. The second plate is capable of separating from the first plate sufficiently to provide inter-plate capillary action. The at least one fluid transport element is bendable about an axis substantially parallel to the longitudinal axis of the fluid storage element. The fluid transport element may substantially envelop the fluid storage element, and it may be attached to the withdrawal end of the fluid storage element, on at least one longitudinal side of the fluid storage element, to itself proximate the withdrawal end of the fluid storage element, and/or to the withdrawal string.

Inventors

BINNER CURT
 CARASSO SAMUEL C
 CHASE DAVID J
 MARSEE ERIN
 GLASGOW TARA
 KIMBALL DAVID L
 IRIS JULIA K
 NG TONY C

Latest standardized assignees - inventors removed

JOHNSON & JOHNSON CONSUMER

Family 55/200 - FAMPAT - ©Questel

Title

(WO2012121767)

Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent

Publication data including kind & date

WO2012121767	A1	2012-09-13	WO2012121767
DE202011110355	U1	2014-02-20	DE202011110355



Abstract

(WO2012121767)

The present invention relates to the reduction in the size of uterine fibroids or uterus by intravaginal administration of low doses of selective progesterone receptor modulator (SPRM), anti-progestin, or anti-progestational agent. According to the present invention, the active drug (i.e., SPRM, anti-progestin, or anti-progestational agent) is delivered directly to the affected tissue(s), particularly the uterine fibroids that are close to the vagina where the delivery device (e.g., vaginal ring or IUD) is placed. As specified herein, effective local concentrations of drug are achievable with doses much lower than those administered by the oral route. When used according to the method of the invention, levels of the SPRM (or anti-progestin, or anti-progestational agent) in systemic circulation are greatly reduced as compared to oral therapies, possibly below detectable limits, leading to a lower incidence of adverse events.

Inventors

RUBIN ARKADY

Latest standardized assignees - inventors removed

ARSTAT


Family 56/200 - FAMPAT - ©Questel

Title

(US5116619)

Vaginal progesterone tablet

Images

**Publication data including kind & date**

US5084277	A	1992-01-28	US5084277
US5116619	A	1992-05-26	US5116619

**Abstract**

(US5116619)

A vaginal progesterone suppository is provided in the form of a tablet which delivers biologically effective amounts of progesterone for at least about 48 hours, and blood amounts above basal levels for 72 hours. The tablet is formulated to preferably have a hardness on its edge of 8-13 kg, and disintegrates from its surface to form a milky suspension in 6-8 hours after it is inserted in the vaginal vault. The tablet contains, by weight, about 13-20% progesterone, 65-85% lactose, 2-10% corn starch paste binder, 3-10% corn starch disintegrant, and 0.1-0.9% magnesium stearate as a lubricant. The ratio by weight of progesterone to lactose is preferably 1:6, and the ratio of starch paste binder to starch disintegrant is preferably 1:1. This dosage form is an effective treatment for many progesterone deficiency conditions, and provides enhanced bioavailability.

Inventors

GRECO JOHN C

MCGINITY JAMES W

Latest standardized assignees - inventors removed


MORGAN LEE

Family 57/200 - FAMPAT - ©Questel

Title

(EP-198883)

Intravaginal device.

Images**Publication data including kind & date**

WO8601998	A1	1986-04-10	WO8601998
GB8610406	D0	1986-06-04	GB8610406
EP0198883	A1	1986-10-29	EP-198883
BR8506965	A	1986-12-23	BR8506965
GB2177303	A	1987-01-21	GB2177303
DE3590494	T1	1987-03-12	DE3590494T
JPS62500636	A	1987-03-19	JP62500636
EP0198883	A4	1987-11-02	EP-198883
US4711235	A	1987-12-08	US4711235
GB2177303	B	1988-04-07	GB2177303

**Abstract**

(EP-198883)

An intravaginal contraceptive device (60) formed of a ring (62) having a central sheet (64) of resilient impermeable material sandwiched between two layers (72, 74) of foam rubber. The foam rubber traps sperm and bacteria in the vaginal recess for a time sufficient to be destroyed by the normal acid pH of the vaginal secretions. The ring (62) defines the sheet material

(64) into a cup-shape with four sides, one pair of opposing sides (82, 84) including a wire core inwardly bent and another pair of sides (68, 66) with one outwardly rounded (68) and the other having a fork configuration (66). A normally closed flap valve (78) is formed in the sheet (64) with an attached extension (80) for opening the flap (78).

Inventors

WILLIS ROBERT E


Family 58/200 - FAMPAT - ©Questel

Title

(EP1620060)

Methods and devices for the sustained release of multiple drugs

Images



Publication data including kind & date

WO2004096151	A2	2004-11-11	WO200496151
CA2523859	A1	2004-11-11	CA2523859
AU2004233997	A1	2004-11-11	AU2004233997
EP1620060	A2	2006-02-01	EP1620060
WO2004096151	A3	2006-05-11	WO200496151
US20070196433	A1	2007-08-23	US20070196433
JP2007525461	A	2007-09-06	JP2007525461
EP1620060	A4	2007-11-28	EP1620060
US20080248017	A1	2008-10-09	US20080248017
US20080286339	A1	2008-11-20	US20080286339
US20080286322	A1	2008-11-20	US20080286322
US20090060982			



	A1	2009-03-05	US20090060982				
US20090274654	A1	2009-11-05	US20090274654				
AU2004233997	B2	2009-12-17	AU2004233997				
AU2004233997	B8	2010-01-14	AU2004233997				
EP1620060	B1	2010-03-24	EP1620060				
AT461681	T	2010-04-15	ATE461681				
DE602004026173	D1	2010-05-06	DE602004026173				
US7829112	B2	2010-11-09	US7829112				
US7833545	B2	2010-11-16	US7833545				
US7838024	B2	2010-11-23	US7838024				
US7883718	B2	2011-02-08	US7883718				
CA2523859	C	2011-08-02	CA2523859				
JP4898431	B2	2012-01-06	JP4898431				
US20120202742	A1	2012-08-09	US20120202742				
AU2004233997	B9	2013-01-10	AU2004233997				
AU2004233997	C1	2014-01-30	AU2004233997				

Abstract

(EP1620060)

The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.

Inventors

RON EYAL S

LANGER ROBER S

CROWLEY WILLIAM F JR

Latest standardized assignees - inventors removed

MIT - MASSACHUSETTS INSTITUTE OF TECHNOLOGY

MASSACHUSETTS GENERAL HOSPITAL


Family 59/200 - FAMPAT - ©Questel

Title

(WO9833452)

Active delivery device and related procedures

Images

**Publication data including kind & date**

WO9833452	A1	1998-08-06	WO9833452
AU5783898	A	1998-08-25	AU9857838
NZ314175	A	1999-10-28	NZ-314175
US6352524	B1	2002-03-05	US6352524

**Abstract**

(WO9833452)

An intravaginal substance delivery device for achieving and maintaining a progesterone plasma level of 2 ng/ml for a period of at least 4 days, comprising an elongated body with a plurality of resilient radially-extending arms, said body further comprising a bladder (19) containing said substance whereupon the bladder (19) is compressed to expel said substance by the pressure of a gas created by passing an electric current through a hydrogel.

Inventors

BUNT CRAIG ROBERT
THOMPSON WILLIAM STANLEY

Latest standardized assignees - inventors removed

INTERAG

Family 60/200 - FAMPAT - ©Questel

Title

(WO2012121778)

Treatment of endometriosis by intravaginal administration of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent

Publication data including kind & date

[WO2012/121778](#) A1 2012-09-13 WO2012121778

[DE202011110356](#) U1 2014-02-20 DE202011110356

**Abstract**

(WO2012121778)

The present invention relates to the reduction in the size of endometrial implants by intravaginal administration of low doses of selective progesterone receptor modulator (SPRM), anti-progestin, or anti-progestational agent.

Inventors

RUBIN ARKADY

Latest standardized assignees - inventors removed

ARSTAT

Family 61/200 - FAMPAT - ©Questel

Title

(EP3297634)

Contraceptive compositions and methods for improved efficacy and modulation of side effects


Images

FIGURE 1

Publication data including kind & date

CA2986039	A1	2016-11-24	CA2986039				
WO2016187269	A1	2016-11-24	WO2016187269				
AU2016264137	A1	2018-01-18	AU2016264137				
MX2017014768	A	2018-03-23	MX2017014768				
EP3297634	A1	2018-03-28	EP3297634				
CN107995864	A	2018-05-04	CN107995864				
US20180125860	A1	2018-05-10	US20180125860				
BR112017024783	A1	2018-05-22	BR112017024783				
JP2018515552	A	2018-06-14	JP2018515552				
BR112017024783	A2	2018-08-07	BR112017024783				

Abstract

(EP3297634)

Compositions and methods for the delivery of progestin hormones that have binding affinity to the Sex Hormone Binding Globulin (SHBG) are disclosed. The compositions combine such progestins with non-progestin SHBG ligands to displace at least part of the progestin from SHBG in the blood plasma, thereby increasing its bioavailability. Also disclosed are methods to modulate progestin and estrogen levels in the blood through the use of SHBG binding and displacement, to optimize the effectiveness of formulations for contraception and minimize the side effects and adverse events.

Inventors

KYDONIEUS AGIS

KAFRISSEN MICHAEL E

MACFARLANE KATIE

Latest standardized assignees - inventors removed

AGILE THERAPEUTICS

Family 62/200 - FAMPAT - ©Questel

Title

(US20040043071)

Intravaginal mucosal or transmucosal delivery of antimigraine and antinausea drugs

Images

FIG. 1




FIG. 2A





FIG. 2B



Publication data including kind & date

US20040043071

A1 2004-03-04

US20040043071

**Abstract**

(US20040043071)

A method, composition and device for intravaginal mucosal or transmucosal delivery of antimigraine and/or antinausea drugs to a female subject for treatment of migraine and other diseases accompanied by or associated with nausea and vomiting. A mucoadhesive composition comprising antimigraine or antinausea drugs, mucoadhesive agent, penetration enhancer or sorption promoter and a hydrophilic or lipophilic carries. An intravaginal device for delivery of antimigraine or antinausea drugs.

Inventors

PAULETTI GIOVANNI M

SODERSTROM RICHARD

RITSCHER WOLFGANG A

Latest standardized assignees - inventors removed


UMD

Family 63/200 - FAMPAT - ©Questel

Title

(EP1372605)

Intravaginal drug delivery devices for the administration of an antimicrobial agent

Images

Publication data including kind & date

WO02076426	A2	2002-10-03	WO200276426				
CA2442281	A1	2002-10-03	CA2442281				
US20030059456	A1	2003-03-27	US20030059456				
WO02076426	A3	2003-04-17	WO200276426				
NO20034268	D0	2003-09-24	NO200304268				
NO20034268	A	2003-11-27	NO200304268				
NO20034268	L	2003-11-27	NO20034268				
EP1372605	A2	2004-01-02	EP1372605				
IL157771	A	2004-03-28	IL-157771				
JP2004524343	A	2004-08-12	JP2004524343				
CN1536986	A	2004-10-13	CN1536986				
NZ528377	A	2005-05-27	NZ-528377				
US6951654	B2	2005-10-04	US6951654				
CA2442281	C	2010-06-08	CA2442281				
JP2011236243	A	2011-11-24	JP2011236243				
JP4959907	B2	2012-03-30	JP4959907				
CN1536986	B	2012-07-04	CN1536986B				
IL157771	B	2015-05-31	IL-157771				

Abstract

(EP1372605)

An intravaginal antimicrobial drug delivery device is disclosed having an antimicrobial agent dispersed throughout a biocompatible elastomeric system. Also disclosed is a method of making the antimicrobial drug delivery device.

Inventors

MALCOLM KARL

WOOLFSON DAVID

ELLIOTT GRANT

SHEPHARD MARTIN

Latest standardized assignees - inventors removed

PROCTER & GAMBLE PHARMACEUTICALS

WARNER CHILCOTT PHARMACEUTICALS

ALLERGAN PHARMACEUTICALS INTERNATIONAL


Family 64/200 - FAMPAT - ©Questel

Title

(US7214219)

Removal string attachment for intravaginal devices

Images



Publication data including kind & date

US20020143303	A1	2002-10-03	US20020143303
US20030130637	A1	2003-07-10	US20030130637
US20050192554	A1	2005-09-01	US20050192554
US7214219	B2	2007-05-08	US7214219



Abstract

(US7214219)

An intravaginal device having an overwrap containing an enclosed material, and a withdrawal string passing through a portion of the overwrap formed into a loop, the withdrawal string enabling a user to remove the intravaginal device after use.

Inventors

INTRAVARTOLO ANTOINETTE

LOUIE LAI-HING

Latest standardized assignees - inventors removed

MCNEIL

Family 65/200 - FAMPAT - ©Questel

Title

(US20140005157)

Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational

Publication data including kind & date[US20140005157](#) A1 2014-01-02 US20140005157**Abstract**

(US20140005157)

A method and intravaginal drug delivery device for reducing size of a uterine fibroid in a female in need thereof are provided. The method includes administering intravaginally to the female a therapeutically effective amount of an active agent, wherein the agent is delivered on a delivery device directly to uterine fibroid, wherein said amount is able to significantly reduce the size of the uterine fibroid, wherein the active agent is any one of selective progesterone receptor modulator (SPRM), an anti-progestin agent, and an anti-progestational agent.

Inventors

RUBIN ARKADY

Latest standardized assignees - inventors removed


ARSTAT

Family 66/200 - FAMPAT - ©Questel

Title

(WO200491570)

Method of treatment

Images**Publication data including kind & date**[WO2004091570](#) A1 2004-10-28 WO200491570**Abstract**

(WO200491570)

The present invention relates to a method of applying a fertility treatment to an animal characterised by the steps of altering the blood plasma level of a substance in the animal with respect to the endogenous blood plasma level of the substance, for a period of time sufficient to control oestrus, and maintaining the blood plasma level of the substance at a sufficiently high level to minimise compromising fertility.

Inventors

BUNT CRAIG ROBERT

BURGGRAAF SHANE

OGLE COLIN ROGER

RATHBONE MICHAEL JOHN

THOMPSON WILLIAM STANLEY

DAY BILLY

Latest standardized assignees - inventors removed

INTERAG

Family 67/200 - FAMPAT - ©Questel

Title

(EP-887074)

Intravaginal drug delivery device

Images

ES2206865	T3	2004-05-16	ES2206865				
DE69819080	T2	2004-06-24	DE69819080				
JP4054114	B2	2007-12-14	JP4054114				
EP0887074	B2	2010-08-04	EP-887074				
DK0887074	T4	2010-11-15	DK-887074T				
ES2206865	T5	2010-12-30	ES2206865				
DE69819080	T3	2011-01-13	DE69819080				

Abstract

(EP-887074)

The invention provides an intravaginal drug delivery system having a first intravaginal part comprising at least one active agent in a polymer matrix, said first part being provided in association with a second part comprising a removable polymer membrane arranged to absorb excess active agent. Use of a polymer membrane in this way serves to substantially reduce the initial high burst of active from the intravaginal part following administration. It also reduces the levels of release of active during the first few weeks of use. Also provided is an intravaginal drug delivery device comprising at least one active agent dispersed in a polymer matrix, wherein the concentration of active agent at the outer surface of the device at the time of use is not substantially higher than the concentration of the active agent in the remainder of the device.

Inventors

NABAHI SHOHRE

Latest standardized assignees - inventors removed

AVENTIS PHARMA

Family 68/200 - FAMPAT - ©Questel

Title

(EP2020236)

Method of contraception based on a progestative and oestrogen

Images

Vacant speech time slots reserved for normal use	x - y - 30	87
--	------------	----

Publication data including kind & date

FR2754179	A1	1998-04-10	FR2754179				
WO9815279	A1	1998-04-16	WO9815279				
CA2268358	A1	1998-04-16	CA2268358				
AU4627397	A	1998-05-05	AU9746273				
ZA9709011	B	1998-06-03	ZA9709011				
MA24370	A1	1998-07-01	MA--24370				
FR2754179	B1	1998-12-24	FR2754179				
NO991593	D0	1999-03-31	NO9901593				
NO991593	A	1999-06-07	NO9901593				
NO991593	L	1999-06-07	NO-991593				
ID21569	A	1999-06-24	ID--21569				
AP9901500	A0	1999-06-30	AP9901500				
AP9901500	D0	1999-06-30	AP9901500				
TH33592	A	1999-07-02	TH--33592				
TR199900764	T2	1999-07-21	TR199900764				
BR9712274	A	1999-08-31	BR9712274				
BRPI9712274	A1	1999-08-31	BRPI9712274				
PL332610	A1	1999-09-27	PL97332610				

EP0956022	A1	1999-11-17	EP-956022				
SK43899	A3	1999-12-10	SK9900438				
CN1239893	A	1999-12-29	CN1239893				
TNSN97164	A1	1999-12-31	TN9700164				
IL129194	A	2000-02-17	IL-129194				
AR009113	A1	2000-03-08	AR---9113				
HU9904508	A2	2000-06-28	HU209904508				
KR20000048981	A	2000-07-25	KR20000048981				
CZ9901120	A3	2000-11-15	CZ9901120				
HU9904508	A3	2001-01-29	HU9904508				
WO200130358	A1	2001-05-03	WO200130358				
CA2388857	A1	2001-05-03	CA2388857				
WO200130355	A1	2001-05-03	WO200130355				
AU1033501	A	2001-05-08	AU200110335				
NZ334876	A	2001-06-29	NZ-334876				
YU18099	A	2002-03-18	YU9900180				
AU745571	B2	2002-03-21	AU-745571				
JP2002509524	A	2002-03-26	JP2002509524				
NO20021948	D0	2002-04-25	NO200201948				
TW491704	B	2002-06-21	TW-491704				
NO20021948	A	2002-06-25	NO200201948				
NO20021948	L	2002-06-25	NO20021948				
AP200202485	A0	2002-06-30	AP200202485				
AP200202485	D0	2002-06-30	AP200202485				
EP1227815	A1	2002-08-07	EP1227815				
CZ20021426	A3	2002-08-14	CZ200201426				
KR20020073333	A	2002-09-23	KR20020073333				
IL149141	A	2002-11-10	IL-149141				
CN1382054	A	2002-11-27	CN1382054				
DZ2327	A1	2002-12-28	DZ---2327				
HU0203443	A2	2003-01-28	HU200203443				
OA11033	A	2003-03-06	OA--11033				
EP0956022	B1	2003-04-23	EP-956022				
AT238057	T	2003-05-15	ATE238057				
DE69721314	D1	2003-05-28	DE69721314				
JP2003518013	A	2003-06-03	JP2003518013				
IL129194	B	2003-06-24	IL-129194				
AP1171	A	2003-06-30	AP---1171				
VN0003574	B	2003-07-25	VN---3574B				
BR0014952	A	2003-07-29	BR200014952				
BRPI0014952	A1	2003-07-29	BRPI0014952				
PT956022	E	2003-07-31	PT-956022				
DK956022	T3	2003-08-04	DK-956022T				
EP1334725	A2	2003-08-13	EP1334725				
MXPA02004083	A	2003-08-20	MX2002PA004083				
HU0203443	A3	2003-12-29	HU200203443				
ES2198006	T3	2004-01-16	ES2198006				
EP1334725	A3	2004-01-21	EP1334725				

PL354518	A1	2004-01-26	PL2000354518				
RU2002113654	A	2004-01-27	RU2002113654				
ZA200203399	B	2004-02-09	ZA200203399				
DE69721314	T2	2004-02-12	DE69721314				
US20040220163	A1	2004-11-04	US20040220163				
US6831073	B1	2004-12-14	US6831073				
IN0459/MUMNP/2002	A	2005-03-18	IN2002MN00459				
US6906049	B1	2005-06-14	US6906049				
CN1205936	C	2005-06-15	CN1205936C				
RU2258512	C2	2005-08-20	RU2258512				
NZ518308	A	2006-01-27	NZ-518308				
KR100549625	B1	2006-02-08	KR100549625				
AU784478	B2	2006-04-13	AU-784478				
RU2274450	C2	2006-04-20	RU2274450				
OA12071	A	2006-05-04	OA--12071				
SK285056	B6	2006-05-04	SK-285056				
KR20060084864	A	2006-07-25	KR20060084864				
IN0073/MUMNP/2006	A	2006-10-06	IN2006MN00073				
PL192979	B1	2006-12-29	PL-192979				
SK285455	B6	2007-01-04	SK-285455				
EP1334725	B1	2007-02-14	EP1334725				
AP1707	A	2007-02-26	AP---1707				
MY128482	A	2007-02-28	MY-128482				
AT353652	T	2007-03-15	ATE353652				
VN0006143	B	2007-03-26	VN---6143B				
DE69737373	D1	2007-03-29	DE69737373				
PT1334725	E	2007-05-31	PT1334725				
DK1334725	T3	2007-06-11	DK1334725T				
DE69737373	T2	2007-06-21	DE69737373				
CZ298402	B6	2007-09-19	CZ-298402				
NO324357	B1	2007-10-01	NO-324357				
ES2282539	T3	2007-10-16	ES2282539				
KR100782638	B1	2007-12-06	KR100782638				
IL149141	B	2008-06-05	IL-149141				
CR6627	A	2008-06-18	CR---6627				
CN101229173	A	2008-07-30	CN101229173				
EP2020236	A1	2009-02-04	EP2020236				
CA2268358	C	2010-04-20	CA2268358				
BRPI0014952	A2	2010-08-17	BR200014952				
CZ301982	B6	2010-08-25	CZ-301982				
AR073972	A2	2010-12-15	AR--73972				
CA2388857	C	2011-06-07	CA2388857				
HU227450	B1	2011-06-28	HU-227450				
NO330885	B1	2011-08-08	NO-330885				
JP4883542	B2	2011-12-16	JP4883542				
NO2012002	I1	2012-02-06	NO2012002				
LU91932	I2	2012-03-13	LU--91932				
DE122012000010	I1	2012-04-19	DE12201200001011				

NO2012002	I2	2013-04-02	NO2012002				
JP5484646	B2	2014-02-28	JP5484646				
CN104706641	A	2015-06-17	CN104706641				
TH46567	B	2015-10-21	TH--46567B				
EP2020236	B1	2016-01-27	EP2020236				
ES2565688	T3	2016-04-06	ES2565688				
HK1210708	A1	2016-05-06	HK1210708				
HU230467	B1	2016-07-28	HU-230467				
HUS1200002	I1	2016-08-29	HU1200002				
HK1129564	A1	2017-01-20	HK1129564				
NO2017043	I1	2017-08-08	NO2017043				
LU91932	I9	2018-12-27	LU--91932				
NO2017043	I2	2019-01-25	NO2017043				

Abstract

(EP2020236)

Female contraceptive compositions (A) comprise nomegestrol (or its ester) as progestational component (I) and estradiol (or its ester) as estrogenic component (II), associated or mixed with a diluent or vehicle, in a weight ratio of (I) to (II) at 0.5-5 (preferably 1-3). An independent claim is included for the production of (A), by combining (I) and (II) with one or more of diluents, filler, compression adjuvants, lubricants and/or disintegrating agents. ACTIVITY : Antifertility. Tests in 18-35 year old women having normal menstrual cycles involving administration of nomegestrol acetate (Ia) and estradiol (IIa) showed that (IIa) at 1.5 mg daily (i.e. a dose insufficient to block ovulation if used alone) potentiated the anti-ovulate effect of (Ia), so that an adequate ovulation inhibiting effect was obtained at low doses of (Ia) (i.e. 0.625 mg per day). MECHANISM OF ACTION : None given.

Inventors

THOMAS JEAN-LOUIS

PARIS JACQUES

Latest standardized assignees - inventors removed

THERAMEX


Family 69/200 - FAMPAT - ©Questel

Title

(EP2627284)

An intravaginal support apparatus

Images



Publication data including kind & date

WO2012049676	A2	2012-04-19	WO201249676
WO2012049676	A3	2012-12-06	WO201249676
US20130192606	A1	2013-08-01	US20130192606
EP2627284	A2	2013-08-21	EP2627284
EP2627284	B1	2017-07-05	EP2627284
US10039666	B2	2018-08-07	US10039666



Abstract

(EP2627284)

An intravaginal support apparatus. The intravaginal support apparatus comprises a pessary ring having a substantially annular configuration and a narrowed configuration, a locking mechanism which retains and switches between the annular configuration and the narrowed configuration, and one or more expandable elements having expanded and unexpanded configurations, attached to one or more of the locking mechanism and the pessary ring. The pessary ring laterally expands from the narrowed configuration to the annular configuration; the expandable element expands outwardly of the pessary ring, from the unexpanded configuration to the expanded configuration.

Inventors

ZIV ELAN

PERLE AMIR

Latest standardized assignees - inventors removed

CONTIPI MEDICAL


Family 70/200 - FAMPAT - ©Questel

Title

(EP2349208)

Intravaginal delivery system and process for manufacturing it

Images



Publication data including kind & date

FI20086093	A0	2008-11-19	FI200806093				
WO2010058070	A1	2010-05-27	WO201058070				
CA2743260	A1	2010-05-27	CA2743260				
AU2009317127	A1	2010-05-27	AU2009317127				
FI121000	B	2010-06-15	FI-121000				
MX2011005222	A	2011-06-01	MX2011005222				
IL212952	A	2011-07-31	IL-212952				
KR20110086862	A	2011-08-01	KR20110086862				
EP2349208	A1	2011-08-03	EP2349208				
US20110208135	A1	2011-08-25	US20110208135				
IN1991/KOLNP/2011	A	2011-09-09	IN2011KN01991				
CN102202650	A	2011-09-28	CN102202650				
JP2012509359	A	2012-04-19	JP2012509359				
ZA201103626	B	2012-07-25	ZA201103626				
RU2011124875	A	2012-12-27	RU2011124875				
AU2009317127	B2	2013-01-10	AU2009317127				
CN102202650	B	2013-08-28	CN102202650B				
EP2349208	A4	2013-12-11	EP2349208				
HK1162311	A1	2014-04-25	HK1162311				
JP5554785	B2	2014-06-06	JP5554785				
RU2541812	C2	2015-02-20	RU2541812				
BRPI0916149	A2	2015-11-03	BR200916149				

Abstract

(EP2349208)

The present invention concerns an intravaginal delivery system, said system comprising at least one compartment comprising a core and a membrane encasing the core, wherein the core and the membrane essentially consist of a same or different polymer composition. Additionally the intravaginal delivery system comprises a coupling means to form a closed continuous delivery system. The present invention also concerns a method for manufacturing said intravaginal delivery system. The core and/or the membrane are preferably prepared by injection moulding or by extrusion.

Inventors

HAKALA OLLI

Latest standardized assignees - inventors removed

BAYER


Family 71/200 - FAMPAT - ©Questel

Title

(EP3319549)

A drug delivery device

Images



CA2991017	A1	2017-01-12	CA2991017
WO2017007342	A1	2017-01-12	WO201707342
AR105308	A1	2017-09-20	AR-105308
AU2016291095	A1	2018-03-01	AU2016291095
BR112018000479	A1	2018-04-03	BR112018000479
EP3319549	A1	2018-05-16	EP3319549
US20180200036	A1	2018-07-19	US20180200036
JP2018520829	A	2018-08-02	JP2018520829
MX2018000355	A	2018-08-16	MX2018000355
BR112018000479	A2	2018-09-18	BR112018000479
EP3319549	A4	2019-02-27	EP3319549



(EP3319549)

There are described delivery devices for insertion into a body cavity of a target mammal, the delivery device comprising a

resilient frame adapted to receive one or more moulded impregnated masses. The frame, together with the impregnated mass, are insertable, retainable and withdrawable from the intended body cavity. The impregnated mass or masses are attached to the frame to present substantially all of each face of the masses to exposure to a fluid of the body cavity when retained therein.

Inventors

RATHBONE MICHAEL

Family 72/200 - FAMPAT - ©Questel


Title

(EP3209251)

Platinum-catalyzed silicone drug delivery devices and methods of use thereof

Images

Figure 1: Mean and Cumulative Daily Release of Micronized Dapivirine Plotted Against Time



Publication data including kind & date

CA2963034	A1	2016-04-28	CA2963034
WO2016065096	A1	2016-04-28	WO201665096



WO2016065096	A8	2016-08-11	WO201665096				
US20170224823	A1	2017-08-10	US20170224823				
EP3209251	A1	2017-08-30	EP3209251				
EP3209251	A4	2018-03-28	EP3209251				

Abstract

(EP3209251)

The present invention provides intravaginal drug delivery devices, such as intravaginal rings, comprising active pharmaceutical ingredients (APIs) having terminal alkene, alkyne or carbonyl functionalities. The devices of the invention exhibit increased recovery of the active pharmaceutical ingredient from platinum-catalyzed silicone polymers due to the optimization of drug particle size and cure conditions. The present invention also provides methods of preventing unintended pregnancy in a female human, methods of preventing unintended pregnancy in a female human and HIV infection in a female human, and methods of preparing intravaginal drug delivery devices.

Inventors

BLANDA WENDY

HOLT JONATHON DARYLL

BRIMER ANDREW NATHAN

MALCOLM KARL

MCCOY CLARE

MURPHY DIARMAID

BOYD PETER JOHN JAMES

Latest standardized assignees - inventors removed

INT PARTNERSHIP FOR MICROBICIDES


Family 73/200 - FAMPAT - ©Questel

Title

(EP2807997)

Method of using intravaginal device with fluid transport plates

Images



Publication data including kind & date

US20050256485	A1	2005-11-17	US20050256485
WO2005112857	A1	2005-12-01	WO2005112857
CA2566680	A1	2005-12-01	CA2566680
AU2005244894	A1	2005-12-01	AU2005244894
US20060236274	A1	2006-10-19	US20060236274
NO20065602	L	2007-02-06	NO20065602
EP1748750	A1	2007-02-07	EP1748750
IL179268	A	2007-03-08	IL-179268
CN1980623	A	2007-06-13	CN1980623
BRPI0511115	A	2007-11-27	BR200511115
BRPI0511115	A1	2007-11-27	BRPI0511115
US20070282289	A1	2007-12-06	US20070282289
JP2007537019	A	2007-12-20	JP2007537019



US7478344	B2	2009-01-13	US7478344				
US20090094563	A1	2009-04-09	US20090094563				
US20100121301	A9	2010-05-13	US20100121301				
AU2005244894	B2	2011-07-21	AU2005244894				
US8015528	B2	2011-09-06	US8015528				
JP4902529	B2	2012-01-13	JP4902529				
US8182455	B2	2012-05-22	US8182455				
CA2566680	C	2013-06-18	CA2566680				
EP2807997	A2	2014-12-03	EP2807997				
EP2807997	A3	2015-03-04	EP2807997				
BRPI0511115	A8	2016-12-06	BR200511115				
BRPI0511115	A8	2017-05-09	BRPI0511115				
BRPI0511115	B1	2018-03-13	BR200511115				
EP1748750	B1	2019-01-23	EP1748750				

Abstract

(EP2807997)

The invention features a fluid management device for use in capturing bodily fluid. The bodily fluid is transferred via at least one fluid transport element that is capable of interfacing with a mammalian body element to provide a substantially uninterrupted fluid conduit. The fluid conduit provides a fluid path between at least one fluid transport element and the storage element. A distal portion of the at least one fluid transport element is capable of extending away from the fluid storage element.

Inventors

CHASE DAVID J

DANYL ERIN

GLASGOW TARA

HOU MARI

CARASSO SAMUEL

Latest standardized assignees - inventors removed

JOHNSON & JOHNSON CONSUMER



Family 74/200 - FAMPAT - ©Questel

Title

(EP1474069)

Control of a biological function

Images

Figure 1**Figure 2****Publication data including kind & date**

WO03065924	A1	2003-08-14	WO200365924
AU2003208679	A1	2003-09-02	AU2003208679
EP1474069	A1	2004-11-10	EP1474069
US20060052341	A1	2006-03-09	US20060052341

**Abstract**

(EP1474069)

This invention relates to improvements in and relating to the control of a biological function via the autonomous delivery of formulations administered at a single site. The invention requires determination of each of: the preferred formulations having efficacy in effecting control of at least one stage of a preferred biological function and includes features of improved permeation of formulations to effect desired bioavailability of at least one actives maintained at a preferred level for a preferred period of time one or more preferred formulations in predetermined concentrations, in predetermined quantities, delivered at predetermined time intervals and over predetermined periods and the delivery regimes for delivery of the

Abstract

(EP2106774)

An applicator for urinary incontinence devices has an insertion barrel, a deployment plunger, and an adjustable insertion depth indicator. The applicators are useful to correct for a consumer's body mass index to ensure that urinary incontinence devices are placed in the appropriate position to be effective.

Inventors

HOU MARI

HULL RAYMOND J JR

SWICK PAUL B

Latest standardized assignees - inventors removed

FIRST QUALITY HYGIENIC



Family 76/200 - FAMPAT - ©Questel

Title

(EP2001350)

Flexible, compressed intravaginal rings, methods of making and using the same, and apparatus for making the same

Images

**FIG. 1A****FIG. 1B**

Publication data including kind & date

WO2007109247	A2	2007-09-27	WO2007109247				
CA2646593	A1	2007-09-27	CA2646593				
US20070254014	A1	2007-11-01	US20070254014				
WO2007109247	A3	2008-02-28	WO2007109247				
MX2008012009	A	2008-10-03	MX2008012009				
NO20084193	L	2008-12-10	NO20084193				
EP2001350	A2	2008-12-17	EP2001350				
IN3954/KOLNP/2008	A	2009-02-27	IN2008KN03954				
CN101448452	A	2009-06-03	CN101448452				
RU2008141282	A	2010-04-27	RU2008141282				
US7910126	B2	2011-03-22	US7910126				
BRPI0709344	A2	2011-07-12	BR200709344				
IL194118	A	2011-08-01	IL-194118				
US20110212155	A1	2011-09-01	US20110212155				
RU2441756	C2	2012-02-10	RU2441756				
CN101448452	B	2012-07-18	CN101448452B				
US8323679	B2	2012-12-04	US8323679				
EP2001350	A4	2013-04-17	EP2001350				
IL194118	B	2015-06-30	IL-194118				
CA2646593	C	2015-12-08	CA2646593				

Abstract

(EP2001350)

The present invention is directed to flexible, compressed intravaginal rings comprising a substantially homogeneous compressed mixture comprising a polymethacrylate, a plasticizer, and an active agent, and methods of making and using the same, and apparatus for making the same.

Inventors

AHMED SALAH U

CHOWDHURY TAHSEEN A

LUO YI

Latest standardized assignees - inventors removed

TEVA WOMENS HEALTH

Family 77/200 - FAMPAT - ©Questel

Title

(DE2657846)

Ring shaped vaginal dispensers - contg. contraceptives etc. in containers on dispenser

Publication data including kind & date

DE2657846	A1	1978-06-22	DE2657846			
---------------------------	----	------------	-----------	---	--	---

Abstract

(DE2657846)

Vaginal dispenser comprises a plurality of containers releasably contg. a biologically active agent (I) and protruding through a dimensionally stable, pliable retaining ring, the containers being held in place because of their bulbous shape. Used for delivering (I), esp. contraceptives, and medicaments, into the vagina; the dispenser is easily fitted by the user and can remain in the vagina during intercourse and during menstruation. The retaining ring is pref. made of hydrocarbon plastics, natural or synthetic rubbers or silicones.

Inventors

DROBISH JAMES LEE

Latest standardized assignees - inventors removed

PROCTER & GAMBLE

Family 78/200 - FAMPAT - ©Questel

Title

(EP2749286)

Use of non-steroidal anti-inflammatory drugs meloxicam and piroxicam, administered intravaginally, for interruption of a woman's ovulation process

Images

温育的天数

美洛昔康

总释放

(µg/mL)

(µg)

1

282,0

18330

3

59,1

1921

13

55,9

363

23

41,8

272

30

38,6

251

Publication data including kind & date[WO2013029194](#)

A1 2013-03-07

WO201329194

[CL2012003423](#)

A1 2013-10-18

CL3423201200

[EP2749286](#)

A1 2014-07-02

EP2749286

[CN104168902](#)

A 2014-11-26

CN104168902

[IN0539/MUMNP/2014](#)

A 2014-12-26

IN2014MN00539

[EP2749286](#)

B1 2017-03-01

EP2749286

**Abstract**

(EP2749286)

The invention relates to the use of the non-steroidal anti-inflammatory compounds meloxicam and piroxicam to inhibit ovulation in women, the medication being administered by topically vaginal delivery.

Inventors

CARDENAS SANKAN HUGO

CROXATTO AVONI HORACIO

RABAGLIATI CANESSA FRANCO

ZAPATA RAMIREZ PAULA

GALVEZ PEREZ PAULA

ALTBIR DRULLINSKY DORA

VELASQUEZ CUMPLIDO LUIS

Latest standardized assignees - inventors removed

UNIVERSIDAD DE SANTIAGO DE CHILE

Family 79/200 - FAMPAT - ©Questel

Title

(EP2977035)

Tampon overwrap

US20100130953	A1	2010-05-27	US20100130953
CA3016994	A1	2010-06-03	CA3016994
WO2010062825	A1	2010-06-03	WO201062825
CA2744327	A1	2010-06-03	CA2744327
AU2009319871	A1	2010-06-03	AU2009319871
EP2367514	A1	2011-09-28	EP2367514
CN102223861	A	2011-10-19	CN102223861
BRPI0921851	A2	2011-12-06	BR200921851
JP2012509742	A	2012-04-26	JP2012509742
RU2011126171	A	2013-01-10	RU2011126171
EP2367514	A4	2013-04-10	EP2367514
US8419700	B2	2013-04-16	US8419700
US20130138071	A1	2013-05-30	US20130138071
US8562579	B2	2013-10-22	US8562579
JP5576388	B2	2014-07-11	JP5576388
RU2523993	C2	2014-07-27	RU2523993
AU2009319871	B2	2014-10-02	AU2009319871
CN102223861	B	2014-10-15	CN102223861B
JP2014210196	A	2014-11-13	JP2014210196
RU2013147395	A	2015-04-10	RU2013147395
RU2549970	C2	2015-05-10	RU2549970
EP2367514	B1	2015-09-09	EP2367514
EP2977035	A2	2016-01-27	EP2977035
EP2977035	A3	2016-03-09	EP2977035
HUE027166	T2	2016-08-29	HUE027166



JP6087321	B2	2017-02-10	JP6087321
EP2977035	B1	2017-09-20	EP2977035
PL2977035	T3	2018-05-30	PL2977035
HUE037277	T2	2018-08-28	HUE037277

**Abstract**

(EP2977035)

A packaged elongate intravaginal device (10) has an overwrap (100; 302) substantially enclosing the elongate intravaginal device. The overwrap has a longitudinal overlap seam (70) disposed generally parallel to the longitudinal axis (X-X). The overwrap has a substantially continuous line of weakness (60; 160; 200; 304) comprising open and land portions, each having a length associated therewith, disposed about the device having an angle to a plane perpendicular to the longitudinal axis of the packaged device of about 20° to about 35°. The line of weakness originates proximate a withdrawal end (46) of the packaged elongate intravaginal device with a ratio of open length to land length along the line of weakness of less than about 3:2 and a ratio of open length to land length along the line of weakness distal the withdrawal end of at least about 2:1.

Inventors

FUNG PAUL Y

LINKEL STEPHAN M

KIMBALL DAVID L

ROBBE LIONEL

MUELLER RALF

XU YANG

Latest standardized assignees - inventors removed

JOHNSON & JOHNSON

JOHNSON & JOHNSON CONSUMER


Family 80/200 - FAMPAT - ©Questel

Title

(US4066075)

U-shape intravaginal device

Images



Publication data including kind & date

[US4066075](#) A 1978-01-03 US4066075

**Abstract**

(US4066075)

A nonobstructive U-shape intravaginal device adapted to be placed in the vagina of a female mammal so that the arcuate-shape, closed-end portion of the device is disposed in the posterior fornix of the vagina, and so that the spaced arms of the device extend generally towards the introitus of the vagina and are adjacent the lateral walls of the vagina. When thus disposed, the device does not materially obstruct the portion of the vagina anterior of the cervix uteri and thus would not be a source of interference or discomfort during sexual intercourse. The device may comprise an effective charge of such beneficial materials as medicaments, contraceptives, or deodorants or the like within a sufficiently permeable structure that the charge is released over an extended period of time by the action of body fluids on the device whereby sustained beneficial effects are achieved.

Inventors

HUGHES AMY GRAY

Latest standardized assignees - inventors removed

PROCTER & GAMBLE

Family 81/200 - FAMPAT - ©Questel

Title

(US9566267)

Biostable, multipurpose, microbicidal intravaginal devices

Publication data including kind & date

[US20100330138](#) A1 2010-12-30 US20100330138

[US9034365](#) B2 2015-05-19 US9034365

[US20150246022](#) A1 2015-09-03 US20150246022

[US9566267](#) B2 2017-02-14 US9566267

**Abstract**

(US9566267)

Biostable, multipurpose, microbicidal intravaginal devices in the form of rings, ringed-meshes, sponges, or diaphragms for use by women and condoms for use by male partners are provided, wherein each of the devices contains a drug effective in treating a particular vaginal infection, while further exhibiting at least one additional function selected from the group dealing with non-hormonal contraception, management of sexually transmitted diseases, viral infections, and retroviral infections as well as the treatment of cervical cancer.

Inventors

SHALABY SHALABY W

HILAS GEORGIOS T

Latest standardized assignees - inventors removed

POLY MEDICAL

Family 82/200 - FAMPAT - ©Questel

Title

(EP2552404)

Parenteral pharmaceutical form which releases aromatase inhibitor and gestagens, for the treatment of endometriosis

Images

CL2012002722	A1	2013-01-18	CL2722201200				
KR20130010047	A	2013-01-24	KR20130010047				
EP2552404	A1	2013-02-06	EP2552404				
CO6630125	A2	2013-03-01	CO6630125				
MA34099	B1	2013-03-05	MA--34099				
CN103002873	A	2013-03-27	CN103002873				
PE05242013	A1	2013-04-26	PE201300524				
DOP2012000255	A	2013-04-30	DO201200255				
EA201201358	A1	2013-04-30	EA201201358				
US20130131027	A1	2013-05-23	US20130131027				
VN33658	A	2013-05-27	VN--33658				
CU20120145	A7	2013-05-31	CU20120145				
JP2013523683	A	2013-06-17	JP2013523683				
BR112012024739	A1	2013-06-25	BR112012024739				
TN2012000468	A1	2014-01-30	TN2012000468				
TH133904	A	2014-05-26	TH-133904				
GT201200267	A	2014-06-04	GT201200267				
NZ602698	A	2014-08-29	NZ-602698				
EP2552404	B1	2015-01-21	EP2552404				
CN103002873	B	2015-02-18	CN103002873B				
PT2552404	E	2015-03-30	PT2552404				
DK2552404	T3	2015-03-30	DK2552404T				
ES2533101	T3	2015-04-07	ES2533101				
SI2552404	T1	2015-04-30	SI2552404T				
HRP20150294	T1	2015-06-19	HRP20150294				
AU2011234587	B2	2015-07-09	AU2011234587				
HK1179531	A1	2015-08-28	HK1179531				
RS53876	B1	2015-08-31	RS--53876				
UA109655	C2	2015-09-25	UA-109655				
ME02159	B	2015-10-20	ME---2159				
IN8493/DELNP/2012	A	2016-01-22	IN2012DN08493				
ZA201206869	B	2016-01-27	ZA201206869				
IL222056	B	2016-03-31	IL-222056				
BR112012024739	A2	2016-06-07	BR112012024739				
JP2016164200	A	2016-09-08	JP2016164200				
TW201632184	A	2016-09-16	TW201632184				
JP6012048	B2	2016-09-30	JP6012048				
EA025582	B1	2017-01-30	EA--25582				
CY1116187	T1	2017-02-08	CY1116187				
MY160353	A	2017-02-28	MY-160353				
TWI576107	B	2017-04-01	TWI576107				

Abstract

(EP2552404)

The subject of the present invention for the treatment of endometriosis is the provision of a parenteral pharmaceutical form (release system) for the controlled release of an aromatase inhibitor (AI) with a daily release rate which does not induce any stimulation of the ovaries by negative feedback of the hypophyseal-ovarian axis (which would induce the secretion of gonadotropins and the stimulation of the ovarian follicular growth), and of a gestagen with a daily release rate of below the ovulation-inhibitory dose, which provides a contraceptive effect based on local effects (for example the reduction and

thickening of the cervical mucus to prevent the ascent of sperm, effects on the endometrium and on tubal motility in order to hinder the implantation and the transport of ovules).

Inventors

PAKKALIN ARTO

KNAUTHE RUDOLF

SCHMITZ HEINZ

TALLING CHRISTINE

JUKARAINEN HARRI

KOROLAINEN HENRIKKA

Latest standardized assignees - inventors removed

BAYER INTELLECTUAL PROPERTY


Family 83/200 - FAMPAT - ©Questel

Title

(EP2109424)

Biodegradable intravaginal devices for delivery of therapeutics

Images



● Drug1
○ Drug 2

▬ PU1, low Tm
▬ PU2, high Tm
| Adhesive

Publication data including kind & date

WO2008089488	A2	2008-07-24	WO200889488
WO2008089488	A3	2008-10-23	WO200889488
KR20090110355	A	2009-10-21	KR20090110355
EP2109424	A2	2009-10-21	EP2109424
IN4856/DELNP/2009	A	2010-03-05	IN2009DN04856
US20100166826	A1	2010-07-01	US20100166826
US20100316691	A2	2010-12-16	US20100316691
EP2109424	A4	2015-04-08	EP2109424



Abstract

(EP2109424)

The present disclosure relates to biodegradable intravaginal rings for the delivery of therapeutic or prophylactic agent, inter

alia, antiviral agents. The present disclosure further relates to biodegradable polyurethanes which will allow therapeutic/prophylactic agents to be released in a controlled manner that will not degrade when in use, but will degrade upon disposal.

Inventors

KISER PATRICK F

TRESCO PATRICK

MITCHNICK MARK

GUPTA KAVITA

ALIYAR HYDER

Latest standardized assignees - inventors removed

UNIVERSITY OF UTAH RESEARCH FOUNDATION

INTERNATIONAL PARTNERSHIP FOR MICROBICIDES

Family 84/200 - FAMPAT - ©Questel

Title

(EP2044942)

Pharmaceutical preparation for continuous hormonal treatment over a period of 21-28 days comprising two ethinylestradio or estradio and drospirenone compositions

Publication data including kind & date

EP1535618	A1	2005-06-01	EP1535618			
WO2005051400	A1	2005-06-09	WO200551400			
CA2547051	A1	2005-06-09	CA2547051			
AU2004292778	A1	2005-06-09	AU2004292778			
UY28631	A1	2005-06-30	UY--28631			
TW200529862	A	2005-09-16	TW200529862			
AR046671	A1	2005-12-14	AR--46671			
GT200400242	A	2006-01-18	GT200400242			
PE10382005	A1	2006-02-08	PE200501038			
PA8618301	A1	2006-05-16	PA8618301			
EP1689409	A1	2006-08-16	EP1689409			
NO20062945	L	2006-08-23	NO20062945			
IL175858	A	2006-10-05	IL-175858			
ECSP066674	A	2006-10-25	EC200606674			
EA200600964	A1	2006-10-27	EA200600964			
KR20060126671	A	2006-12-08	KR20060126671			
BRPI0416924	A	2007-01-16	BR200416924			
BRPI0416924	A1	2007-01-16	BRPI0416924			
CN1905885	A	2007-01-31	CN1905885			
JP2007512291	A	2007-05-17	JP2007512291			
CR8450	A	2007-06-06	CR---8450			
IN2945/DELNP/2006	A	2007-08-03	IN2006DN02945			
RS20060348	A	2008-08-07	RS200600348			
US20080234240	A1	2008-09-25	US20080234240			
EP2044942	A1	2009-04-08	EP2044942			
ZA200605224	B	2009-10-28	ZA200605224			
BRPI0416924	A2	2012-05-15	BR200416924			

Abstract

(EP2044942)

A pharmaceutical preparation to obtain a continuous hormonal treatment over a desired period of time longer than 21-28

days comprising a first composition containing at least one estrogen and/or at least one progestin in a predetermined amount to be administered in the first 21-28 days and a second composition which contains at least one estrogen and/or at least one progestin in a predetermined amount higher than the amount of the first composition and comprises a mono or multiphase sequence of pharmaceutical dosages.

Inventors

DUESTERBERG BERND

ENDRIKAT JAN

SCHUERMANN ROLF

Latest standardized assignees - inventors removed


BAYER SCHERING PHARMA

Family 85/200 - FAMPAT - ©Questel

Title

(EP-646008)

Minimizing progestin associated breakthrough bleeding

Images**FIG 1**

WO9321927	A1	1993-11-11	WO9321927				
CA2131911	A1	1993-11-11	CA2131911				
WO9321926	A1	1993-11-11	WO9321926				
AU4368593	A	1993-11-29	AU9343685				
AU1918092	A	1993-11-29	AU9219180				
ZA9303153	B	1993-12-06	ZA9303153				
CN1079651	A	1993-12-22	CN1079651				
NO944210	A	1994-11-04	NO9404210				
NO944210	D0	1994-11-04	NO9404210				
NO944210	L	1994-11-04	NO-944210				
FI945207	A	1994-11-04	FI9405207				
FI945207	A0	1994-11-04	FI9405207				
KR19957000745	A	1995-02-20	KR19957000745				
EP0646008	A1	1995-04-05	EP-646008				
EP0646008	A4	1995-10-11	EP-646008				
AU667729	B2	1996-04-04	AU-667729				
JPH08509456	A	1996-10-08	JP08509456				
US5622943	A	1997-04-22	US5622943				
NZ253405	A	1997-06-24	NZ-253405				
EP0646008	B1	1999-12-15	EP-646008				
AT187644	T	2000-01-15	ATE187644				
DE69327319	D1	2000-01-20	DE69327319				
ES2142345	T3	2000-04-16	ES2142345				
PT646008	E	2000-04-28	PT-646008				
DK0646008	T3	2000-05-15	DK-646008T				
GR3032797	T3	2000-06-30	GR3032797				
DE69327319	T2	2000-07-13	DE69327319				
NO308581	B1	2000-10-02	NO-308581				
CN1073422	C	2001-10-24	CN1073422C				
KR100274660	B1	2001-11-22	KR100274660				
CA2131911	C	2005-12-27	CA2131911				
JP3937240	B2	2007-04-06	JP3937240				

Abstract

(EP-646008)

A method for minimizing menstrual bleeding irregularities in individuals using progesting-only pharmaceutical preparations, such as contraceptives, is disclosed.

Inventors

HODGEN GARY D

Latest standardized assignees - inventors removed

MEDICAL COLLEGE OF HAMPTON ROADS


Family 86/200 - FAMPAT - ©Questel

Title

(US20190091141)

Geometrically complex intravaginal rings, systems and methods of making the same

Images

**Publication data including kind & date**[US20190091141](#)

A1

2019-03-28

US20190091141

**Abstract**

(US20190091141)

Geometrically complex intravaginal rings, systems and methods of making the same are provided herein. Disclosed herein are geometrically complex intravaginal rings with tunable and enhanced drug release, which in some embodiments can be fabricated by 3D printing technologies. The disclosed IVRs include a ring structure comprising a plurality of unit cells or macroscopic and/or microscopic architecture, which can be tuned to control the loading capacity of an active compound within the IVR, the diffusion of an active compound from the IVR, the surface area of the IVR, and/or the mechanical properties of the IVR. The disclosed geometrically complex IVRs can provide superior control over drug loading and drug release compared to conventional IVRs fabricated by injection molding or hot-melt extrusion.

Inventors

BENHABBOUR SOUMYA RAHIMA

JANUSZIEWICZ RIMA

MECHAM SUE J

Latest standardized assignees - inventors removed


UNIVERSITY OF NORTH CAROLINA

Family 87/200 - FAMPAT - ©Questel

Title

(WO201774886)

Vaginal ring with visual indication of use

Images**Publication data including kind & date**

[WO2017/074886](#)

A1 2017-05-04

WO201774886

[US20190070104](#)

A1 2019-03-07

US20190070104

**Abstract**

(WO201774886)

The disclosure provides biomedical devices comprising indicator agents sensitive to the environment of use, methods of using same to enhance adherence to a treatment or usage regimen, and systems for monitoring compliance of use of the biomedical device. The biomedical device may be an intravaginal ring comprised of biocompatible polymeric material having indicator agent incorporated therein capable of producing a detectable change in response to a stimulus within the vaginal environment.

Inventors

JOHNSON LEAH MARIE

SWARNER STEPHANIE LYNN

ROTHROCK GINGER DENSON

VAN DER STRATEN PONTBOZ ARIANE

STONER BRIAN RHYS

Latest standardized assignees - inventors removed

RTI INTERNATIONAL

Family 88/200 - FAMPAT - ©Questel


Title

(EP3139908)

Formulations and methods for vaginal delivery of antiprogestins

Images

Figure 1



Publication data including kind & date

CA2948287	A1	2015-11-12	CA2948287
WO2015171319	A1	2015-11-12	WO2015171319
AU2015256473	A1	2016-11-17	AU2015256473
CN106232107	A	2016-12-14	CN106232107
IL248621	A	2017-01-31	IL-248621
MX2016014256	A	2017-02-06	MX2016014256
EP3139908	A1	2017-03-15	EP3139908
JP2017514851	A	2017-06-08	JP2017514851
US20170181965	A1	2017-06-29	US20170181965
HK1232125	A1	2018-01-05	HK1232125
EP3139908	A4	2018-05-16	EP3139908
AU2015256473	B2	2018-07-12	AU2015256473
US10064815	B2	2018-09-04	US10064815
US20180325810	A1	2018-11-15	US20180325810



Abstract

(EP3139908)

The subject matter of the present invention is pertinent to the field of vaginal delivery of pharmaceutically active agents. Embodiments of the instant invention disclose methods for treating a variety of progesterone related disorders by vaginal administration of a pullulan capsule and a fill formulation comprising one or more antiprogestins dispersed in a mixture of isopropyl palmitate or isopropyl myristate and a polyethylene glycol.

Inventors

PODOLSKI JOSEPH S

HSU KUANG

Latest standardized assignees - inventors removed


REPROS THERAPEUTICS

Family 89/200 - FAMPAT - ©Questel

Title

(EP2552357)

Medical device for treatment of urinary incontinence in females

Images**Publication data including kind & date**

WO2011121591	A2	2011-10-06	WO2011121591
CA2794826	A1	2011-10-06	CA2794826
IL221978	A	2012-11-29	IL-221978
AU2011233977	A2	2012-12-13	AU2011233977
WO2011121591	A3	2012-12-27	WO2011121591
EP2552357	A2	2013-02-06	EP2552357
US20130053627	A1	2013-02-28	US20130053627
EP2552357	A4	2015-10-07	EP2552357
AU2011233977	B2	2016-02-18	AU2011233977
US9820836	B2	2017-11-21	US9820836
US20180132991	A1	2018-05-17	US20180132991

**Abstract**

(EP2552357)


An intra-vaginal device for controlling urinary incontinence, designed to be placed longitudinally in the vagina, comprises: a. a deformable distal portion, placed in the subvesical region of the vagina, characterized by a deformable state and an undeformable state; b. a deformable proximal portion placed in the suburethral portion of the vagina, characterized by a deformable state and an undeformable state; c. a deformation controlling mechanism interconnecting said distal portion and said proximal portion, adapted to at reversibly transform said distal portion and said proximal portion from said deformable state to said undeformable state; and from said undeformable state to said deformable state; wherein upon predetermined amount of intra-vaginal pressure applied on said proximal pressure, said deformation controlling mechanism is adapted to transform proximal portion from said undeformable state to said deformable state such that pressure is applied on said urethra.

Inventors

BERCOVICH EYAL

GYNAMICS WOMENS HEALTH

Images



NO20070433



EP1789002	A1	2007-05-30	EP1789002				
IL180291	A	2007-06-03	IL-180291				
CN1980619	A	2007-06-13	CN1980619				
BRPI0512838	A	2008-04-08	BR200512838				
BRPI0512838	A1	2008-04-08	BRPI0512838				
CN1980619	B	2011-10-05	CN1980619B				
AU2005260774	B2	2011-10-20	AU2005260774				
CA2571771	C	2012-10-02	CA2571771				
US8702670	B2	2014-04-22	US8702670				
EP1789002	B1	2014-04-23	EP1789002				
BRPI0512838	B1	2017-08-29	BRPI0512838				

Abstract

(EP1789002)

Controlled expansion of an intravaginal device can be achieved by selectively attaching either a primary or secondary cover to the primary absorbent device having a fluid storage element, we can determine that certain portions of the tampon will expand while other portions will be restricted to substantially the compressed structure. The primary cover can be attached to the primary absorbent device either before or after the absorbent device is compressed into final tampon form. The compression may be in the axial or radial direction or a combination of both directions. The secondary cover, if used, can be attached after the tampon pledget has been compressed into the final tampon form.

Inventors

BIGGS JEHANN

CARASSO SAMUEL C

DANYI ERIN

GLASGOW TARA

KOZOROVITSKY JULIA

MARCUS GINA J

Latest standardized assignees - inventors removed

MCNEIL

Family 91/200 - FAMPAT - ©Questel

Title

(EP-988007)

Intravaginal drug delivery system and discharge collection device

Images




Fig. 1B




Fig. 1A

Publication data including kind & date

US20090137478	A1	2009-05-28	US20090137478
US9056072	B2	2015-06-16	US9056072
US20150273020	A1	2015-10-01	US20150273020



Abstract

(US9056072)

The present invention discloses a novel method of prevention of birth defects, miscarriages and infertility in women. The two therapies, disclosed herein, the hormone normalization therapy and the aromatase inhibitor-hormone normalization therapy, focus on restoring young hormonal levels in women in order to prevent female infertility and miscarriages, guide follicular and oocyte maturation, and promote correct chromosomal segregation in oocytes and early embryos.

Inventors

BERNSTEIN LORI R


Family 93/200 - FAMPAT - ©Questel

Title

(EP1890661)

Intravaginal device with improved rim designs and methods of making same

Images



Publication data including kind & date

WO2006125159	A2	2006-11-23	WO2006125159
US20060260619	A1	2006-11-23	US20060260619
WO2006125159	A3	2007-09-27	WO2006125159
EP1890661	A2	2008-02-27	EP1890661
US7845355	B2	2010-12-07	US7845355
EP1890661	A4	2013-12-25	EP1890661



Abstract

(EP1890661)

The present invention provides improved rim designs for diaphragms or any similar intravaginal device and methods for producing same. The rim designs of the present invention improve, among other characteristics of the rim, structural durability, manufacturability, ease of insertion, comfort in use, and ease of removal of intravaginal devices. These designs incorporate one or more recesses in the inner portion of a rim piece that provide an attachment site for a separate dome piece. Attachment within a recess shields the exposed outer edge of the dome material from contact with epithelial

[HK1070003](#)

A1 2006-12-22 HK1070003

[SI1482948](#)

T1 2006-12-31 SI1482948T

[ES2269999](#)

T3 2007-04-01 ES2269999

[DE60307602](#)

T2 2007-10-04 DE60307602

**Abstract**

(EP1482948)

ABSTRACTA method of hormone replacement therapy is disclosed comprising the step of administering continuously to a post-menopausal or estrogen deficient female in need of such therapy a combination of estrogen in an effective hormone replacement amount and a progestogen which is a potent sulfatase inhibiting progestogen in an amount which is both an effective endometrium protective amount and an effective breast protective amount.

Inventors

CAUBEL PATRICK MICHEL

FRIEDMEN ANDREW JOSEPH

Latest standardized assignees - inventors removed


JANSSEN PHARMACEUTICA

Family 95/200 - FAMPAT - ©Questel

Title

(US20170014217)

Intravaginal incontinence device

Images**Publication data including kind & date**[US20170014217](#)

A1 2017-01-19 US20170014217

**Abstract**

(US20170014217)

An intravaginal incontinence device includes a longitudinal component for insertion into a vagina, wherein the longitudinal component includes a bladder support component configured to provide intravaginal support to a neck of a bladder.

Inventors


PATRUSKY KAREN L

Family 96/200 - FAMPAT - ©Questel

Title

(CN105581976)

Intravaginal drug delivery devices for the delivery of macromolecules and watersoluble drugs

Images**Publication data including kind & date**[CN105581976](#)

A

2016-05-18

CN105581976

**Abstract**

(CN105581976)

An intravaginal drug delivery device comprises a device body comprising a hydrophobic carrier material having at least one channel defining at least one opening to the exterior of said device body, said at least one channel being adapted to receive at least one drug-containing insert; at least one drug-containing insert positioned in said at least one channel, said drug-containing insert capable of releasing a pharmaceutically effective amount of at least one drug suitable for intravaginal administration and containing about 1% to about 70% of at least one water-soluble release enhancer, both the drug and the water-soluble release enhancer dispersed in an insert carrier material; wherein said hydrophobic carrier material and said insert carrier material may be the same or different; and wherein said at least one drug-containing insert is exposed on said exterior of said device body when said intravaginal drug delivery device is in use.

Inventors

WOOLFSON DAVID AARON

MALCOLM KARL

Latest standardized assignees - inventors removed

WARNER CHILCOTT


Family 97/200 - FAMPAT - ©Questel

Title

(EP2861234)

Progesterone formulations

Images

**FIG. 1****Publication data including kind & date**

US20130129818	A1	2013-05-23	US20130129818
CA2856520	A1	2013-05-30	CA2856520
WO2013078422	A2	2013-05-30	WO201378422
CA2861346	A1	2013-08-01	CA2861346



WO2013112947	A1	2013-08-01	WO2013112947				
US20130338123	A1	2013-12-19	US20130338123				
US20130338122	A1	2013-12-19	US20130338122				
CA2876977	A1	2013-12-27	CA2876977				
CA2876968	A1	2013-12-27	CA2876968				
CA2876947	A1	2013-12-27	CA2876947				
CA2876964	A1	2013-12-27	CA2876964				
WO2013192251	A1	2013-12-27	WO2013192251				
WO2013/192250	A1	2013-12-27	WO2013192250				
WO2013192249	A1	2013-12-27	WO2013192249				
WO2013192248	A1	2013-12-27	WO2013192248				
US8633178	B2	2014-01-21	US8633178				
US20140088051	A1	2014-03-27	US20140088051				
US20140094441	A1	2014-04-03	US20140094441				
US20140094440	A1	2014-04-03	US20140094440				
US20140100205	A1	2014-04-10	US20140100205				
US20140100204	A1	2014-04-10	US20140100204				
US20140100206	A1	2014-04-10	US20140100206				
US20140099362	A1	2014-04-10	US20140099362				
AU2012340589	A1	2014-06-12	AU2012340589				
AU2013211876	A1	2014-08-07	AU2013211876				
BR112014012444	A1	2014-08-19	BR112014012444				
BR112014018439	A1	2014-08-26	BR112014018439				
US8846649	B2	2014-09-30	US8846649				
US8846648	B2	2014-09-30	US8846648				
EP2782584	A2	2014-10-01	EP2782584				
MX2014006256	A	2014-10-24	MX2014006256				
US20140329783	A1	2014-11-06	US20140329783				
EP2806742	A1	2014-12-03	EP2806742				
WO2013078422	A3	2014-12-04	WO201378422				
US20140371185	A1	2014-12-18	US20140371185				
US20140371184	A1	2014-12-18	US20140371184				
US20140371183	A1	2014-12-18	US20140371183				
US20140371182	A1	2014-12-18	US20140371182				
US8933059	B2	2015-01-13	US8933059				
AU2013277236	A1	2015-01-22	AU2013277236				
AU2013277235	A1	2015-01-22	AU2013277235				
AU2013277234	A1	2015-01-22	AU2013277234				
AU2013277233	A1	2015-01-22	AU2013277233				
US20150031654	A1	2015-01-29	US20150031654				
US20150045335	A1	2015-02-12	US20150045335				
JP2015504924	A	2015-02-16	JP2015504924				
IL236359	B	2015-02-26	IL-236359				
IL236358	B	2015-02-26	IL-236358				
MX2014015898	A	2015-03-03	MX2014015898				
MX2014015899	A	2015-03-03	MX2014015899				
MX2014015897	A	2015-03-03	MX2014015897				
JP2015507607	A	2015-03-12	JP2015507607				

KR20150028302	A	2015-03-13	KR20150028302				
BR112014031914	A1	2015-03-24	BR112014031914				
BR112014031910	A1	2015-03-24	BR112014031910				
BR112014031837	A1	2015-03-24	BR112014031837				
BR112014031824	A1	2015-03-24	BR112014031824				
US8987238	B2	2015-03-24	US8987238				
US8987237	B2	2015-03-24	US8987237				
KR20150032560	A	2015-03-26	KR20150032560				
US8993549	B2	2015-03-31	US8993549				
US8993548	B2	2015-03-31	US8993548				
US9006222	B2	2015-04-14	US9006222				
US9012434	B2	2015-04-21	US9012434				
EP2861233	A1	2015-04-22	EP2861233				
EP2861073	A1	2015-04-22	EP2861073				
EP2861234	A1	2015-04-22	EP2861234				
EP2861072	A1	2015-04-22	EP2861072				
US20150148323	A1	2015-05-28	US20150148323				
MX2014009093	A	2015-06-02	MX2014009093				
JP2015519405	A	2015-07-09	JP2015519405				
JP2015520237	A	2015-07-16	JP2015520237				
JP2015520235	A	2015-07-16	JP2015520235				
JP2015520236	A	2015-07-16	JP2015520236				
US20150196640	A1	2015-07-16	US20150196640				
MX2014015900	A	2015-07-17	MX2014015900				
US20150202211	A1	2015-07-23	US20150202211				
EP2806742	A4	2015-07-29	EP2806742				
US20150224118	A1	2015-08-13	US20150224118				
US20150224117	A1	2015-08-13	US20150224117				
US9114146	B2	2015-08-25	US9114146				
US9114145	B2	2015-08-25	US9114145				
EP2861233	A4	2015-10-07	EP2861233				
AR095619	A1	2015-10-28	AR--95619				
EP2861234	A4	2015-10-28	EP2861234				
US20150352126	A1	2015-12-10	US20150352126				
US20150359737	A1	2015-12-17	US20150359737				
EP2861073	A4	2015-12-23	EP2861073				
EP2861072	A4	2015-12-23	EP2861072				
EP2782584	A4	2015-12-23	EP2782584				
US9248136	B2	2016-02-02	US9248136				
US9301920	B2	2016-04-05	US9301920				
AU2012340589	B2	2016-05-12	AU2012340589				
US20160213685	A1	2016-07-28	US20160213685				
RU2015100533	A	2016-08-10	RU2015100533				
RU2015100531	A	2016-08-10	RU2015100531				
AU2013211876	B2	2017-02-09	AU2013211876				
AU2013277236	B2	2017-04-20	AU2013277236				
ZA201500212	B	2017-04-26	ZA201500212				
AU2013277234	B2	2017-04-27	AU2013277234				

BR112014012444	A2	2017-06-06	BR112014012444				
BR112014018439	A2	2017-06-20	BR112014018439				
BR112014031914	A2	2017-06-27	BR112014031914				
BR112014031910	A2	2017-06-27	BR112014031910				
BR112014031837	A2	2017-06-27	BR112014031837				
BR112014031824	A2	2017-06-27	BR112014031824				
BR112014018439	A8	2017-07-11	BR112014018439				
AU2017206262	A1	2017-08-10	AU2017206262				
AU2017208300	A1	2017-08-17	AU2017208300				
USD801518	S1	2017-10-31	USD801518				
JP2018024688	A	2018-02-15	JP2018024688				
JP2018024685	A	2018-02-15	JP2018024685				
JP6285866	B2	2018-02-28	JP6285866				
JP6298460	B2	2018-03-20	JP6298460				
AU2013277235	B2	2018-04-19	AU2013277235				
JP6334519	B2	2018-05-30	JP6334519				
AU2013277233	B2	2018-05-31	AU2013277233				
JP6342389	B2	2018-06-13	JP6342389				
JP6342334	B2	2018-06-13	JP6342334				
MX358435	B	2018-08-03	MX-358435				
US10052386	B2	2018-08-21	US10052386				
AU2018222947	A1	2018-09-20	AU2018222947				
JP6397402	B2	2018-09-26	JP6397402				
JP2018199711	A	2018-12-20	JP2018199711				
US20190008968	A1	2019-01-10	US20190008968				
US20190046542	A1	2019-02-14	US20190046542				
EP2861234	B1	2019-03-27	EP2861234				
EP2806742	B1	2019-03-27	EP2806742				

Abstract

(EP2861234)

Pharmaceutical formulations for oral use in hormone replacement therapy comprising ultra-micronized progesterone are disclosed, wherein the ultra-micronized progesterone is combined with a suitable excipient. The preferred excipients comprise medium chain fatty acid-glycol esters and a nonionic surfactant comprising a polyethylene glycol fatty acid ester. In some embodiments C8 to C18 fatty acid esters of glycerol and polyethylene glycol are the preferred nonionic surfactants.

Inventors

CACACE JANICE LOUISE

PERSICANER PETER H R

Latest standardized assignees - inventors removed

THERAPEUTICSMD


Family 98/200 - FAMPAT - ©Questel

Title

(EP2108348)

Compact intravaginal device applicator

Images



Publication data including kind & date

MX2009003437	A	2009-09-29	MX2009003437
CA2660607	A1	2009-09-30	CA2660607
US20090247930	A1	2009-10-01	US20090247930
EP2108348	A2	2009-10-14	EP2108348
AU2009201245	A1	2009-10-15	AU2009201245
JP2009240787	A	2009-10-22	JP2009240787
US8029456	B2	2011-10-04	US8029456
EP2108348	A3	2012-11-07	EP2108348
JP5290018	B2	2013-06-14	JP5290018
AU2009201245	B2	2013-07-18	AU2009201245



Abstract

(EP2108348)

The present invention provides a compact intravaginal device applicator assembly having a longitudinal axis comprises an elongated barrel with an insertion end and an opposite gripper end; an intravaginal device and a plunger with a restraint.

Inventors

FUNG PAUL Y

Latest standardized assignees - inventors removed

MCNEIL


Family 99/200 - FAMPAT - ©Questel

Title

(EP1061987)

Drug delivery system

Images



Publication data including kind & date

WO9940966	A1	1999-08-19	WO9940966				
CA2320993	A1	1999-08-19	CA2320993				
AU2553899	A	1999-08-30	AU9925538				
EP1061987	A1	2000-12-27	EP1061987				
AU741072	B2	2001-11-22	AU-741072				
NZ506120	A	2002-02-01	NZ-506120				
US20030039679	A1	2003-02-27	US20030039679				
EP1061987	A4	2003-04-09	EP1061987				
US6770288	B2	2004-08-03	US6770288				
EP1061987	B1	2006-05-17	EP1061987				
DE69931354	D1	2006-06-22	DE69931354				
ES2265181	T3	2007-02-01	ES2265181				
DE69931354	T2	2007-02-01	DE69931354				
CA2320993	C	2008-05-06	CA2320993				

Abstract

(EP1061987)

A drug delivery device for delivering hormonal and other veterinary treatments intra-vaginally. A substance dispenser (21) is separate from the supporting device (20). The dispenser is in the form of drug impregnated gills or vanes (6, 7). In other aspects the drug may be dispensed by a micro-pump in the supporting device or the drug may be coated on the dispenser.

Inventors

DUIRS GRAHAM FRANCOIS

DUIRS LINDSAY ALISON

Latest standardized assignees - inventors removed

TELESTA THERAPEUTICS


Family 100/200 - FAMPAT - ©Questel

Title

(US4983393)

Intra-vaginal device and method for sustained drug release

Images

**Publication data including kind & date**[US4983393](#)

A

1991-01-08

US4983393

**Abstract**

(US4983393)

The invention disclosed provides an intra-vaginal device prepared using ingredients which slowly release in the vagina over a significant period of time. The present intra-vaginal device also usefully serves as a drug release means for controllably releasing a drug in the vagina. A method for controlled drug release in the vagina is also disclosed.

Inventors

COHEN ROBERT S

PIERCE JAMES M

KINSEY WILLIAM H

Latest standardized assignees - inventors removed

CONTRACT FURNITURE DESIGN

BELMAC MAXIMED PARTNERSHIP

CPEX PHARMACEUTICALS


Family 101/200 - FAMPAT - ©Questel

Title

(FR2439014)

MICROPARTICLES CONTAINING MEDICINAL OR THERAPEUTIC AGENTS AND THEIR USE AS CONTRACEPTIVE

Images



Publication data including kind & date

IT7926288	D0	1979-10-05	IT7926288
IL58471	A	1980-01-31	IL--58471
IE791966	L	1980-04-17	IE7901966
SE7908520	L	1980-04-18	SE7908520
NL7907432	A	1980-04-21	NL7907432
AU5169679	A	1980-04-24	AU7951696
DE2940146	A1	1980-04-30	DE2940146
FR2439014	A1	1980-05-16	FR2439014
GB2034182	A	1980-06-04	GB2034182
CA1143289	A	1983-03-22	CA1143289
AU528186	B2	1983-04-21	AU-528186
IL58471	B	1983-05-15	IL--58471
GB2034182	B	1983-07-27	GB2034182
FR2439014	B1	1983-12-09	FR2439014
NZ191837	A	1984-07-31	NZ-191837
CH645545	A5	1984-10-15	CH-645545
IE48851	B1	1985-05-29	IE--48851
IT1124572	B	1986-05-07	IT1124572
NL184723	B	1989-05-16	NL-184723
NL184723	C	1989-10-16	NL-184723
PH25638	A	1991-08-31	PH--25638
DE2940146	C2	1991-12-05	DE2940146



Abstract

(FR2439014)

Microparticles for the treatment of the internal female reproductive organs, comprise microparticles of a pharmaceutical agent incorporated in a matrix material which is biocompatible and biologically degradable, said microparticles being capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.

(From GB2034182 A)

Inventors

BECK, LEE R.

FLOWERS, CHARLES F.

COWSAR, DONALD R.

TANWUARY, ALBERT C., BIRMINGHAM, ALA., US

Latest standardized assignees - inventors removed

STOLLE RESEARCH & DEVELOPMENT

Family 102/200 - FAMPAT - ©Questel


Title

(WO201902486)

Intravaginally applicable devices comprising antiviral compounds

Images

Figure 1 A



Publication data including kind & date

[WO2019002486](#)

A1 2019-01-03

WO201902486



Abstract

(WO201902486)

The present invention relates to field of intravaginally applicable devices that release antiviral compounds. In particular, the present invention relates to vaginal rings comprising a matrix releasing at least one antivirally active compound, in

particular anti-herpetic compound N-[5- (aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide (in the following also referred to as "Pritelivir") or salts thereof. The present invention therefore relates to the treatment and prevention of herpes infections.

Inventors

BACHHAV YOGESHWAR

BONSMANN SUSANNE

PFAFF TAMARA

BIRKMANN ALEXANDER

MALCOLM KARL

Latest standardized assignees - inventors removed

AICURIS

Family 103/200 - FAMPAT - ©Questel

Title

(WO2014169395)

Aromatase inhibitor-releasing intravaginal device

Images

FIG. 1A





FIG. 1B



Publication data including kind & date

WO2014169395	A1	2014-10-23	WO2014169395
BR112015026298	A1	2015-12-08	BR112015026298
US20160067225	A1	2016-03-10	US20160067225
BR112015026298	A2	2017-07-25	BR112015026298
US10004723	B2	2018-06-26	US10004723



Abstract

(WO2014169395)

Described herein is an intravaginal device that provides biologically active circulating concentrations of an aromatase inhibitor for at least about of 4 days. Three compounds with estradiol inhibitory capability (letrozole, anastrozole and

fenbendazole) were tested in vitro using bovine granulosa cell culture. Letrozole was found to be the most efficient and potent inhibitor. Liposome-based and a wax-based formulations were used to assess letrozole diffusion through bovine vaginal mucosa in a diffusion chamber study. Samples were collected over a 24 h period. The wax-based vehicle was selected for further development of a letrozole intravaginal device based on its steady release rate. In an in vivo study in cattle, 3 different intravaginal devices containing 3 g of letrozole were tested: Wax (with 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine, DOPE) + gel coat (n=2), Wax + gel coat (n=4) and Wax (n=4). Blood samples were collected serially from time 0 to 120 h, and daily thereafter to measure circulating concentrations of letrozole by LC/MS/MS. The addition of a letrozole-containing gel coating improved initial absorption and hastened the increase on plasma concentrations of the active ingredient, while the letrozole-containing wax-based vehicle maintained prolonged delivery from the intravaginal device.

Inventors

ADAMS GREGG PATRICK

YAPURA MARIA JIMENA

PIERSON ROGER A

BADEA ILDIKO

Latest standardized assignees - inventors removed

UNIVERSITY OF SASKATCHEWAN

Family 104/200 - FAMPAT - ©Questel

Title

(EP2655394)

Novel 19-nor-steroids and their use for treating progesterone-dependent conditions

Images

AU2011345341	A1	2013-07-04	AU2011345341				
MX2013006732	A	2013-07-17	MX2013006732				
ZA201207688	B	2013-07-31	ZA201207688				
SG191207	A1	2013-07-31	SG-191207				
US20130274234	A1	2013-10-17	US20130274234				
EP2655394	A1	2013-10-30	EP2655394				
CN103403017	A	2013-11-20	CN103403017				
EA201390959	A1	2013-11-29	EA201390959				
KR20130132955	A	2013-12-05	KR20130132955				
JP2014500316	A	2014-01-09	JP2014500316				
NZ602525	A	2014-01-31	NZ-602525				
ZA201304381	B	2014-03-26	ZA201304381				
NZ612295	A	2014-07-25	NZ-612295				
TH136245	A	2014-08-27	TH-136245				
SG10201504913U	A	2015-07-30	SG10201504913U				
AU2010348967	B2	2015-10-29	AU2010348967				
UA110030	C2	2015-11-10	UA-110030				
IN8248/DELNP/2012	A	2016-01-01	IN2012DN08248				
SG10201510568W	A	2016-01-28	SG10201510568W				
AU2016200575	A1	2016-02-18	AU2016200575				
JP2016029083	A	2016-03-03	JP2016029083				
JP5894143	B2	2016-03-04	JP5894143				
AU2010348967	C1	2016-04-28	AU2010348967				
BR112012023281	A2	2016-05-17	BR112012023281				
BR112013015509	A1	2016-05-24	BR112013015509				
EA023743	B1	2016-07-29	EA--23743				
BR112013015509	A2	2016-09-13	BR112013015509				
JP2016180004	A	2016-10-13	JP2016180004				
AU2011345341	B2	2016-10-20	AU2011345341				
UA113283	C2	2017-01-10	UA-113283				
TWI581797	B	2017-05-11	TWI581797				
CN107260746	A	2017-10-20	CN107260746				
CN107260745	A	2017-10-20	CN107260745				
AU2017251837	A1	2017-11-16	AU2017251837				
AU2016200575	B2	2017-11-16	AU2016200575				
MY164622	A	2018-01-30	MY-164622				
IL255679	A	2018-01-31	IL-255679				
JP2018016655	A	2018-02-01	JP2018016655				
IL221820	B	2018-06-28	IL-221820				
KR20180104180	A	2018-09-19	KR20180104180				

Abstract

(EP2655394)

The subject matter of the instant invention is pertinent to the field of treatment of hormone-dependent conditions. New compounds and methods for treating these conditions are disclosed. Embodiments of the instant invention disclose methods for treating endometriosis, dysmenorrhea, breast cancer, uterine fibroids and endometrial hyperproliferation.

Inventors

PODOLSKI JOSEPH S

WIEHLE RONALD D

Latest standardized assignees - inventors removed

REPROS THERAPEUTICS

Family 105/200 - FAMPAT - ©Questel


Title

(WO201085363)

Estrus synchronization preparations and effective cidr-less protocols


Images

FIG. 1
(PRIOR ART)



Publication data including kind & date

WO2010085363	A1	2010-07-29	WO201085363
CA2750530	A1	2010-07-29	CA2750530
CR20110441	A	2011-12-07	CR20110441
CN102291992	A	2011-12-21	CN102291992
US20120046518	A1	2012-02-23	US20120046518
CO6410259	A2	2012-03-30	CO6410259
BRPI1006984	A1	2012-11-20	BR201006984
US20140194677	A1	2014-07-10	US20140194677
BRPI1006984	A2	2015-08-25	BR201006984
US20170258808	A9	2017-09-14	US20170258808
US9763962	B2	2017-09-19	US9763962



Abstract

(WO201085363)

An injectable preparation of estrogenic and progestogenic hormonal compounds in an anhydrous excipient injected to synchronize estrus in non- menstruating placental female animals, and a five to nine day protocol to apply the unique preparation to achieve estrus synchronization.

Inventors

WITT HAL

YOAKUM JENNIFER

Latest standardized assignees - inventors removed

HAL WITT


JENNIFER JOKAM

Family 106/200 - FAMPAT - ©Questel

Title

(EP2106773)

Applicator for intravaginal devices

Images**Publication data including kind & date**

MX2009003438	A	2009-09-29	MX2009003438
CA2660603	A1	2009-09-30	CA2660603
US20090247928	A1	2009-10-01	US20090247928
EP2106773	A1	2009-10-07	EP2106773
AU2009201240	A1	2009-10-15	AU2009201240
JP2009240786	A	2009-10-22	JP2009240786
US7935098	B2	2011-05-03	US7935098

**Abstract**

(EP2106773)

An applicator for intravaginal devices includes an elongate handle, an insertion sleeve, and an intravaginal device support member. The elongate handle has an open first end that defines a cavity extending into the handle. The insertion sleeve extends from the open first end of the handle; it is arranged and configured to slide into the cavity of the handle and to accommodate an intravaginal device; and it has associated therewith a trigger. The intravaginal device support member is disposed in the cavity of the handle; it is operatively connected to the handle; and it has a bearing surface disposed proximate the open first end of the handle. The applicators are useful to ensure that intravaginal devices are placed in the appropriate position to be effective.

Inventors

BARTNING MICHELLE

HOU MARI

HULL RAYMOND J JR

LUEHRS FREISLINGER KIRSTEN

RUSSEL SCOTT M

SWICK PAUL B

MAVINKURVE PRAMOD

Latest standardized assignees - inventors removed


FIRST QUALITY HYGIENIC

Family 107/200 - FAMPAT - ©Questel

Title

(DE10162529)

Insertion system for tampons and other intravaginal devices comprises applicator acting with intravaginal device

ImagesFig. 1**Publication data including kind & date**[DE10162529](#)

A1 2003-07-24

DE10162529

**Abstract**

(DE10162529)

The applicator comprises an applicator tube for a tampon and a liquid dispenser. The tube is cylindrical and 5-8 cm long and the tampon is inserted into the tube and maintains its position in the tube through adhesive friction. The tampon incorporates an elastic core, which is encased completely by a water-tight casing. The applicator (10) comprises an applicator tube (20) for a tampon (30) and a liquid dispenser (40). The tube is cylindrical and 5-8 cm long and the tampon is inserted into the tube and maintains its position in the tube through adhesive friction. The tampon incorporates an elastic core (32), which is encased completely by a water-tight casing. The elastic materials of the core (elastic fibres, foams etc.) are pressed together to provide for storing of potential expansion energy. An Independent claim is included for the insertion process for the system.

Inventors

KRAEMER ROBERT

BUZOT HERVET

Latest standardized assignees - inventors removed

JOHNSON & JOHNSON


Family 108/200 - FAMPAT - ©Questel

Title

(EP2316376)

Applicator for self-expanding intravaginal urinary incontinence devices

Images



Publication data including kind & date

IL208365	A	2011-02-28	IL-208365				
CA2716693	A1	2011-04-30	CA2716693				
EP2316376	A1	2011-05-04	EP2316376				
US20110105830	A1	2011-05-05	US20110105830				
JP2011092728	A	2011-05-12	JP2011092728				
CN102058419	A	2011-05-18	CN102058419				
AU2010224466	A1	2011-05-19	AU2010224466				
AR078839	A1	2011-12-07	AR--78839				
RU2010144460	A	2012-05-10	RU2010144460				
ZA201007762	B	2012-10-31	ZA201007762				
BRPI1004057	A2	2013-02-19	BR201004057				
US20130165843	A1	2013-06-27	US20130165843				
AU2010224466	B2	2014-11-20	AU2010224466				
RU2541283	C2	2015-02-10	RU2541283				
AU2010224466	A8	2015-03-19	AU2010224466				
AU2010224466	B8	2015-03-19	AU2010224466				
CN102058419	B	2015-05-27	CN102058419B				
JP5754614	B2	2015-06-05	JP5754614				
US9408685	B2	2016-08-09	US9408685				
EP2316376	B1	2016-09-07	EP2316376				
ES2600787	T3	2017-02-10	ES2600787				
CA2716693	C	2018-07-10	CA2716693				

Abstract

(EP2316376)

An applicator for a self-expanding intravaginal device has a barrel and a plunger that can substantially contain the self-expanding intravaginal device without significant insertion barrel distortion while maintaining comfortable applicator insertion. The barrel has an insertion end, an opposed gripper end, and a central portion therebetween, and it is arranged and configured to substantially contain the self-expanding intravaginal device. The plunger is in telescoping relation with the barrel, and it is arranged and configured to expel the self-expanding intravaginal device out of the insertion end of the barrel when the plunger is pushed into the gripper end of the barrel. A plurality of flexible petals substantially closes the insertion end of the barrel, and the central portion of the barrel has a load to 3 mm deflection of at least about 15 Newtons. Other aspects of the invention include a self-expanding intravaginal urinary incontinence system, and methods of making

the applicator.

Inventors

HOU MARI

HULL RAYMOND J JR

TROJANOWSKI ALAN

Latest standardized assignees - inventors removed

FIRST QUALITY HYGIENIC

Family 109/200 - FAMPAT - ©Questel



Title

(EP2034984)

Method of treating atrophic vaginitis

Images

(I)



Tamoxifen citrate

CA2654152	A1	2007-12-13	CA2654152				
AU2007256718	A1	2007-12-13	AU2007256718				
US20080026035	A1	2008-01-31	US20080026035				
WO2007143607	A3	2008-02-21	WO2007143607				
EP2034984	A2	2009-03-18	EP2034984				
KR20090029237	A	2009-03-20	KR20090029237				
IN10689/DELNP/2008	A	2009-03-20	IN2008DN10689				
US20090092656	A1	2009-04-09	US20090092656				
CN101489529	A	2009-07-22	CN101489529				
IL195579	A	2009-09-01	IL-195579				
JP2009539775	A	2009-11-19	JP2009539775				
BRPI0711525	A2	2011-11-01	BR200711525				
JP5193196	B2	2013-02-08	JP5193196				
EP2034984	A4	2013-03-06	EP2034984				
US9675546	B2	2017-06-13	US9675546				
US9693953	B2	2017-07-04	US9693953				

Abstract

(EP2034984)

The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen.

Inventors

CHOLLET JANET A

MERMELSTEIN FRED

Latest standardized assignees - inventors removed

PEAR TREE WOMEN S HEALTH CARE

Family 110/200 - FAMPAT - ©Questel

Title

(EP1274409)

Antiproggestins with partial agonist activity

Images




FIG. 1

Publication data including kind & date

WO200172293	A2	2001-10-04	WO200172293
CA2404172	A1	2001-10-04	CA2404172
AU4940801	A	2001-10-08	AU200149408
WO200172293	A3	2002-06-27	WO200172293
EP1274409	A2	2003-01-15	EP1274409
JP2003528137	A	2003-09-24	JP2003528137
US20030207854	A1	2003-11-06	US20030207854
AU2001249408	B2	2006-03-09	AU2001249408



Abstract

(EP1274409)

The present invention features methods of inhibiting progestin activity in a cell or in a subject in need of such inhibition, and methods of treating or preventing progestin-dependent conditions in a subject in need of such treatment or prevention. The methods include administering an effective amount of a C-17-derivatized dexamethasone antiprogestin to the cell or the subject. The invention also provides methods of screening substances for progestin or antiprogestin activity, and methods of detecting progestins, progestin agonists, or antiprogestins in a sample, using the C-17-derivatized dexamethasone

antiprogestins of the invention.

Inventors

SIMONS S STONEY JR

Latest standardized assignees - inventors removed

US DEPARTMENT OF HEALTH & HUMAN SERVICES

Family 111/200 - FAMPAT - ©Questel

Title

(EP3432889)

Geometrically complex intravaginal rings, systems and methods of making the same

Images




FIG. 4A

Publication data including kind & date

CA3018148	A1	2017-09-28	CA3018148
WO2017/165624	A1	2017-09-28	WO2017165624
EP3432889	A1	2019-01-30	EP3432889



Abstract

(EP3432889)

Geometrically complex intravaginal rings, systems and methods of making the same are provided herein. Disclosed herein are geometrically complex intravaginal rings with tunable and enhanced drug release, which in some embodiments can be fabricated by 3D printing technologies. The disclosed IVRs include a ring structure comprising a plurality of unit cells or macroscopic and/or microscopic architecture, which can be tuned to control the loading capacity of an active compound within the IVR, the diffusion of an active compound from the IVR, the surface area of the IVR, and/or the mechanical properties of the IVR. The disclosed geometrically complex IVRs can provide superior control over drug loading and drug release compared to conventional IVRs fabricated by injection molding or hot-melt extrusion.

Inventors

BENHABBOUR SOUMYA RAHIMA

JANUSZIEWICZ RIMA

MECHAM SUE J

Latest standardized assignees - inventors removed


UNIVERSITY OF NORTH CAROLINA

Family 112/200 - FAMPAT - ©Questel

Title

(EP3359127)

Methods and compositions for managing reproduction

Images**FIG 1****Publication data including kind & date**

GB201616851	D0	2016-11-16	GB201616851
CA3003668	A1	2017-04-13	CA3003668
WO2017060685	A1	2017-04-13	WO2017060685
GB2548649	A	2017-09-27	GB2548649
AU2016334795	A1	2018-05-24	AU2016334795
SG11201803604U	A	2018-05-30	SG11201803604U
CN108289836	A	2018-07-17	CN108289836
EP3359127	A1	2018-08-15	EP3359127
JP2018531940	A	2018-11-01	JP2018531940

**Abstract**

(EP3359127)

The present invention relates to methods, compositions and kits for controlling, managing or manipulating the non-human mammalian female reproductive cycle. The methods include oestrus induction and/or synchronisation, induction of ovulation and/or superovulation and optionally further includes a method of providing an immunopermissive uterine environment prior to insemination or implantation of embryos.

Inventors

ORSI NICOLAS MICHEL
 GOPICHANDRAN NADIA
 BROOKE DAVID ANDREW

Latest standardized assignees - inventors removed

OSTARA BIOMEDICAL


Family 113/200 - FAMPAT - ©Questel

Title
(EP1423165)

Intravaginal administration of an aromatase inhibitor for the treatment of oestrogen-dependent proliferative disorders

Images

FIG. 1A



Publication data including kind & date

GB0120147	D0	2001-10-10	GB200120147				
WO03015872	A2	2003-02-27	WO200315872				
CA2459434	A1	2003-02-27	CA2459434				
WO03015872	A3	2003-07-10	WO200315872				
EP1423165	A2	2004-06-02	EP1423165				
JP2005501854	A	2005-01-20	JP2005501854				
US20050049231	A1	2005-03-03	US20050049231				
AU2002321498	B2	2008-02-28	AU2002321498				
JP2009102429	A	2009-05-14	JP2009102429				

Abstract

(EP1423165)

The invention relates to a method for the treatment of an oestrogen-dependent proliferative disorder of the uterus such as endometriosis and uterine fibroids in a patient, by administering an aromatase inhibitor to the patient intravaginally. This achieves high local levels of aromatase inhibitor Locally, and therefore avoids some of the adverse reactions that are observed when aromatase inhibitors are delivered orally. Further, intravaginal delivery allows inhibition of the local lesional production without significantly affecting the circulating levels which have been produced by the ovaries. This results in minimal side-effects and will allow for longer term treatment than current therapies.

Inventors

KNOX PETER

PAPPA HELEN

Latest standardized assignees - inventors removed

ARES TRADING

Family 114/200 - FAMPAT - ©Questel

Title

(EP1227814)

Hormonal composition based on norgestrel acetate and an oestrogen and use thereof

Images*10.4***Publication data including kind & date**

WO200130357	A1	2001-05-03	WO200130357				
CA2389025	A1	2001-05-03	CA2389025				
WO200130356	A1	2001-05-03	WO200130356				
AU1032601	A	2001-05-08	AU200110326				
NO20021949	D0	2002-04-25	NO200201949				
NO20021949	L	2002-04-25	NO20021949				
AP200202475	A0	2002-06-30	AP200202475				
KR20020057979	A	2002-07-12	KR20020057979				
EP1227814	A1	2002-08-07	EP1227814				
CZ20021427	A3	2002-08-14	CZ200201427				
IL148953	A	2002-11-10	IL-148953				
BR0014979	A	2002-11-26	BR200014979				
BRPI0014979	A1	2002-11-26	BRPI0014979				
CN1382053	A	2002-11-27	CN1382053				
HU0203721	A2	2003-03-28	HU200203721				
JP2003515531	A	2003-05-07	JP2003515531				

HU0203721	A3	2003-07-28	HU200203721			
MXPA02004084	A	2003-08-20	MX2002PA004084			
ZA200203398	B	2003-12-03	ZA200203398			
RU2002113652	A	2004-03-27	RU2002113652			
PL356847	A1	2004-07-12	PL2000356847			
AU777704	B2	2004-10-28	AU-777704			
EP1227814	B1	2005-01-05	EP1227814			
AT286400	T	2005-01-15	ATE286400			
NZ518145	A	2005-01-28	NZ-518145			
DE60017281	D1	2005-02-10	DE60017281			
IN0460/MUMNP/2002	A	2005-03-18	IN2002MN00460			
DK1227814	T3	2005-04-11	DK1227814T			
PT1227814	E	2005-05-31	PT1227814			
SI1227814	T1	2005-06-30	SI1227814T			
HK1050472	A1	2005-07-08	HK1050472			
ES2235967	T3	2005-07-16	ES2235967			
RU2261106	C2	2005-09-27	RU2261106			
DE60017281	T2	2005-12-08	DE60017281			
OA12072	A	2006-05-04	OA--12072			
AP1625	A	2006-07-04	AP---1625			
KR100623788	B1	2006-09-18	KR100623788			
VN0006137	B	2007-03-26	VN---6137B			
IN201239	B	2007-05-05	IN-201239			
IL148953	B	2007-06-03	IL-148953			
PL199848	B1	2008-11-28	PL-199848			
CN100553637	C	2009-10-28	CN100553637C			
NO327973	B1	2009-11-02	NO-327973			
CA2389025	C	2009-12-08	CA2389025			
BRPI0014979	A2	2010-06-15	BR200014979			
US8168619	B1	2012-05-01	US8168619			
CZ303248	B6	2012-06-20	CZ-303248			
JP5036943	B2	2012-07-13	JP5036943			
US20130172300	A1	2013-07-04	US20130172300			
HU229382	B1	2013-11-28	HU-229382			
US9084796	B2	2015-07-21	US9084796			
BRPI0014979	B1	2016-08-02	BR200014979			

Abstract

(EP1227814)

The invention relates to the field of therapeutic chemistry, in particular the field of pharmaceutical hormone technology. More specifically, the invention relates to novel hormonal pharmaceutical compositions comprising an oestrogen-progesterone combination consisting of an oestrogen compound and a progesterone compound combined or mixed with one or more pharmaceutically compatible, inert, non-toxic excipient that is/are suitable for oral administration. The invention also relates to the use of said oestrogen-progesterone mixture in which the oestrogen component and the progesterone component are administered in a combined manner. This combination can be prescribed continuously or intermittently, for treating oestrogen-progesterone deficiencies, for preventing osteoporosis and cardiovascular diseases in menopausal women. The invention also relates to a method for producing these novel pharmaceutical oestrogen-progesterone compositions.

Inventors

PARIS JACQUES

THOMAS JEAN-LOUIS

Latest standardized assignees - inventors removed

THERAMEX

Family 115/200 - FAMPAT - ©Questel

Title

(EP1287817)

Method of treating uterine leiomyomas and intravaginal drug delivery vehicle for use in such method

Publication data including kind & date[EP1287817](#)

A1 2003-03-05 EP1287817

**Abstract**

(EP1287817)

The present invention relates to a method of treating uterine leiomyomas (fibroids or myomas) in mammal females. More particularly the present invention relates to such a method comprising intravaginal administration of a drug delivery vehicle to a female mammal suffering from uterine leiomyomas, said drug delivery vehicle containing an estrogen activity suppressant selected from the group consisting of aromatase inhibitors, anti-estrogens and mixtures thereof, wherein the method provides the estrogen activity suppressant in a therapeutically effective dosage to inhibit the growth and/or to achieve atrophy of the myomas. The intravaginal administration of estrogen activity suppressant, in comparison to other routes of administration, achieves the desired clinical effect at lower dosage levels and/or without seriously affecting overall estrogen blood serum levels. Another aspect of the invention is concerned with a drug delivery vehicle for intravaginal use, which drug delivery vehicle comprises at least 10 mu g of an aromatase inhibitor and/or at least 10 mu g of an anti-estrogen and pharmaceutically acceptable excipient.

Inventors

COELINGH BENNINK HERMAN JAN TI

THIJSSSEN JOSEPH HELENUS HUBERT

Latest standardized assignees - inventors removed

PANTARHEI BIOSCIENCE


Family 116/200 - FAMPAT - ©Questel

Title

(US6264638)

Intravaginal drug delivery system and discharge collection device

Images

**Publication data including kind & date**[US6264638](#)

B1 2001-07-24 US6264638

**Abstract**

(US6264638)

A device is provided for reliably, comfortably and conveniently introducing agents, including drugs and other substances, into the vaginal canal. A discharge collection device is also disclosed. The disclosed devices may be formed of an elastomeric rim and a flexible film. The rim may have a non-circular cross section. The film may be collapsible into a low profile insertion configuration. The devices may be disposable, and may be constructed so as to be convenient to use, comfortable to wear internally, and reliable. Preferably, the devices are formed of thermoplastic material that softens in response to body temperature to provide improved comfort and handling.

Inventors

CONTENTE AUDREY

Latest standardized assignees - inventors removed

BRICKHAVEN II

EVOFEM

Family 117/200 - FAMPAT - ©Questel

Title

(US20140030313)

Treatment of menstrual pain and excessive menstrual blood loss by intravaginal administration of a low dose of antifibrinolytic or hemostatic agent in combination with non-steroidal anti-inflammatory drug

Publication data including kind & date[US20140030313](#)

A1 2014-01-30 US20140030313

**Abstract**

(US20140030313)

A method for relieving menstrual pain and reducing menstrual blood loss in a female is provided. The method comprises administering intravaginally to the female a first therapeutically effective amount of a non-steroidal anti-inflammatory drug (NSAID) that relieves menstrual pain and a second therapeutically effective amount of an active agent that reduces menstrual blood loss, wherein the NSAID and the active agent are simultaneously administered by the same drug delivery

CN1235549	A	1999-11-17	CN1235549				
UA66772	C2	1999-12-29	UA--66772				
BR9710918	A	2000-01-11	BR9710918				
BRPI9710918	A1	2000-01-11	BRPI9710918				
LV12342	B	2000-01-20	LV--12342				
AU715740	B2	2000-02-10	AU-715740				
AR009407	A1	2000-04-12	AR---9407				
US6054447	A	2000-04-25	US6054447				
HU9904045	A2	2000-04-28	HU209904045				
KR20000053056	A	2000-08-25	KR20000053056				
HU9904045	A3	2000-11-28	HU9904045				
NZ335306	A	2000-12-22	NZ-335306				
GEP20022630	B	2001-11-12	GE200202630				
JP2002503215	A	2002-01-29	JP2002503215				
AU715740	C	2004-04-29	AU-715740				
KR100434623	B1	2004-06-05	KR100434623				
IL127455	B	2005-03-20	IL-127455				
MY121627	A	2006-02-28	MY-121627				
EP0956023	B1	2006-03-29	EP-956023				
AT321558	T	2006-04-15	ATE321558				
DE69735598	D1	2006-05-18	DE69735598				
RO120607	B1	2006-05-30	RO-120607				
HK1020534	A1	2006-06-02	HK1020534				
DK0956023	T3	2006-08-07	DK-956023T				
PT956023	E	2006-08-31	PT-956023				
ES2262196	T3	2006-11-16	ES2262196				
DE69735598	T2	2006-12-28	DE69735598				
CA2270565	C	2007-02-20	CA2270565				
NO324278	B1	2007-09-17	NO-324278				
CN100341512	C	2007-10-10	CN100341512C				

Abstract

(EP-956023)

The present invention provides a method of treating or reducing ischemia or incidence of cardiovascular events by administering progesterone. Progesterone, unlike synthetic progestins, has been demonstrated to supplement, rather than to decrease, the beneficial effects of estrogen therapy on myocardial ischemia in females.

Inventors

LEVINE HOWARD L

BOLOGNA WILLIAM J

Latest standardized assignees - inventors removed

COLUMBIA LAB BERMUDA


Family 119/200 - FAMPAT - ©Questel

Title

(US4402695)

Device for delivering agent in vagina

Images

**Publication data including kind & date**[US4402695](#)

A 1983-09-06 US4402695

**Abstract**

(US4402695)

An intravaginal therapeutic system for the pre-programmed, unattended delivery of a drug is disclosed. The system comprises (a) a drug, (b) a delivery module comprising a reservoir for storing the drug in an amount for execution of the program, a rate controller which maintains the rate of drug delivered in a therapeutically effective amount throughout the life of the system, an energy source for transferring drug from the reservoir to the vagina, and a portal for releasing the drug from the module to the vagina, (c) a platform which integrates the module into a unit sized, shaped and adapted for insertion and retention in a vagina, and (d) therapeutic program which provides for the controlled release of drug to produce a beneficial effect over a prolonged period of time.

Inventors

WONG PATRICK S

Latest standardized assignees - inventors removed

ALZA


Family 120/200 - FAMPAT - ©Questel

Title

(EP-923357)

An intra-vaginal device

Images



Publication data including kind & date

WO9842281	A1	1998-10-01	WO9842281
AU6604398	A	1998-10-20	AU9866043
WO9842281	A9	1999-03-25	WO9842281
EP0923357	A1	1999-06-23	EP-923357
EP0923357	A4	2000-06-14	EP-923357
JP2000510757	A	2000-08-22	JP2000510757
US20020007106	A1	2002-01-17	US20020007106
US6413206	B2	2002-07-02	US6413206
AU750463	B2	2002-07-18	AU-750463
EP0923357	B1	2005-07-13	EP-923357
AT299357	T	2005-07-15	ATE299357
DE69830832	D1	2005-08-18	DE69830832



Abstract

(EP-923357)

An intra-vaginal device (30) to aid in controlling urinary incontinence. The device (30) has a base (31) from which there projects a rear part (34). The rear part (34) engages the posterior vaginal wall and rests on the pelvic floor and projects towards the cervix. The base (31) has a convex surface (33) which engages the anterior vaginal wall to support the vaginal wall and the urethra therebehind.

Inventors

BISWAS NICHOLAS

Latest standardized assignees - inventors removed

NIQUOOLA

Family 121/200 - FAMPAT - ©Questel

Title

(WO2017161136)

Acid salts for vaginal drug delivery

Images




Figure 1B




Figure 1A

Publication data including kind & date[WO2017/161136](#)

A1 2017-09-21

WO2017161136

**Abstract**

(WO2017161136)

The disclosure provides a composition comprising a drug that is the salt of one or more basic nitrogen atoms targeted for vaginal delivery and one or more acidic excipients. The disclosure further provides a method comprising administering the

composition to the vagina of a subject, and a kit comprising a container comprising the composition and instructions for the use thereof.

Inventors

BAUM MARC M

GUNAWARDANA MANJULA

MOSS JOHN A

Latest standardized assignees - inventors removed

OAK CREST INSTITUTE OF SCIENCE PASADENA



Family 122/200 - FAMPAT - ©Questel

Title

(EP2585010)

Methods of treating conditions associated with overactive bladder

Images

**FIG. 1****FIG. 2**

Publication data including kind & date

WO2011163356	A2	2011-12-29	WO2011163356				
CA2803872	A1	2011-12-29	CA2803872				
WO2011163356	A3	2012-03-22	WO2011163356				
TW201212910	A	2012-04-01	TW201212910				
US20120107385	A1	2012-05-03	US20120107385				
AU2011270995	A1	2013-01-10	AU2011270995				
SG186815	A1	2013-02-28	SG-186815				
MX2013000002	A	2013-04-29	MX2013000002				
EP2585010	A2	2013-05-01	EP2585010				
AR084700	A1	2013-06-05	AR--84700				
CN103153245	A	2013-06-12	CN103153245				
PE06392013	A1	2013-06-15	PE201300639				
BR112012032953	A1	2013-07-02	BR112012032953				
JP2013534923	A	2013-09-09	JP2013534923				
EA201291299	A1	2013-09-30	EA201291299				
KR20130118296	A	2013-10-29	KR20130118296				
CL2012003658	A1	2014-02-14	CL3658201200				
IN0178/KOLNP/2013	A	2014-02-21	IN2013KN00178				
CL2013003488	A1	2014-08-08	CL3488201300				
EP2585010	A4	2014-10-01	EP2585010				
ZA201209757	B	2015-06-24	ZA201209757				
SG10201504871P	A	2015-07-30	SG10201504871P				

Abstract

(EP2585010)

The present invention is directed to a method of treating a condition associated with an overactive bladder, comprising administering to a female an intravaginal device, comprising: (a) an annular first matrix comprising a pocket and a pocket wall, wherein the pocket wall has a uniform thickness, and wherein the pocket wall encompasses the pocket; and (b) a second matrix comprising an anticholinergic agent located in the pocket.

Inventors

MAHASHABDE ANU

TSAO JIAXIANG

Latest standardized assignees - inventors removed

TEVA WOMENS HEALTH


Family 123/200 - FAMPAT - ©Questel

Title

(CN103784259)

Tampon overwrap

Images



Publication data including kind & date

CN103784259	A	2014-05-14	CN103784259
CN103784259	B	2016-05-18	CN103784259B



Abstract

(CN103784259B)

A packaged elongate intravaginal device is provided and has an overwrap substantially enclosing the device. The overwrap has a longitudinal overlap seam disposed generally parallel to the longitudinal axis. The seam includes one ply of overwrap material disposed at a first margin of a overwrap blank superposed on a second ply of overwrap material disposed at a second margin of the overwrap blank, opposite the first. The overwrap has a substantially continuous line of weakness that intersects a plane including the longitudinal axis of the packaged device at at least three unique locations. The line of weakness extends across the longitudinal overlap seam and includes weakness components superposed in each ply of the overlap seam, and the line of weakness is arranged and configured in a manner to permit the overwrap to remain as a unitary structure upon destruction of the line of weakness.

Inventors

L Robbie

R MILLER

XU YUN, OBIAS HONORIO V., NOVIKOV ALEXANDER, BARNET ALFRED G., THONG STEPHEN H.

Latest standardized assignees - inventors removed

MCNEIL

JOHNSON & JOHNSON


Family 124/200 - FAMPAT - ©Questel

Title

(US20130165308)

Methods of packaging intravaginal devices

Images

**Publication data including kind & date**[US20130165308](#)

A1 2013-06-27

US20130165308

**Abstract**

(US20130165308)

A method of folding a plurality of flexible elements about a central fluid storage element includes of urging an intravaginal device into a folding device; imparting relative rotation between at least a portion of the folding device and the intravaginal device; and contacting the plurality of flexible extensions with the folding device. Wherein the intravaginal device includes a fluid storage element and a plurality of flexible extensions extending therefrom, and the flexible extensions are folded about the fluid storage element in a uniform direction. Alternatively, in place of relative rotation, the flexible extensions are folded by means of guide rails of the folding device. Several apparatus may be employed in this and related methods.

Inventors

BINNER CURT

CARASSO SAMUEL C

CHASE DAVID J

MARSEE ERIN

GLASGOW TARA

KIMBALL DAVID L

IRIS JULIA K

NG TONY C

Latest standardized assignees - inventors removed

JOHNSON & JOHNSON CONSUMER

Abstract

(EP2763680)

Methods and systems for identifying and treating a patient suspected of having a tumor susceptible to growth inhibition by anti-progestins are provided. The degree of focal distribution of the progesterone receptor can be used to identify tumors susceptible to treatment with anti-progestin therapy.

Inventors

GILLES ERARD

Latest standardized assignees - inventors removed


INVIVIS PHARMACEUTICALS

Family 126/200 - FAMPAT - ©Questel

Title

(GB2425260)

Intra-vaginal catamenial device with outlet

Images**Fig 1a****Publication data including kind & date**

GB0508010	D0	2005-05-25	GB200508010
GB2425260	A	2006-10-25	GB2425260

**Abstract**

(GB2425260)

An intra-vaginal catamenial device 10 comprises an inlet 16, an outlet 26 and a collection chamber 12, in which the outlet is moveable in relation to the inlet to outside the vagina for the expression of menstrual fluid. A method of expressing menstrual fluid is also disclosed, comprising pooling fluid within the vagina, moving a fluid outlet 26 from a position within the vagina (Fig. 2a) to a position outside the vagina (Fig. 2b), and actuating flow of the fluid from inside to outside.

Inventors

POTTER CHRISTOPHER DAVID

Latest standardized assignees - inventors removed

KEA FLEX MOULDINGS

Family 127/200 - FAMPAT - ©Questel

Title

(EP1187618)

Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use

Publication data including kind & date

WO200074684	A1	2000-12-14	WO200074684
AU5181200	A	2000-12-28	AU200051812
EP1187618	A1	2002-03-20	EP1187618
JP2003501390	A	2003-01-14	JP2003501390

**Abstract**

(EP1187618)

Disclosed are pharmaceutical formulations containing various combinations of an estrogen, a progestin, an androgen, a selective estrogen receptor modulator, a selective androgen receptor modulator, and/or a selective progestin receptor modulator for use in treating postmenopausal or perimenopausal women. Also disclosed are methods for treating such women with the pharmaceutical formulations of the invention.

Inventors

MARTIN KATHRYN A

CROWLEY WILLIAM F JR

Latest standardized assignees - inventors removed

MASSACHUSETTS GENERAL HOSPITAL

Family 128/200 - FAMPAT - ©Questel

Title

(EP-862396)

Intravaginal rings with insertable drug-containing core

Images

FIG. 1 is a perspective view of a ring-shaped device 10. The device has a central opening 12 and a curved, hinged structure 14 at the bottom. A label 16 points to the outer edge of the ring.

WO9804220	A1	1998-02-05	WO9804220
CA2232635	A1	1998-02-05	CA2232635
AU4043197	A	1998-02-20	AU9740431
MX9802349	A	1998-08-30	MX9802349
EP0862396	A1	1998-09-09	EP-862396
CN1198091	A	1998-11-04	CN1198091
BR9706802	A	1999-08-31	BR9706802
BRPI9706802	A1	1999-08-31	BRPI9706802
US5972372	A	1999-10-26	US5972372
JPH11512965	A	1999-11-09	JP11512965



EP0862396	A4	2000-09-06	EP-862396				
US6126958	A	2000-10-03	US6126958				
CA2232635	C	2002-09-17	CA2232635				
CN1154455	C	2004-06-23	CN1154455C				
EP0862396	B1	2005-03-16	EP-862396				
AT290836	T	2005-04-15	ATE290836				
DE69732760	D1	2005-04-21	DE69732760				
DK862396	T3	2005-07-11	DK-862396T				
PT862396	E	2005-07-29	PT-862396				
ES2239363	T3	2005-09-16	ES2239363				
DE69732760	T2	2006-04-13	DE69732760				
JP3970936	B2	2007-06-15	JP3970936				
BRPI9706802	B1	2007-09-11	BRPI9706802				

Abstract

(EP-862396)

Disclosed is a vaginal ring containing a ring body made of a first polymeric material having at least one hollow internal channel defining an opening to the exterior of said body and which channel is adapted to receive a drug-containing core through said opening, and a core containing at least one intravaginally administerable drug dispersed in a second polymeric material disposed in the channel. The core is positioned in the vaginal ring body suitably prior to use in order to substantially avoid initial bursts of drug into the tissues of the subject and resultant side effects such as nausea and vomiting. Representative drugs include contraceptive agents and other steroidal substances for use in hormone replacement therapy. Also disclosed are methods for preparing the vaginal rings, kits for assembling the vaginal rings, and methods of using the vaginal rings to achieve intravaginal delivery of drugs to a female.

Inventors

SALEH SALEH ISMAIL

NASH HAROLD

BARDIN C WAYNE

HARMON TROY

Latest standardized assignees - inventors removed

POPULATION COUNCIL

Family 129/200 - FAMPAT - ©Questel


Title

(WO201984469)

Devices, systems, and methods for training pelvic floor muscles

Images

FIG. 1

**Publication data including kind & date**[WO2019/084469](#)

A1 2019-05-02

WO201984469

**Abstract**

(WO201984469)

Featured are intravaginal devices and methods of using the devices to observe the state of an individual's pelvic floor muscles in order to diagnose, treat, or prevent pelvic floor disorders (e.g., pelvic organ prolapse and incontinence) and their accompanying symptoms and methods of using the devices to treat or prevent vaginal disorders (e.g., skin laxity) in a subject using an energy transmitter (e.g., a radiofrequency transmitter).

Inventors

BEER, Marc, D.

IGLESIAS, Ramon, Jose

LORIE, Yolanda

Latest standardized assignees - inventors removed

RENOVIA

Family 130/200 - FAMPAT - ©Questel

Title

(EP3154519)

Intravaginal formulations comprising gnrh

Images

FEENSTRA KENNETH L

LUO LAIBIN

SUCHETA SUSAN C

WICKS NICHOLAS A

KOLBASA KAREN P

Latest standardized assignees - inventors removed

ZOETIS SERVICES

Family 131/200 - FAMPAT - ©Questel


Title

(EP3106167)

Method for on-demand contraception

Images

I

**Publication data including kind & date**

WO2010119029	A1	2010-10-21	WO2010119029
CA2757496	A1	2010-10-21	CA2757496
AU2010237120	A1	2011-11-03	AU2010237120
IL215524	A	2011-12-29	IL-215524
EP2419108	A1	2012-02-22	EP2419108
CN102395373	A	2012-03-28	CN102395373
US20120122828	A1	2012-05-17	US20120122828
ZA201107543	B	2012-06-27	ZA201107543
JP2012523446	A	2012-10-04	JP2012523446
BRPI1014035	A1	2012-12-04	BR201014035
RU2011146058	A	2013-05-20	RU2011146058
NZ595790	A	2013-11-29	NZ-595790
NZ615430	A	2014-06-27	NZ-615430
RU2542779	C2	2015-02-27	RU2542779
US20150174140	A1	2015-06-25	US20150174140
AU2010237120	B2	2015-10-22	AU2010237120
AU2010237120	B8	2015-11-26	AU2010237120



US9283233	B2	2016-03-15	US9283233				
BRPI1014035	A2	2016-04-12	BR201014035				
JP5951480	B2	2016-06-17	JP5951480				
EP2419108	B1	2016-08-17	EP2419108				
US20160317555	A1	2016-11-03	US20160317555				
JP2016188232	A	2016-11-04	JP2016188232				
PT2419108	T	2016-11-07	PT2419108T				
DK2419108	T3	2016-12-05	DK2419108T				
EP3106167	A1	2016-12-21	EP3106167				
LT2419108	T	2016-12-27	LT2419108				
SMT201600399	B	2017-01-10	SMT201600399				
HRP20161437	T1	2017-02-10	HRP20161437				
ES2602134	T3	2017-02-17	ES2602134				
ME02548	B	2017-02-20	ME---2548				
HUE029434	T2	2017-02-28	HUE029434				
SI2419108	T1	2017-02-28	SI2419108T				
RS55331	B1	2017-03-31	RS--55331				
US9616073	B2	2017-04-11	US9616073				
CY1118236	T1	2017-06-28	CY1118236				
PL2419108	T3	2017-08-31	PL2419108				
HK1232150	A1	2018-01-05	HK1232150				
US10159681	B2	2018-12-25	US10159681				

Abstract

(EP3106167)

The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17 α -acetoxy-11b-[4-N, N-dimethylamino-phenyl]-19-norpregna- 4, 9-diene-3, 20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.

Inventors

ULMANN ANDRÉ

GAINER ERIN

BLITHE DIANA

NIEMAN LYNNETTE

MATHE HENRI CAMILLE

Latest standardized assignees - inventors removed

LABORATOIRE HRA PHARMA

US DEPARTMENT OF HEALTH & HUMAN SERVICES

Family 132/200 - FAMPAT - ©Questel

Title

(EP1541168)

Method of synchronising ovulation in cattle

Images

Figure 1: protocol





Figure 2: Percentage of fertility after AI – Example 1

**Publication data including kind & date**

EP1541168	A1	2005-06-15	EP1541168
EP1541168	B1	2010-11-24	EP1541168
AT489097	T	2010-12-15	ATE489097
DE602004030206	D1	2011-01-05	DE602004030206
ES2354978	T3	2011-03-21	ES2354978

**Abstract**

(EP1541168)

A method for synchronising ovulation in cattle by sequential administration of GnRH together with a progesterone delivery device, prostaglandin F2 alpha , and PMSG together with the removal of the progesterone delivery device, followed by fixed time artificial insemination.

Inventors

DRIANCOURT MARC-ANTOINE

Latest standardized assignees - inventors removed

INTERVET INTERNATIONAL

Family 133/200 - FAMPAT - ©Questel

Title

(EP1485103)

Sulfatase inhibiting continuous progestogen contraceptive regimens

Images




FIGURE 1

Publication data including kind & date

WO03077925	A1	2003-09-25	WO200377925
CA2478206	A1	2003-09-25	CA2478206
AU2003213842	A1	2003-09-29	AU2003213842
US20030225048	A1	2003-12-04	US20030225048
EP1485103	A1	2004-12-15	EP1485103
JP2005519962	A	2005-07-07	JP2005519962
CN1652797	A	2005-08-10	CN1652797



Abstract

(EP1485103)

A method of contraception is described comprising the step of administering to a menstruating female a cycle of contraceptive therapy, said cycle of therapy including, for at most 35 successive days, the administration of a combination of an estrogen and a progestogen in a contraceptively effective daily dosage wherein said progestogen is a potent sulfatase inhibiting progestogen and said cycle of therapy including 4-8 days in which said progestogen is administered in the absence of estrogen administration following said at most 35 successive days.

Inventors

CAUBEL PATRICK MICHEL
FRIEDMAN ANDREW JOSEPH

Latest standardized assignees - inventors removed

JANSSEN PHARMACEUTICA

Family 134/200 - FAMPAT - ©Questel

Title

Intravaginal drug delivery devices for the administration of 17beta-oestradiol precursors

Images




FIG. 1

IL116433	A	1996-03-31	IL-116433
IES950959	A2	1996-06-26	IES9500959
IES68528	B2	1996-06-26	IE-S68528
WO9619196	A1	1996-06-27	WO9619196
CA2207622	A1	1996-06-27	CA2207622
AU4399196	A	1996-07-10	AU9643991
TR199501599	A2	1996-07-21	TR199501599



PE62796	A1	1996-12-28	PE9600627			
NO972798	D0	1997-06-17	NO9702798			
FI972579	A	1997-06-17	FI9702579			
FI972579	A0	1997-06-17	FI9702579			
NO972798	L	1997-08-19	NO-972798			
EP0799025	A1	1997-10-08	EP-799025			
AR002010	A1	1998-01-07	AR---2010			
CN1170353	A	1998-01-14	CN1170353			
AU692659	B2	1998-06-11	AU-692659			
JPH10510825	A	1998-10-20	JP10510825			
US5855906	A	1999-01-05	US5855906			
EP0799025	B1	1999-03-31	EP-799025			
AT178204	T	1999-04-15	ATE178204			
DE69508791	D1	1999-05-06	DE69508791			
ES2133841	T3	1999-09-16	ES2133841			
DK0799025	T3	1999-10-18	DK-799025T			
GR3030614	T3	1999-10-29	GR3030614			
NZ298490	A	1999-11-29	NZ-298490			
DE69508791	T2	1999-12-02	DE69508791			
IL116433	B	2002-02-10	IL-116433			
CN1138526	C	2004-02-18	CN1138526C			
NO316707	B1	2004-04-13	NO-316707			
CA2207622	C	2006-10-17	CA2207622			
FI119414	B	2008-11-14	FI-119414			

Abstract

(EP-799025)

The invention relates to an intravaginal drug delivery device for administration to a female mammal of certain 17 beta - oestradiol precursors at a substantially constant rate for a period of at least three weeks. The 17 beta -oestradiol precursor is a 17 beta -oestradiol moiety in which the, or each, hydroxyl group of the 17 beta -oestradiol moiety is blocked by a blocking group, which blocking group is readily removed from the 17 beta -oestradiol moiety in vivo. The 17 beta -oestradiol precursor must either have a solubility in liquid silicone of not less than 0.1 mg/100 ml or have a standard k value of not less than 0.1 mu g/day/mm. The 17 beta -oestradiol precursor must also have a solubility in distilled water of not less than 1 mu g/100 ml.

Inventors

MCCLAY ALLEN

Latest standardized assignees - inventors removed

GALEN

PROCTER & GAMBLE PHARMACEUTICALS

WARNER CHILCOTT

WARNER CHILCOTT PHARMACEUTICALS


Family 135/200 - FAMPAT - ©Questel

Title

(US5069906)

Intra-vaginal device and method

Images

**Publication data including kind & date**[US5069906](#)

A 1991-12-03 US5069906

**Abstract**

(US5069906)

The invention disclosed provides an intra-vaginal device prepared using ingredients which slowly release in the vagina over a significant period of time. The present intra-vaginal device also usefully serves as a drug release means for controllably releasing a drug in the vagina. A method for controlled drug release in the vagina is also disclosed.

Inventors

COHEN ROBERT S

PIERCE JAMES M

KINSEY WILLIAM H

Latest standardized assignees - inventors removed

CONTRACT FURNITURE DESIGN

BELMAC MAXIMED PARTNERSHIP

BENTLEY PHARMACEUTICALS

Family 136/200 - FAMPAT - ©Questel

Title

(WO2018128956)

Contraceptive use of triterpenoids

Publication data including kind & date[WO2018128956](#)

A1 2018-07-12 WO2018128956

**Abstract**

(WO2018128956)

Disclosed are systemic and intravaginal non-hormonal contraceptives comprising a spermicidal triterpenoid. The contraceptive may be in the form of a foam, cream or gel, or in unit form of a pill, vaginal contraceptive film (VCF), suppository, sponge, transdermal or hypodermal patches or a slow release intravaginal device or intrauterine device such

as a drug-impregnated silicone elastomer vaginal ring or polymeric IUD.

Inventors

LISHKO POLINA V

MANNOWETZ NADJA

Latest standardized assignees - inventors removed

UNIVERSITY OF CALIFORNIA

Family 137/200 - FAMPAT - ©Questel

Title

(EP3125964)

Contraceptive and related device

Publication data including kind & date

CA2944436	A1	2015-10-08	CA2944436			
WO2015/153817	A1	2015-10-08	WO2015153817			
US20170020718	A1	2017-01-26	US20170020718			
EP3125964	A1	2017-02-08	EP3125964			
CN106456838	A	2017-02-22	CN106456838			
IN201617036424	A	2017-03-24	IN201617036424			
JP2017517288	A	2017-06-29	JP2017517288			
EP3125964	A4	2018-02-28	EP3125964			

Abstract

(EP3125964)

An intravaginal ring for the controlled release of at least one bioactive agent may further contain at least one of a non-bioabsorbable microparticulate ion-exchanging polymer, a fully bioabsorbable polymeric matrix, a biostable hydrophilic elastomeric polymeric matrix, a biostable amphiphilic elastomeric polymeric matrix, a biostable elastomeric polymeric matrix containing an inorganic microparticulate, and a biostable elastomeric porous polymeric matrix, each to aid in the release and/or modulate the release of the bioactive agent.

Inventors

GRAY KENNETH DAVID JR

VAUGHN MICHAEL AARON

HILAS GEORGIOS THEOFANIS

Latest standardized assignees - inventors removed

POLY MEDICAL


Family 138/200 - FAMPAT - ©Questel

Title

(EP2799043)

Vaginal ring including meloxicam and an agent for modulating the release of the active principle, which can be used as a continuous-use contraceptive in women

Images

FIGURE 1

UY34554	A	2013-01-31	UY--34554				
CA2860108	A1	2013-07-04	CA2860108				
WO2013098591	A1	2013-07-04	WO201398591				
CL2011003351	A1	2014-06-06	CL3351201100				
AR088705	A1	2014-07-02	AR--88705				
BR112014015053	A1	2014-08-19	BR112014015053				
MX2014007523	A	2014-08-27	MX2014007523				
KR20140112040	A	2014-09-22	KR20140112040				
EP2799043	A1	2014-11-05	EP2799043				
CN104203169	A	2014-12-10	CN104203169				
EA201491167	A1	2014-12-30	EA201491167				
JP2015503544	A	2015-02-02	JP2015503544				
EP2799043	A4	2015-08-05	EP2799043				
US20150328319	A1	2015-11-19	US20150328319				
JP5902318	B2	2016-03-18	JP5902318				
IN5754/CHENP/2014	A	2016-07-01	IN2014CN05754				
CN104203169	B	2016-07-13	CN104203169B				
CA2860108	C	2016-10-04	CA2860108				
US9533050	B2	2017-01-03	US9533050				
BR112014015053	A2	2017-06-13	BR112014015053				
BR112014015053	A8	2017-06-13	BR112014015053				
BR112014015053	A8	2017-06-27	BR112014015053				
EA027564	B1	2017-08-31	EA--27564				
KR101785414	B1	2017-10-16	KR101785414				
MX354579	B	2018-03-12	MX-354579				
BR112014015053	A8	2018-12-18	BR112014015053				
BR112014015053	A8	2019-04-09	BR112014015053				

Abstract

(EP2799043)

The invention relates to a sustained-release vaginal ring which includes meloxicam and an agent for modulating the release of the active principle, such as polyvinylpyrrolidone K-30, which releases the active principle over at least 90 days and which can be used as a continuous-use contraceptive in women. The vaginal ring preferably includes 5 wt % to 30 wt % of meloxicam, relation to total weight of the formulation.

Inventors

CHEN SHU-CHEN

BELTRÁN APABLAZA MARIANELA DEL CARMEN

Latest standardized assignees - inventors removed

LABORATORIOS ANDROMACO


Family 139/200 - FAMPAT - ©Questel

Title

(EP2272519)

Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications

Images



Publication data including kind & date

WO2009128692	A1	2009-10-22	WO2009128692				
CA2721509	A1	2009-10-22	CA2721509				
IL208723	A	2010-12-30	IL-208723				
EP2272519	A1	2011-01-12	EP2272519				
EP2272519	A4	2011-04-27	EP2272519				
US20110104289	A1	2011-05-05	US20110104289				
CN102056611	A	2011-05-11	CN102056611				
MX2010011296	A	2011-05-19	MX2010011296				
JP2011516606	A	2011-05-26	JP2011516606				
VN27918	A	2011-11-25	VN--27918				
IN7704/DELNP/2010	A	2012-02-24	IN2010DN07704				
BRPI0822165	A2	2015-06-16	BR200822165				

Abstract

(EP2272519)

The invention relates to the development of a method and pharmaceutical compositions for obtaining plasmatic progesterone levels in humans and for maintaining a plasmatic progesterone concentration between 42 and 3.5 ng/mL for eight days as well as maximum plasmatic concentrations (Cmax) between 12 and 42 ng/mL, sufficient for use in different therapeutic options that require said progesterone concentrations.

Inventors

SAVOIR VILBOEUF JOHN CLAUDE
DE GYVES LOPEZ LENA AURELIO
MARTINEZ DE LEON JUAN RAMON

Latest standardized assignees - inventors removed

POSI VISIONARY SOLUTIONS

Family 140/200 - FAMPAT - ©Questel

Title

(EP1755515)

Intravaginal device with fluid transport plates

Images

BINNER CURT

CARASSO SAMUEL C

CHASE DAVID J

DANYI ERIN

GLASGOW TARA

KIMBALL DAVID L

KOZOROVITSKY JULIA

NG TONY C

Latest standardized assignees - inventors removed

JOHNSON & JOHNSON CONSUMER

Family 141/200 - FAMPAT - ©Questel

Title

(EP2617411)

Methods for the Treatment of Endometriosis

Publication data including kind & date

WO2005020880	A2	2005-03-10	WO200520880			
CA2537702	A1	2005-03-10	CA2537702			
AU2004267956	A1	2005-03-10	AU2004267956			
US20050085453	A1	2005-04-21	US20050085453			
WO2005020880	A3	2006-05-26	WO200520880			
EP1660009	A2	2006-05-31	EP1660009			
NO20061502	L	2006-06-02	NO20061502			
MA28083	A1	2006-08-01	MA--28083			
IL174014	A	2006-08-01	IL-174014			
EA200600524	A1	2006-08-25	EA200600524			
VN13088	A	2006-09-25	VN--13088			
BRPI0413200	A	2006-10-03	BR200413200			
BRPI0413200	A1	2006-10-03	BRPI0413200			
CN1845723	A	2006-10-11	CN1845723			
KR20070017946	A	2007-02-13	KR20070017946			
JP2007509032	A	2007-04-12	JP2007509032			
ZA200602695	B	2007-06-27	ZA200602695			
IN1038/DELNP/2006	A	2007-08-17	IN2006DN01038			
TNSN06070	A1	2007-10-03	TN0600070			
EP1660009	A4	2010-02-17	EP1660009			
UA90095	C2	2010-04-12	UA--90095			
IN7561/DELNP/2009	A	2010-07-09	IN2009DN07561			
CN1845723	B	2010-07-21	CN1845723B			
AU2004267956	B2	2010-09-16	AU2004267956			
CN101849906	A	2010-10-06	CN101849906			
HK1095529	A1	2010-11-26	HK1095529			
IN245019	B	2010-12-31	IN-245019			
EA015356	B1	2011-06-30	EA--15356			
CA2537702	C	2012-01-03	CA2537702			
KR20120005062	A	2012-01-13	KR20120005062			
JP2013035866	A	2013-02-21	JP2013035866			
KR101285137	B1	2013-07-11	KR101285137			
EP2617411	A1	2013-07-24	EP2617411			

KR101288265	B1	2013-07-26	KR101288265			
JP5651279	B2	2014-11-21	JP5651279			
EP1660009	B1	2015-01-28	EP1660009			
US20150044291	A1	2015-02-12	US20150044291			
DK1660009	T3	2015-04-27	DK1660009T			
ES2535430	T3	2015-05-11	ES2535430			
PT1660009	E	2015-05-18	PT1660009			
HRP20150440	T1	2015-07-03	HRP20150440			
SI1660009	T1	2015-07-31	SI1660009T			
HUE025239	T2	2016-03-29	HUE025239			
US9468647	B2	2016-10-18	US9468647			
US9532995	B2	2017-01-03	US9532995			
CY1116267	T1	2017-02-08	CY1116267			
VN0016595	B	2017-03-27	VN--16595B			
IN285557	B	2017-07-28	IN-285557			
BRPI0413200	A2	2018-12-11	BRPI0413200			

Abstract

(EP2617411)

Endometriosis, including endometriosis externa, endometrioma, adenomyosis, adenomyomas, adenomyotic nodules of the uterosacral ligaments, and endometriotic nodules, such as scar endometriosis are effectively treated by the intralesional administration, including transvaginal, endoscopic or open surgical administration including via laparotomy, of a progestogen. Compositions therefor also are provided.

Inventors

GOVINDARAJAN MIRUDHUBASHINI

Latest standardized assignees - inventors removed

MISCON TRADING

Family 142/200 - FAMPAT - ©Questel

Title

(EP-559240)

Contraceptive packages containing oestrogen and progestin

Publication data including kind & date

NO884230	D0	1988-09-23	NO8804230			
FI884378	A0	1988-09-23	FI8804378			
DK529688	D0	1988-09-23	DK8805296			
FI884378	A	1989-03-25	FI8804378			
NO884230	L	1989-03-28	NO-884230			
EP0309263	A2	1989-03-29	EP-309263			
AU2276088	A	1989-04-06	AU8822760			
JP01132523	A	1989-05-25	JP01132523			
DK529688	A	1989-05-25	DK8805296			
EP0309263	A3	1989-08-02	EP-309263			
HUT50043	A	1989-12-28	HU-T50043			
CN1041528	A	1990-04-25	CN1041528			
NZ226316	A	1991-10-25	NZ-226316			
AU630334	B2	1992-10-29	AU-630334			
AU3044892	A	1993-02-11	AU9230448			
EP0559240	A2	1993-09-08	EP-559240			
EP0559240	A3	1993-12-22	EP-559240			

EP0309263	B1	1994-03-09	EP-309263			
AT102484	T	1994-03-15	ATE102484			
DE3888269	D1	1994-04-14	DE3888269			
DE3888269	T2	1994-07-07	DE3888269			
ES2061672	T3	1994-12-16	ES2061672			
NO301689	B1	1997-12-01	NO-301689			
HU214598	B	1998-04-28	HU-214598			
FI101601	B	1998-07-31	FI-101601			
CN1042296	C	1999-03-03	CN1042296C			
JP11286446	A	1999-10-19	JP11286446			
JP3208482	B2	2001-09-10	JP3208482			
EP0559240	B1	2001-12-05	EP-559240			
AT209919	T	2001-12-15	ATE209919			
DE3856508	D1	2002-01-17	DE3856508			
DK174071	B1	2002-05-21	DK-174071			
DE3856508	T2	2002-06-06	DE3856508			
ES2169030	T3	2002-07-01	ES2169030			
JP3314207	B2	2002-08-12	JP3314207			
IE20030160	A1	2003-07-09	IE60200301			

Abstract

(EP-559240)

This invention is concerned with a contraceptive formulation and a method of contraception which employs a combination of estrogen and progestin and wherein a short period of relatively dominant estrogenic activity alternates with a short period of relatively dominant progestagenic activity. The invention also concerns a hormonal replacement formulation and method for use in menopausal or castrate women which employs a similar combination of estrogen and progestin.

Inventors

CASPER ROBERT F

Latest standardized assignees - inventors removed

JENCAP RESEARCH

Family 143/200 - FAMPAT - ©Questel

Title

(WO2012138542)

Treatment of menstrual pain and excessive menstrual blood loss by intravaginal administration of a low dose of antifibrinolytic or hemostatic agent in combination with non-steroidal anti-inflammatory drug

Publication data including kind & date

WO2012138542	A1	2012-10-11	WO2012138542			
DE202012012761	U1	2013-12-19	DE202012012761			

Abstract

(WO2012138542)

The present invention relates to the relief of menstrual pain and the reduction of menstrual blood loss by simultaneous intravaginal administration of a non-steroidal anti-inflammatory drug in combination with a low dose of an antifibrinolytic or hemostatic agent. This treatment can be used by women with painful menstrual periods (including those clinically diagnosed with dysmenorrhea) accompanied with heavy menstrual bleeding (including those clinically diagnosed with menorrhagia).

Inventors

RUBIN ARKADY

Latest standardized assignees - inventors removed

ARSTAT

Family 144/200 - FAMPAT - ©Questel

Title

(EP1482946)

Progesterone oral drug delivery system

Publication data including kind & date

WO03077923	A1	2003-09-25	WO200377923
CA2479295	A1	2003-09-25	CA2479295
AU2002242339	A1	2003-09-29	AU2002242339
EP1482946	A1	2004-12-08	EP1482946
CN1622810	A	2005-06-01	CN1622810
JP2005526083	A	2005-09-02	JP2005526083



Abstract

(EP1482946)

Provided is an oral dosage form suitable to deliver a combined dosage of progesterone and which upon delivery through the gastrointestinal tract provides a blood concentration of from about 0.1 ng/ml to about 400 ng/ml progesterone; said dosage form comprising a combination that includes (a) a first solid form comprising from about 25 mg to about 500 mg micronized progesterone in a solid polyethylene glycol carrier having an average molecular weight of from about 1000 to 10,000 and constituting at least about 30 % of said first solid form; and (b) a second solid form comprising an estrogen.

Inventors

TAN DOMINGO Y

Latest standardized assignees - inventors removed

WATSON PHARMACEUTICALS


Family 145/200 - FAMPAT - ©Questel

Title

(WO200280827)

Menstrual fluid collection device

Images

**Publication data including kind & date**[GB0108801](#)

D0 2001-05-30

GB200108801

[WO02080827](#)

A1 2002-10-17

WO200280827

**Abstract**

(WO200280827)

A menstrual fluid collection device (1) intended for intra-vaginal use comprises: (i) a generally cup-shaped collection body (2) of liquid-proof, soft elastomeric material, (ii) a flexing spring member (4) to which one half of the mouth of the cup (2) is attached, said spring member (4) having a first concave configuration which serves to maintain the mouth of the cup open, and (v) a string (5) attached to said spring member. The device (1) is such that pulling on the string (5) when the spring member (4) is in the first concave configuration causes the spring member (4) to adopt a second convex configuration in which the spring member seals the mouth of the body.

Inventors

WILLIAMS ALEX

SUN QIAN

Latest standardized assignees - inventors removed

UNIVERSITY OF SALFORD





Family 146/200 - FAMPAT - ©Questel

Title

(US3545439)

Medicated devices and methods

Images

*fig 1**fig 2**fig 3**fig 4*

BE726454	A	1969-07-03	BE-726454				
NL6818655	A	1969-07-08	NL6818655				
DE1900196	A1	1969-07-31	DE1900196				
GT196811877	A	1970-05-29	GT196811877				
ES360946	A1	1970-08-01	ES-360946				
US3545439	A	1970-12-08	US3545439				
FR1604934	A	1971-05-15	FR1604934				
GB1252021	A	1971-11-03	GB1252021				
BR6905338	D0	1973-03-07	BR6905338				
SE369375	B	1974-08-26	SE-369375				
CH554172	A	1974-09-30	CH-554172				
MY7500059	A	1975-12-31	MY7500059				
CA985173	A	1976-03-09	CA-985173				
JPS5125677	B2	1976-08-02	JP76025677				

Abstract

(US3545439)

1,252,021. Medicated devices. UPJOHN CO. 2 Jan., 1969 [4 Jan., 1968], No. 339/69. Heading A5R. A medicated resilient generally annular device for intravaginal use in female mammals, in which the body of the device comprises a polymeric drug-permeable substance and includes a medicament which may be released into the vagina by diffusion through the body. The medicament may be disposed throughout the body or located in one or more cavities in the body. The polymer may be an organopolysiloxane elastomer and the medicament may include progestational compounds or an estrogenic substance. A coiled steel spring may be encased in the body.

(From GB1252021 A)

Inventors

DUNCAN GORDON W

Latest standardized assignees - inventors removed

UPJOHN


Family 147/200 - FAMPAT - ©Questel

Title

(US20190105192)

Combination therapy intravaginal rings

Images

Ring configurations**Publication data including kind & date**

US20150136143	A1	2015-05-21	US20150136143
US10137031	B2	2018-11-27	US10137031
US20190105192	A1	2019-04-11	US20190105192

**Abstract**

(US20190105192)

The present invention provides improved intravaginal drug delivery devices, i.e., intravaginal rings, useful for the prophylactic administration of dapivirine in combination with either an antimicrobial compound or a contraceptive to a human. The present invention also provides methods of blocking DNA polymerization by an HIV reverse transcriptase enzyme, methods of preventing HIV infection in a female human, methods of treating HIV infection in a female human, methods of preventing unintended pregnancy in a female human, and methods of preparing intravaginal rings.

Inventors

DEVLIN BRID

HOLT JONATHON DARYLL

BRIMER ANDREW NATHAN

NUTTALL JEREMY PETER

MALCOLM KARL

FETHERSTON SUSAN MARGARET

BOYD PETER JOHN JAMES

Latest standardized assignees - inventors removed

INTERNATIONAL PARTNERSHIP FOR MICROBICIDES


Family 148/200 - FAMPAT - ©Questel

Title

(WO2010138527)

Analytical methods for measuring synthetic progesterone

Images

**Figure 1****Publication data including kind & date**

WO2010138527	A1	2010-12-02	WO2010138527
US20100304426	A1	2010-12-02	US20100304426

**Abstract**

(WO2010138527)

Embodiments relating to methods, processes and systems for measuring progesterone are provided. In particular, methods permit measurement and quantification of synthetic and/or endogenous progesterone from a progesterone-containing blood fluid sample by measuring a progesterone carbon isotope ratio by mass spectrometry and calculating the fraction of synthetic progesterone in the sample from the isotope ratio. Also provided are methods of evaluating bioequivalence of a synthetic progesterone composition using any of the methods provided herein. In an embodiment, methods of precise measurements of plasma levels are described for detection of progesterone analytes such as total progesterone, endogenous animal progesterone, and synthetic progesterone. Correcting for fluctuations in endogenous progesterone levels following application of synthetic progesterone allows a significant reduction in the number of test subjects required to evaluate bioequivalence of a synthetic progesterone composition.

Inventors

OSBORNE DAVID

WINKLER PAUL

Latest standardized assignees - inventors removed

TOLMAR


Family 149/200 - FAMPAT - ©Questel

Title

(JP2011026206)

Method for synchronizing estrus of bovine and kit therefor

Images



Publication data including kind & date

JP2011026206

A 2011-02-10

JP2011026206

JP5435422

B2 2013-12-20

JP5435422

Abstract

(JP5435422)



PROBLEM TO BE SOLVED: To provide a method and a means for estrus synchronization that permits free selection of an estrus synchronization date from the date of the beginning of a treatment.

SOLUTION: The method for synchronizing estrus of a bovine comprises (i) a step of treating a bovine concurrently with a luteolytic drug and an intravaginal indwelling progesterone preparation and (ii) a step of removing the intravaginal indwelling progesterone preparation from the bovine.

COPYRIGHT: (C)2011,JPO&INPIT

Inventors

Naoki Takenouchi

Yuji Hirao

Shimizu

Kosuke Iga

Latest standardized assignees - inventors removed

NATIONAL AGRICULTURE & FOOD RESEARCH ORGANIZATION

Family 150/200 - FAMPAT - ©Questel

Title

(EP1646363)

Intravaginal drug delivery devices

Images




Figure 1




Figure 1 cont.

Publication data including kind & date

WO2005004837	A1	2005-01-20	WO200504837
CA2531640	A1	2005-01-20	CA2531640
IL172620	A	2006-04-10	IL-172620
EP1646363	A1	2006-04-19	EP1646363
WO2005004837	A8	2006-05-18	WO200504837
CN1822815	A	2006-08-23	CN1822815
IN2675/KOLNP/2005	A	2006-10-27	IN2005KN02675
US20070043332	A1	2007-02-22	US20070043332



IN0600/KOLNP/2009	A	2009-05-15	IN2009KN00600
IL172620	B	2011-12-29	IL-172620
CN1822815	B	2012-04-11	CN1822815B
CA2531640	C	2013-06-18	CA2531640
EP1646363	B1	2013-10-16	EP1646363
ES2442675	T3	2014-02-12	ES2442675

**Abstract**

(EP1646363)

The invention relates to an intravaginal drug delivery device comprising at least one reservoir, the, or each, reservoir containing at least one pharmacologically active agent dispersed in a carrier system; and a sheath discontinuously surrounding the at least one reservoir, so that, in use, at least part of that reservoir is directly exposed to the vaginal environment. Preferably, the sheath defines one or more holes or openings, the, or each, hole or opening extending through the sheath to the at least one reservoir, so that at least part of that reservoir is exposed, in use, to the vaginal environment.

Inventors

MALCOLM KARL

WOOLFSON DAVID

Latest standardized assignees - inventors removed

PROCTER & GAMBLE PHARMACEUTICALS

WARNER CHILCOTT PHARMACEUTICALS


ALLERGAN PHARMACEUTICALS INTERNATIONAL

Family 151/200 - FAMPAT - ©Questel

Title

(US4961931)

Method for the management of hyperplasia

Images

[US4961931](#)

A 1990-10-09 US4961931

Abstract

(US4961931)

The invention is for a vaginal dispenser comprising a wall surrounding an internal lumen and having a pair of ends with one end placed inside the other end to form a closed dispenser. A vaginally administrable beneficial agent is housed in the lumen for release by the dispenser over time.

Inventors

WONG PATRICK S-L

Latest standardized assignees - inventors removed


ALZA

Family 152/200 - FAMPAT - ©Questel

Title

(US4250611)

Process for making drug delivery device with reservoir

Images**Publication data including kind & date**[US4250611](#)

A 1981-02-17 US4250611

**Abstract**

(US4250611)

An intravaginal contraceptive system for the pre-programmed, unattended delivery of an antifertility steroid is disclosed. The system comprises (a) an antifertility steroid, (b) a delivery module comprising a reservoir for storing the steroid in an amount for execution of the program, a rate controller which maintains the rate of steroid delivered in a contraceptive effective amount throughout the life of the system, an energy source for transferring steroid from the reservoir to the vagina, and a portal for releasing the steroid from the module to the vagina, (c) a platform which integrates the module into

a unit sized, shaped and adapted for insertion and retention in a vagina, and (d) a contraceptive program which provides for the controlled release of steroid to produce an antifertility effect over a prolonged period of time.

Inventors

WONG PATRICK S

Latest standardized assignees - inventors removed

ALZA

Family 153/200 - FAMPAT - ©Questel

Title

(EP-448644)

Transdermal estrogen/progestin dosage unit and system.

Images

Auswahl- kriterien	Messverfahren		
		direkt $(\omega = 0)$	indirekt $(\omega \neq 0)$
Zeitdauer der Messung		proportional zu der Anzahl der Winkelinkremente; eine hohe Auflösung führt zu einer grossen Messdauer.	unabhängig von der Winkelauflösung; sehr kurze Messdauer (abhängig von der Rotordrehzahl).
Benötigte Messgrössen zur Ermittlung des statischen Momentes		* Motorstrom und * Drehmoment-Strom-Charakteristik des Antriebsmotors; * Winkelposition;	zusätzlich: * Gesamtträgheitsmoment des Prüfsystems; * Drehzahlabhängigkeit des Reibungsmomentes; * Ermittlung der Winkelgeschwindigkeit und Beschleunigung aus $\varphi(t)$.
Unsicherheit des Messresultates		sehr klein;	aufgrund der zusätzlich benötigten Messparameter höhere Unsicherheit.
Gesamtaufwand		umfangreichere Hardware;	grösserer Rechenaufwand für die Auswertung.

Publication data including kind & date

CA2005714	A1	1990-06-16	CA2005714
WO9006736	A1	1990-06-28	WO9006736
AU4831490	A	1990-07-10	AU9048314



NO903619	D0	1990-08-16	NO9003619				
DK195390	D0	1990-08-16	DK9001953				
NO903619	L	1990-10-11	NO-903619				
DK195390	A	1990-10-12	DK9001953				
KR19917000044	A	1991-03-13	KR19917000044				
FI912856	A0	1991-06-13	FI9102856				
EP0448644	A1	1991-10-02	EP-448644				
EP0448644	A4	1992-01-08	EP-448644				
JPH04504109	A	1992-07-23	JP04504109				
JPH0587052	B2	1993-12-15	JP93087052				
AU652336	B2	1994-08-25	AU-652336				
EP0448644	B1	1996-03-27	EP-448644				
AT135924	T	1996-04-15	ATE135924				
DE68926122	D1	1996-05-02	DE68926122				
ES2087149	T3	1996-07-16	ES2087149				
DE68926122	T2	1996-12-19	DE68926122				
CA2005714	C	2000-08-01	CA2005714				

Abstract

(EP-448644)

Transdermal estrogen/progestin absorption dosage units have been developed which comprise a backing layer, an adjoining polymer layer is an adhesive layer in which at least minimum effective dose of an estrogen is dissolved or microdispersed. Adhered to the polymer layer is an adhesive layer in which is dissolved and/or microdispersed at least minimum doses of progestin. Presently preferred is use of the natural estrogen, 17-beta-estradiol, or ethinyl estradiol or combinations thereof and of the progestin. The units have biologically acceptable adhesive and polymer layers. The adhesive layer can have dispersed one or more skin permeation enhancing agents. A separating layer can optionally be used in making the dosage units, which separate the adhesive and polymer layers, which permits estrogen transmission from the polymer layer during treatment. Dosage units are provided which transdermally deliver at least minimum daily doses of the estrogen and progestin for multiple days, such as for one week. The invention also provides a process of fertility control and estrogen replacement therapy using the novel dosage units. Also, the invention provides a fertility control system for fertility control using the novel dosage units.

Inventors

CHIEN YIE W

CHIEN TE-YEN

Latest standardized assignees - inventors removed

RUTGERS UNIVERSITY




Family 154/200 - FAMPAT - ©Questel

Title

(FR2224119)

Intravaginal device.

Images



Publication data including kind & date

BE813298	A	1974-07-31	BE-813298
NL7404545	A	1974-10-08	NL7404545
DE2415607	A1	1974-10-24	DE2415607
FR2224119	A1	1974-10-31	FR2224119
BR7402634	D0	1974-11-19	BR7402634
JPS5029366	A	1975-03-25	JP50029366
ZA7401957	B	1975-05-28	ZA7401957
AU6760874	A	1975-10-09	AU7467608



BR7402634	A	1975-12-09	BR7402634
GB1461847	A	1977-01-19	GB1461847
CH584540	A5	1977-02-15	CH-584540
IT1019572	B	1977-11-30	IT1019572
CA1024839	A	1978-01-24	CA1024839

**Abstract**

(FR2224119)

An intra-vaginal device for a female animal (e.g., dog or cat) formed of an elongate member including a barrier means at its posterior means, an extension element at its anterior means and a coupling means therebetween. The device is inserted so that the barrier means is posterior of the vaginal sphincter muscle and the extension element is anterior of the same. The extension element is of sufficient length to orient the device along the normal undistended vaginal axis. With the device used for contraception, the barrier means is of sufficient size to block penile insertion anterior thereof. The device is capable of long-term retention within the vagina and so is also useful as a vaginal drug delivery system.

(From US3854476 A)

Inventors

DICKINSON III BEN WADE OAKES

Latest standardized assignees - inventors removed

DICKINSON BEN

Family 155/200 - FAMPAT - ©Questel


Title

(EP2533799)

Methods for the use of progestogen as a glucocorticoid sensitizer

Images

FIG. 1



Publication data including kind & date

WO2011/097571	A2	2011-08-11	WO201197571
US20110195031	A1	2011-08-11	US20110195031
US20110262502	A1	2011-10-27	US20110262502
WO2011/097571	A3	2011-12-29	WO201197571
CN102811730	A	2012-12-05	CN102811730
BR112012019725	A1	2012-12-11	BR112012019725
EP2533799	A2	2012-12-19	EP2533799



WO2013006333	A1	2013-01-10	WO201306333				
JP2013518908	A	2013-05-23	JP2013518908				
EP2533799	A4	2013-07-31	EP2533799				
IN1873/MUMNP/2012	A	2013-11-29	IN2012MN01873				
CN103582484	A	2014-02-12	CN103582484				
RU2012135985	A	2014-03-20	RU2012135985				
CN102811730	B	2014-07-09	CN102811730B				
CN103582484	B	2016-01-20	CN103582484B				
US20160045517	A1	2016-02-18	US20160045517				
US20160045396	A1	2016-02-18	US20160045396				
RU2575824	C2	2016-02-20	RU2575824				
JP5913136	B2	2016-04-08	JP5913136				
RU2016101363	A	2018-11-21	RU2016101363				
RU2016101363	A3	2018-11-21	RU2016101363				
US10231976	B2	2019-03-19	US10231976				

Abstract

(EP2533799)

Provided are methods and kits for administering progestogen as a glucocorticoid sensitizer to restore corticosteroid sensitivity or reverse the glucocorticoid insensitivity or enhance glucocorticoid sensitivity, in order to treat one or more glucocorticoid insensitivity related diseases or conditions. For example, these include methods for reversing the glucocorticoid insensitivity in a subject having no history of menstrual cycle-related exacerbation or allergy to self-hormones, particularly progesterone, such as premenstrual or perimenstrual deterioration in the symptoms, e.g., premenstrual worsening of atopic dermatitis or premenstrual exacerbations of asthma, and exhibiting relatively or totally refractory responses to glucocorticoid therapy, e.g., glucocorticoid resistance. The methods and kits provide for the administration of a sex hormone to the subject who is corticosteroid dependent or corticoid resistant or unresponsive or intolerant to corticosteroids.

Inventors

DU TAO TOM

Latest standardized assignees - inventors removed

PRAIRIE PHARMACEUTICALS

Family 156/200 - FAMPAT - ©Questel

Title

(EP3470055)

Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs

Images

Figure 1




Figure 2





Figure 3



Publication data including kind & date

WO2009003125	A1	2008-12-31	WO200903125				
CA2698143	A1	2008-12-31	CA2698143				
US20090004246	A1	2009-01-01	US20090004246				
WO2009003125	A8	2010-02-11	WO200903125				
EP2170276	A1	2010-04-07	EP2170276				
IL202614	A	2010-06-30	IL-202614				
IN8331/DELNP/2009	A	2010-07-23	IN2009DN08331				
CN101827581	A	2010-09-08	CN101827581				
SG195525	A1	2013-12-30	SG-195525				
US8962010	B2	2015-02-24	US8962010				
CA2698143	C	2016-01-19	CA2698143				
IL202614	B	2016-09-29	IL-202614				
IN297833	B	2018-06-19	IN-297833				
EP2170276	B1	2018-08-22	EP2170276				
ES2696999	T3	2019-01-21	ES2696999				
EP3470055	A1	2019-04-17	EP3470055				

Abstract

(EP3470055)

An intravaginal drug delivery device comprises a device body comprising a hydrophobic carrier material having at least one channel defining at least one opening to the exterior of said device body, said at least one channel being adapted to receive at least one drug-containing insert; at least one drug-containing insert positioned in said at least one channel, said drug-containing insert capable of releasing a pharmaceutically effective amount of at least one drug suitable for intravaginal administration and containing about 1% to about 70% of at least one water-soluble release enhancer, both the drug and the water-soluble release enhancer dispersed in an insert carrier material; wherein said hydrophobic carrier material and said insert carrier material may be the same or different; and wherein said at least one drug-containing insert is exposed on said exterior of said device body when said intravaginal drug delivery device is in use.

Inventors

WOOLFSON AARON DAVID

MALCOLM KARL

Latest standardized assignees - inventors removed

ALLERGAN PHARMACEUTICALS INTERNATIONAL

Family 157/200 - FAMPAT - ©Questel

Title


(EP1844765)

Slow release estradiol-progesterone formulation

Images

ESTRADIOL MEAN PLASMA PROFILE. ARITHMETIC SCALE

STUDY No. BIO 2002 01

ESTRADIOL PLASMA PROFILE $\pm$ STANDARD ERROR

Publication data including kind & date

CA2849228	A1	2004-12-23	CA2849228				
WO2004110408	A2	2004-12-23	WO2004110408				
CA2528545	A1	2004-12-23	CA2528545				
AU2004246870	A1	2004-12-23	AU2004246870				
US20050025827	A1	2005-02-03	US20050025827				
WO2004110408	A3	2005-04-14	WO2004110408				
TW200514560	A	2005-05-01	TW200514560				
NO20060200	L	2006-01-13	NO20060200				
IL172466	A	2006-04-10	IL-172466				
EP1663161	A2	2006-06-07	EP1663161				
BRPI0411335	A	2006-07-25	BR200411335				
BRPI0411335	A1	2006-07-25	BRPI0411335				
EA200600029	A1	2006-08-25	EA200600029				
CN1835737	A	2006-09-20	CN1835737				
JP2006527263	A	2006-11-30	JP2006527263				
OA13307	A	2007-04-13	OA--13307				
EP1820494	A2	2007-08-22	EP1820494				
EP1820494	A3	2007-09-19	EP1820494				
EP1844765	A1	2007-10-17	EP1844765				
IN5827/DELNP/2005	A	2007-11-30	IN2005DN05827				
MX2008014654	A	2009-03-09	MX2008014654				
US20090081303	A1	2009-03-26	US20090081303				
IN2777/DELNP/2009	A	2009-06-19	IN2009DN02777				
AU2004246870	B2	2009-07-23	AU2004246870				
IN234817	B	2009-07-31	IN-234817				
US7589082	B2	2009-09-15	US7589082				
EA200900451	A1	2009-12-30	EA200900451				
EA012783	B1	2009-12-30	EA--12783				
EP1820494	B1	2010-01-13	EP1820494				

AT454885	T	2010-01-15	ATE454885				
DE602004025156	D1	2010-03-04	DE602004025156				
CN100594907	C	2010-03-24	CN100594907C				
PT1820494	E	2010-04-14	PT1820494				
DK1820494	T3	2010-05-25	DK1820494T				
ES2340422	T3	2010-06-02	ES2340422				
HK1106717	A1	2010-06-11	HK1106717				
SI1820494	T1	2010-08-31	SI1820494T				
CN101816662	A	2010-09-01	CN101816662				
HK1097735	A1	2010-11-12	HK1097735				
TWI336623	B	2011-02-01	TWI336623				
IL210851	A	2011-04-28	IL-210851				
JP2011157386	A	2011-08-18	JP2011157386				
IL172466	B	2011-11-30	IL-172466				
JP4956185	B2	2012-03-23	JP4956185				
US8163722	B2	2012-04-24	US8163722				
EA018356	B1	2013-07-30	EA--18356				
EA201201221	A1	2014-02-28	EA201201221				
CA2528545	C	2014-08-12	CA2528545				
CY1109967	T1	2014-09-10	CY1109967				
EP1663161	B1	2015-01-14	EP1663161				
EP1844765	B1	2015-01-21	EP1844765				
CN101816662	B	2015-01-28	CN101816662B				
DK1844765	T3	2015-04-27	DK1844765T				
DK1663161	T3	2015-04-27	DK1663161T				
PT1663161	E	2015-05-13	PT1663161				
PT1844765	E	2015-05-20	PT1844765				
SI1844765	T1	2015-05-29	SI1844765T				
SI1663161	T1	2015-05-29	SI1663161T				
ES2537563	T3	2015-06-09	ES2537563				
ES2537551	T3	2015-06-09	ES2537551				
HK1109586	A1	2015-10-02	HK1109586				
HK1147426	A1	2015-11-27	HK1147426				
HUE025147	T2	2016-03-29	HUE025147				
IL210851	B	2016-05-31	IL-210851				
CA2849228	C	2016-09-20	CA2849228				
IN278115	B	2016-12-16	IN-278115				
CY1116203	T1	2017-02-08	CY1116203				
CY1116194	T1	2017-02-08	CY1116194				
EA026709	B1	2017-05-31	EA--26709				
NO341540	B1	2017-12-04	NO-341540				
BRPI0411335	A2	2018-12-04	BRPI0411335				

Abstract

(EP1844765)

The invention provides a method for effecting simultaneous contraception and hormone replacement therapy in a female mammal comprising administering to said mammal a pharmaceutical formulation comprising particles of 17-²-estradiol and cholesterol in about a 1:1 molar ratio, and particles of progesterone; wherein the weight ratio of 17-²-estradiol to progesterone is about 1:40.

Inventors

SAVOIR JOHN CLAUDE

ANGELES URIBE JUAN

Latest standardized assignees - inventors removed

SKENDI FINANCE

Family 158/200 - FAMPAT - ©Questel

Title

(EP-723439)

Combination of progesterone antagonists and anti-oestrogens with partial agonistic action for use in hormone-replacement therapy for peri- and post-menopausal women

Publication data including kind & date

DE4335876	A1	1995-04-20	DE4335876			
WO9511013	A2	1995-04-27	WO9511013			
CA2174327	A1	1995-04-27	CA2174327			
AU7856494	A	1995-05-08	AU9478564			
WO9511013	A3	1995-06-29	WO9511013			
NO961502	D0	1996-04-16	NO9601502			
NO961502	L	1996-06-14	NO-961502			
HU9600992	D0	1996-06-28	HU9600992			
EP0723439	A1	1996-07-31	EP-723439			
CZ111196	A3	1996-08-14	CZ9601111			
KR19967004535	A	1996-10-09	KR19967004535			
CN1135176	A	1996-11-06	CN1135176			
HUT74430	A	1996-12-30	HU-T74430			
SK48496	A3	1997-01-08	SK9600484			
JPH09503774	A	1997-04-15	JP09503774			
US5719136	A	1998-02-17	US5719136			
AU691839	B2	1998-05-28	AU-691839			
CZ285690	B6	1999-10-13	CZ-285690			
EP0723439	B1	2000-09-13	EP-723439			
AT196251	T	2000-09-15	ATE196251			
NO308584	B1	2000-10-02	NO-308584			
DE59409522	D1	2000-10-19	DE59409522			
DK0723439	T3	2000-10-30	DK-723439T			
ES2150503	T3	2000-12-01	ES2150503			
PT723439	E	2001-01-31	PT-723439			
SK281312	B6	2001-02-12	SK-281312			
GR3035054	T3	2001-03-30	GR3035054			
NZ274510	A	2001-03-30	NZ-274510			
KR100348116	B1	2002-11-25	KR100348116			
CN1128613	C	2003-11-26	CN1128613C			
CA2174327	C	2007-05-22	CA2174327			

Abstract

(EP-723439)

PCT No. PCT/EP94/03408 Sec. 371 Date Jul. 5, 1996 Sec. 102(e) Date Jul. 5, 1996 PCT Filed Oct. 17, 1994 PCT Pub. No. WO95/11013 PCT Pub. Date Apr. 27, 1995 This invention describes the use of at least one compound having a progesterone-antagonistic (PA) action and at least one compound having an antiestrogenic (AOE) action with a simultaneous partial agonistic action for the production of pharmaceutical agents for hormone substitution therapy (HRT)

for perimenopausal and postmenopausal women. In the case of combined use of progesterone antagonist and antiestrogen, the stimulation of the endometrium by the progesterone antagonist that is caused by its partial agonistic action when an antiestrogen is used by itself is inhibited. For example, a pharmaceutical agent according to the invention contains onapristone (progesterone antagonist) and tamoxifen (antiestrogen).

Inventors

CHWALISZ KRISTOF

STOECKEMANN KLAUS

Latest standardized assignees - inventors removed

BAYER SCHERING PHARMA

Family 159/200 - FAMPAT - ©Questel

Title

(EP-556908)

Intrauterine and/or intravaginal device

Images




Fig.1

Publication data including kind & date

EP0556908	A1	1993-08-25	EP-556908
NL9200308	A	1993-09-16	NL9200308
JPH0833665	A	1996-02-06	JP08033665
EP0556908	B1	1996-10-09	EP-556908
AT143790	T	1996-10-15	ATE143790
DE69305194	D1	1996-11-14	DE69305194
ES2094457	T3	1997-01-16	ES2094457
DE69305194	T2	1997-03-06	DE69305194
DK0556908	T3	1997-03-17	DK-556908T
GR3022161	T3	1997-03-31	GR3022161
SG48267	A1	1998-04-17	SG--48267

**Abstract**

(EP-556908)

The invention relates to an intrauterine and/or intravaginal device comprising an elongated stem (2). The elongated stem is anchored in the cervix (9) with the aid of a suitable anchoring means (3). The anchoring means is a knot, screw, thread, etc. and forms an integral part of the stem. The anchoring means and the stem are made from a metal and/or metal alloy, usually stainless steel, or from plastic which is acceptable for the body.

Inventors

VAN OS WILLEM ARTHUR ADRIAAN

Latest standardized assignees - inventors removed

TECHNOLOGY DEVELOPMENT

Family 160/200 - FAMPAT - ©Questel

Title

(WO2018202574)

Intravaginal drug delivery system, method for manufacturing such system and its use in gynecological therapies and contraception

Images

Inert carrier ring with punch holes (without inserts)




Fig. 1

Publication data including kind & date

[WO2018202574](#)

A1 2018-11-08

WO2018202574



Abstract

(WO2018202574)

The invention relates to an intravaginal ring consisting of an inert carrier material (A) embedding at least one drug containing insert, wherein the insert(s) are made of a biocompatible polymer material (B) which is enclosed with a cylinder wall (sleeve) made of an inert material impermeable to the drug to reduce the amount of unused drug substance at the end of the wearing period and thus reducing the environmental burden when the IVR is disposed.

Inventors

JUKARAINEN HARRI

RISTO HAKALA

Latest standardized assignees - inventors removed

BAYER

Family 161/200 - FAMPAT - ©Questel

Title

(EP1427390)

Drug delivery system

Images




Fig. 1a




Fig. 1b

Publication data including kind & date

WO03017971	A1	2003-03-06	WO200317971				
CA2457979	A1	2003-03-06	CA2457979				
PE03162003	A1	2003-04-03	PE200300316				
NO20041315	A	2004-03-30	NO200401315				
NO20041315	L	2004-03-30	NO20041315				
KR20040036928	A	2004-05-03	KR20040036928				
EP1427390	A1	2004-06-16	EP1427390				
AR036310	A1	2004-08-25	AR--36310				
CN1549703	A	2004-11-24	CN1549703				
HU0401438	A2	2004-11-29	HU200401438				
US20040247674	A1	2004-12-09	US20040247674				
JP2005503389	A	2005-02-03	JP2005503389				
PL367961	A1	2005-03-07	PL2002367961				
RU2004109575	A	2005-08-20	RU2004109575				
CN1289064	C	2006-12-13	CN1289064C				
RU2302883	C2	2007-07-20	RU2302883				
AU2002313517	B2	2007-09-06	AU2002313517				
HU0401438	A3	2008-04-28	HU200401438				

Abstract

(EP1427390)

The invention relates to a delivery system comprising at least one core and a membrane. The core and the membrane consist of an elastomer composition comprising e.g. poly (dimethylsiloxane), a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units and/or poly(alkylene oxide) groups, present as alkoxy-terminated grafts or blocks linked to the polysiloxane units by silicon-carbon bonds, or as a mixture of these forms. The delivery system is preferably an implant or an intrauterine, intracervical or intravaginal system.

Inventors

HAAPAKUMPU TIMO

ALA-SORVARI JUHA

AALTONEN MARKO

KEINAENEN ANTTI

AHOLA MANJA

Latest standardized assignees - inventors removed

BAYER

Family 162/200 - FAMPAT - ©Questel

Title

(EP3079660)

Drug delivery system.

Images




FIG.1

Publication data including kind & date

US20150157561	A1	2015-06-11	US20150157561
CA2931559	A1	2015-06-18	CA2931559
WO2015086491	A1	2015-06-18	WO201586491
TW201607563	A	2016-03-01	TW201607563
AU2014363724	A1	2016-05-26	AU2014363724
AP201609223	A0	2016-05-31	AP201609223
BR112016013325	A1	2016-06-21	BR112016013325
IL245544	A	2016-06-30	IL-245544
PH12016501083	A1	2016-07-25	PH12016501083
SG11201604660V	A	2016-07-28	SG11201604660V
PE06802016	A1	2016-07-31	PE201600680
DOP2016000132	A	2016-07-31	DO2016000132
KR20160095110	A	2016-08-10	KR20160095110



CR20160261	A	2016-08-16	CR20160261				
IN201647017530	A	2016-08-31	IN201647017530				
CN105979930	A	2016-09-28	CN105979930				
EA201691193	A1	2016-09-30	EA201691193				
MX2016007681	A	2016-10-14	MX2016007681				
EP3079660	A1	2016-10-19	EP3079660				
MD20160079	A2	2016-10-31	MD20160079				
SV2016005214	A	2016-11-21	SV2016005214				
VN49437	A	2016-11-25	VN--49437				
CL2016001459	A1	2016-12-09	CL1459201600				
JP2016539991	A	2016-12-22	JP2016539991				
AU2014363724	B2	2017-02-23	AU2014363724				
BR112016013325	A2	2017-08-08	BR112016013325				
HK1224208	A1	2017-08-18	HK1224208				
TN2016000171	A1	2017-10-06	TN2016000171				
KR101808977	B1	2017-12-13	KR101808977				
JP6251396	B2	2017-12-20	JP6251396				
CA2931559	C	2018-03-15	CA2931559				
MA39059	A1	2018-08-31	MA--39059				
EA031802	B1	2019-02-28	EA--31802				

Abstract

(EP3079660)

Described herein is an intra-vaginal drug delivery system comprising (i) a core comprising a first thermoplastic polymer and a first therapeutic agent, wherein the first therapeutic agent is dissolved in the first thermoplastic polymer, and (ii) a skin surrounding the core comprising a second thermoplastic polymer, wherein the first therapeutic agent is less permeable in the second thermoplastic polymer than the first thermoplastic polymer, and a second therapeutic agent in solid form, wherein the second therapeutic agent is loaded in a portion of the skin.

Inventors

VERHOEVEN WILLY J H

DE GRAAFF WOUTER

Latest standardized assignees - inventors removed

MERCK SHARP & DOHME

Family 163/200 - FAMPAT - ©Questel

Title

(EP-929304)

Prevention of ovarian cancer by administration of progestin products

Publication data including kind & date

WO9810771	A1	1998-03-19	WO9810771			
CA2265697	A1	1998-03-19	CA2265697			
AU4424297	A	1998-04-02	AU9744242			
EP0929304	A1	1999-07-21	EP-929304			
US6028064	A	2000-02-22	US6028064			
WO9810771	A8	2000-09-28	WO9810771			
US6310054	B1	2001-10-30	US6310054			
US6319911	B1	2001-11-20	US6319911			
US20020028795	A1	2002-03-07	US20020028795			
US6977250	B2	2005-12-20	US6977250			

Abstract

(EP-929304)

The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as estrogen products.

Inventors

HUGHES CLAUDE

Latest standardized assignees - inventors removed

NEW LIFE PHARMACEUTICALS

Family 164/200 - FAMPAT - ©Questel

Title

(DE2657845)

Dispenser for retention in vaginal cavity - to release medicaments, contraceptives etc. over prolonged time

Publication data including kind & date

[DE2657845](#)

A1 1978-06-22 DE2657845

**Abstract**

(DE2657845)

Article for use in the vaginal cavity comprises a plurality of containers having walls releasably contng. a biologically active agent (I), the containers being connected by a thin, flexible seal fin in the plane perpendicular to the plane of the article so that the article is circular and each of the containers abuts adjacent containers.

Inventors

DROBISH JAMES LEE

GOUGEON THOMAS WILLIAM

Latest standardized assignees - inventors removed

PROCTER & GAMBLE

Family 165/200 - FAMPAT - ©Questel

Title

(EP-854705)

Hormone dispenser for hormone replacement therapy method

Images

EP0854705	A2	1998-07-29	EP-854705				
PL325978	A1	1998-08-17	PL96325978				
MX9802370	A	1998-08-30	MX9802370				
IL123691	A	1998-10-30	IL-123691				
CN1198093	A	1998-11-04	CN1198093				
HU9802608	A2	1999-02-01	HU9802608				
BR9610915	A	1999-03-30	BR9610915				
BRPI9610915	A1	1999-03-30	BRPI9610915				
US5897539	A	1999-04-27	US5897539				
CZ95598	A3	1999-06-16	CZ9800955				
US5922349	A	1999-07-13	US5922349				
HU9802608	A3	1999-07-28	HU9802608				
JPH11512703	A	1999-11-02	JP11512703				
AU714084	B2	1999-12-16	AU-714084				
KR20000004898	A	2000-01-25	KR20000004898				
IL123691	B	2001-10-31	IL-123691				
PL185848	B1	2003-08-29	PL-185848				
EP0854705	B1	2003-12-03	EP-854705				
AT255406	T	2003-12-15	ATE255406				
DE69630968	D1	2004-01-15	DE69630968				
DK854705	T3	2004-04-13	DK-854705T				
PT854705	E	2004-04-30	PT-854705				
ES2211983	T3	2004-07-16	ES2211983				
CN1158206	C	2004-07-21	CN1158206C				
DE69630968	T2	2004-10-21	DE69630968				
HK1016887	A1	2005-04-29	HK1016887				
NO320491	B1	2005-12-12	NO-320491				
IN2211/DEL/1996	A	2007-01-12	IN1996DE02211				
BRPI9610915	B1	2007-09-11	BR9610915				

Abstract

(EP-854705)

Varying the daily dose of either or both of the estrogen and the progestogen administered for hormone replacement therapy (HRT) is readily and inexpensively accomplished, without the necessity of the physician prescribing a new product each time the daily dose of the estrogen or progestogen is changed, by administering preferably transdermally the estrogen and progestogen contained in separate extrudable pharmaceutical compositions from a dispenser which contains means, preferably adjustable only by the attending physician or dispensing pharmacist, for varying the volume of either or both of the respective compositions which is dispensed as a single dose from the dispenser in response to a defined digital dispensing manipulation of the dispenser, thereby facilitating optimal compliance to a combination HRT with individually adjusted dosages of the estrogen and progestogen. 00000

Inventors

ELLIESEN JOERG

RIEDL JUTTA

Latest standardized assignees - inventors removed

BAYER SCHERING PHARMA


Family 166/200 - FAMPAT - ©Questel

Title


(EP2207544)

Treatment of oestrogen dependant conditions in pre-menopausal women



Images



E1MATE



E2MATE (J995)



Publication data including kind & date

WO2009037539	A2	2009-03-26	WO200937539
CA2698814	A1	2009-03-26	CA2698814
WO2009037539	A3	2009-07-16	WO200937539
KR20100068287	A	2010-06-22	KR20100068287
EP2207544	A2	2010-07-21	EP2207544
US20100204146	A1	2010-08-12	US20100204146
JP2010539153	A	2010-12-16	JP2010539153
JP5543920	B2	2014-05-16	JP5543920
BRPI0817045	A2	2015-03-24	BR200817045

**Abstract**

(EP2207544)

The present invention relates to a method for treating and/or preventing ovarian cycle disturbance, prolonged un-opposed secretion of estrogens, and/or ovarian follicular cyst formation in pre-menopausal women with functional ovaries when treated with steroid sulfatase inhibitors (STS-I) for an estrogen-dependant condition.

Inventors

LOUMAYE ERNEST

GOTTELAND JEAN-PIERRE

Latest standardized assignees - inventors removed


PREGLEM

Family 167/200 - FAMPAT - ©Questel

Title

(EP1658029)

Transdermal hormone delivery system: compositions and methods

Images**Publication data including kind & date**

WO200137770	A1	2001-05-31	WO200137770
CA2391430	A1	2001-05-31	CA2391430
AU1788301	A	2001-06-04	AU200117883



NO20022420	D0	2002-05-22	NO200202420				
NO20022420	L	2002-07-18	NO20022420				
KR20020072280	A	2002-09-14	KR20020072280				
EP1242012	A1	2002-09-25	EP1242012				
IL149655	A	2002-11-10	IL-149655				
CN1399533	A	2003-02-26	CN1399533				
BR0015802	A	2003-06-24	BR200015802				
BRPI0015802	A1	2003-06-24	BRPI0015802				
ZA200203525	B	2003-07-18	ZA200203525				
AR030037	A1	2003-08-13	AR--30037				
MXPA02005224	A	2003-09-25	MX2002PA005224				
JP2003533434	A	2003-11-11	JP2003533434				
IN0573/MUMNP/2002	A	2004-02-28	IN2002MN00573				
NZ518723	A	2004-04-30	NZ-518723				
WO2005002482	A1	2005-01-13	WO200502482				
CA2533312	A1	2005-01-13	CA2533312				
AU2004253593	A1	2005-01-13	AU2004253593				
WO2005002482	A8	2005-03-31	WO200502482				
AU784196	B2	2006-02-23	AU-784196				
MXPA06000542	A	2006-03-30	MX2006PA000542				
TWI253350	B	2006-04-21	TWI253350				
US7045145	B1	2006-05-16	US7045145				
KR20060054320	A	2006-05-22	KR20060054320				
EP1658029	A1	2006-05-24	EP1658029				
EP1242012	A4	2006-05-31	EP1242012				
AU2006201918	A1	2006-06-01	AU2006201918				
IL173152	A	2006-06-11	IL-173152				
IN0047/MUMNP/2006	A	2006-09-01	IN2006MN00047				
CN1835722	A	2006-09-20	CN1835722				
US20070065495	A1	2007-03-22	US20070065495				
IN0439/DELNP/2006	A	2007-08-24	IN2006DN00439				
JP2007524648	A	2007-08-30	JP2007524648				
KR100758757	B1	2007-09-14	KR100758757				
IL149655	B	2008-02-10	IL-149655				
EP1658029	A4	2008-04-16	EP1658029				
AU2006201918	B2	2009-07-30	AU2006201918				
CA2391430	C	2009-10-06	CA2391430				
US20090311312	A1	2009-12-17	US20090311312				
EP1242012	B1	2009-12-30	EP1242012				
US20090324697	A1	2009-12-31	US20090324697				
AT453374	T	2010-01-15	ATE453374				
DE60043621	D1	2010-02-11	DE60043621				
PT1242012	E	2010-03-31	PT1242012				
DK1242012	T3	2010-04-26	DK1242012T				
ES2338860	T3	2010-05-13	ES2338860				
BRPI0015802	A2	2010-06-29	BR200015802				
CN101897683	A	2010-12-01	CN101897683				
CN1835722	B	2010-12-22	CN1835722B				

AU2004253593	B2	2011-01-27	AU2004253593				
IN246164	B	2011-02-25	IN-246164				
HK1096014	A1	2011-09-09	HK1096014				
IL173152	B	2011-09-27	IL-173152				
JP4841781	B2	2011-10-14	JP4841781				
NO331218	B1	2011-11-07	NO-331218				
JP2011231125	A	2011-11-17	JP2011231125				
JP2012092130	A	2012-05-17	JP2012092130				
US8221785	B2	2012-07-17	US8221785				
US8221784	B2	2012-07-17	US8221784				
CN101897683	B	2013-04-03	CN101897683B				
IN256476	B	2013-06-28	IN-256476				
HK1151464	A1	2013-12-13	HK1151464				
US20140072615	A1	2014-03-13	US20140072615				
BR0015802	B1	2014-04-29	BR200015802				
US8883196	B2	2014-11-11	US8883196				
US20150037395	A1	2015-02-05	US20150037395				
CY1110615	T1	2015-04-29	CY1110615				

Abstract

(EP1658029)

A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix comprising an effective amount of at least a progestin hormone, delivery of which is enhanced by one or more skin permeation enhancing agents present in pre-determined amounts. The THDS is capable of providing effective daily doses of progestin and estrogen hormones from a small surface area in contact with the skin, e.g., less than 20 square centimeters. Methods of fertility control and various types of hormone replacement therapy utilizing the THDS are also disclosed.

Inventors

CHIEN TE-YEN

Latest standardized assignees - inventors removed

AGILE THERAPEUTICS

Family 168/200 - FAMPAT - ©Questel

Title

(EP-703802)

Intravaginal delivery system

Images

EP0703802	B1	1999-03-17	EP-703802				
CZ284989	B6	1999-04-14	CZ-284989				
AT177657	T	1999-04-15	ATE177657				
DE69417232	D1	1999-04-22	DE69417232				
ES2130423	T3	1999-07-01	ES2130423				
PL176664	B1	1999-07-30	PL-176664				
EE03202	B1	1999-08-16	EE---3202				
DK703802	T3	1999-10-11	DK-703802T				
GR3030565	T3	1999-10-29	GR3030565				
DE69417232	T2	1999-11-04	DE69417232				
LV12452	A	2000-04-20	LV--12452				
HU217950	B	2000-05-28	HU-217950				
LV12452	B	2000-09-20	LV--12452				
NO311498	B1	2001-12-03	NO-311498				
BRPI9407118	B1	2002-04-02	BR9407118				
KR100312764	B1	2002-11-23	KR100312764				
CN1126574	C	2003-11-05	CN1126574C				
JP3803714	B2	2006-05-19	JP3803714				
CA2165282	C	2006-10-10	CA2165282				

Abstract

(EP-703802)

The object of the present invention is an intravaginal delivery system comprising a flexible support means, and a delivery means carried by the support means and containing active agent. The system is characterized in that the support means (1) consists of a core member (1') substantially in the form of an open ring, and the delivery means consists of at least one sleeve-like polymer body (2) which encircles the core member in a beltwise manner along a part of the length of the core member.

Inventors

LEHTINEN MATTI

TALLING CHRISTINE

Latest standardized assignees - inventors removed

LEIRAS


Family 169/200 - FAMPAT - ©Questel

Title

(EP-235133)

Intravaginal device, particularly for contraception

Images



Publication data including kind & date

WO8602826	A1	1986-05-22	WO8602826
AU5066685	A	1986-06-03	AU8550666
CN85108812	A	1986-06-10	CN85108812
ZA8508646	B	1986-07-30	ZA8508646
FI872017	A	1987-05-06	FI8702017
FI872017	A0	1987-05-06	FI8702017
GB8710743	D0	1987-06-10	GB8710743
JPS62501476	A	1987-06-18	JP62501476
SE8702845	D0	1987-07-13	SE8702845
SE8702845	L	1987-07-13	SE8702845
NL8520373	A	1987-08-03	NL8520373
EP0235133	A1	1987-09-09	EP-235133
DE3590580	D2	1987-09-17	DE3590580
BR8507277	A	1987-10-27	BR8507277
GB2190593	A	1987-11-25	GB2190593
ES548874	A0	1987-12-16	ES-548874
ES8801113	A1	1987-12-16	ES8801113
KR19877000333	A	1987-12-28	KR19877000333
ES557579	A0	1988-03-16	ES-557579
ES8801983	A1	1988-03-16	ES8801983
GB2190593	B	1988-07-20	GB2190593
OA8598	A	1988-11-30	OA---8598
AU580817	B2	1989-02-02	AU-580817
IN164507	B	1989-04-01	IN-164507
ATA362284	A	1989-06-15	AT8403622
EP0235133	B1	1989-10-18	EP-235133
US4883071	A	1989-11-28	US4883071
AT389634	B	1990-01-10	AT-389634
CN1007779	B	1990-05-02	CN1007779B
CH677602	A5	1991-06-14	CH-677602



MX164212	B	1992-07-20	MX-164212
BRPI8507277	A1	1992-11-24	BR8507277
HUT62446	A	1993-05-28	HU-T62446
AR243071	A1	1993-07-30	AR-243071
JPH0728888	B2	1995-04-05	JP95028888
DE3590580	C1	1995-08-31	DE3590580
SE502195	C2	1995-09-11	SE-502195
HU212567	B	1996-08-29	HU-212567



Abstract

(EP-235133)

The intravaginal device is comprised of a plastic body (2) wherein a drug is contained. Said device may be particularly used for contraception. A support (8) is arranged into the body which is formed of a preferably cylindrical block of plastic foam. It has an opening (15) parallel and preferably centred to the axis of the cylinder forming the block. This opening may preferably be a blind hole. The support is arranged in the opening. Said support is connected with the body by means of an element embedded in the foam. The invention also discloses a method for handling said device as well as a handling device for implementing the method for introducing, respectively removing said device.

Inventors

PICKHARD, EWALD

Latest standardized assignees - inventors removed

KNOGLER WOLFGANG

PICKHARD EWALD


Family 170/200 - FAMPAT - ©Questel

Title

(EP2308465)

Transmucosal drug delivery device and method including chemical permeation enhancers

Images



Publication data including kind & date

EP2308465	A2	2011-04-13	EP2308465
US20110087192	A1	2011-04-14	US20110087192
JP2011078770	A	2011-04-21	JP2011078770
EP2308465	A3	2011-12-21	EP2308465
EP2308465	B1	2014-07-23	EP2308465
US8882748	B2	2014-11-11	US8882748



[EP2308465](#)

B8 2014-11-19 EP2308465

[US20150065997](#)

A1 2015-03-05 US20150065997

[JP5715368](#)

B2 2015-03-20 JP5715368

**Abstract**

(EP2308465)

Devices and methods are provided for transmucosal drug delivery. The transmucosal drug delivery device may include a housing configured for intraluminal deployment, such as intravaginally, into a human or animal subject; a drug-dispensing portion which contains at least one drug, the drug-dispensing portion being configured to dispense the drug from the housing by positive displacement; and a permeability enhancer-dispensing portion configured to release or generate a permeability enhancing substance to disrupt at least one region of a mucosal barrier adjacent to the housing at a selected time while intralumenally deployed in the human or animal subject. The device may be operable to dispense the drug from the housing to a region of the mucosal barrier disrupted by the permeability enhancing substance.

Inventors

UHLAND SCOTT

PEETERS ERIC

FATAKDAWALA HUSSAIN

Latest standardized assignees - inventors removed

PALO ALTO RESEARCH CENTER



Family 171/200 - FAMPAT - ©Questel

Title

(EP2227220)

Vaginal delivery system

Images



KR20100090708	A	2010-08-16	KR20100090708				
CR11493	A	2010-08-23	CR--11493				
EP2227220	A1	2010-09-15	EP2227220				
CN101873850	A	2010-10-27	CN101873850				
EA201070639	A1	2010-10-29	EA201070639				
US20100285097	A1	2010-11-11	US20100285097				
IL205588	A	2010-11-30	IL-205588				
JP2011504484	A	2011-02-10	JP2011504484				
CO6290642	A2	2011-06-20	CO6290642				
ZA201002122	B	2011-06-29	ZA201002122				
BRPI0815936	A2	2011-08-30	BR200815936				
IN1521/KOLNP/2010	A	2011-11-25	IN2010KN01521				
NZ584216	A	2012-03-30	NZ-584216				
SG186002	A1	2012-12-28	SG-186002				
EA018112	B1	2013-05-30	EA--18112				

Abstract

(EP2227220)

The present invention is related to an intravaginal delivery system for the controlled release of drospirenone and an estrogen, optionally also comprising one or more therapeutically active or a health-promoting substance capable of giving and/or enhancing protection against bacterial and fungal infections, and/or enhancing protection against sexually transmitted diseases. The delivery system consists of one or more compartments (2, 4, 5), one of each comprising a core (7) and a membrane (3) encasing the core, said core and membrane essentially consisting of a same or different polymer composition, wherein at least one compartment comprises drospirenone and at least one compartment which may be the same or different from the one comprising drospirenone, comprises an estrogen or a mixture of drospirenone and an estrogen, and wherein the membrane or the surface of the membrane or at least one of the cores comprises said therapeutically active or a health-promoting substance.

Inventors

TALLING CHRISTINE

HANES VLADIMIR

KEINAENEN ANTTI

HOLMBERG SVANTE

NIKANDER HANNU

Latest standardized assignees - inventors removed

BAYER

Family 172/200 - FAMPAT - ©Questel


Title

(EP1983998)

Method of treating atrophic vaginitis

Images

(I)

**Publication data including kind & date**

WO2007085020	A2	2007-07-26	WO200785020				
CA2637608	A1	2007-07-26	CA2637608				
AU2007205862	A1	2007-07-26	AU2007205862				
US20070264309	A1	2007-11-15	US20070264309				
WO2007085020	A3	2007-12-21	WO200785020				
IN6312/DELNP/2008	A	2008-10-24	IN2008DN06312				
EP1983998	A2	2008-10-29	EP1983998				
MX2008009177	A	2008-12-05	MX2008009177				
IL192811	A	2009-02-11	IL-192811				
KR20090031847	A	2009-03-30	KR20090031847				
CN101405006	A	2009-04-08	CN101405006				
US20090137538	A1	2009-05-28	US20090137538				
JP2009523831	A	2009-06-25	JP2009523831				
BRPI0706925	A2	2011-04-19	BR200706925				

Abstract

(EP1983998)

This invention relates to a method and pharmaceutical composition useful in treating a condition responsive to hormone replacement therapy. Specifically, the invention is related to the long term treatment of symptoms associated with atrophic vaginitis. The composition contains effective amounts of an estrogen, a progesterone compound and a pharmaceutically accepted vehicle, carrier and/or diluent.

Inventors

CHOLLET JANET A

MERMELSTEIN FRED

Latest standardized assignees - inventors removed

PEAR TREE PHARMACEUTICALS

Family 173/200 - FAMPAT - ©Questel

Title

(EP1279381)

Intravaginal device for prevention of femal urinary incontinence

Images

JP2002503696

A 2002-02-05

JP2002503696

BRPI9908338

A2 2011-12-13

BR9908338

**Abstract**

(EP1054675)

Controlled release compositions and methods for inducing pseudopregnancy in gilts and sows are disclosed. In the preferred embodiment, the formulation includes polylactide microspheres releasing estradiol 17 beta at physiologically useful levels over a period of time between five and thirty days. Following induction of pseudopregnancy, the pseudopregnancy can be terminated and estrus induced by administration of a compound such as PGF2 alpha. The advantages of inducing pseudopregnancy followed by induction of estrus are that the breeding patterns of large numbers of gilts and sows can be controlled.

Inventors

BURNS PATRICK J

Latest standardized assignees - inventors removed


THORN BIOSCIENCE

Family 175/200 - FAMPAT - ©Questel

Title

(EP1201209)

Vaginal discharge collection and drug delivery device

Images**Publication data including kind & date**

WO9400168

A1 1994-01-06

WO9400168

CA2138668

A1 1994-01-06

CA2138668

AU4654793

A 1994-01-24

AU9346547

EP0647144

A1 1995-04-12

EP-647144

EP0647144

A4 1995-08-23

EP-647144

AU684717

B2 1998-01-08

AU-684717

BR9306596

A 1998-12-08

BR9306596

BRPI9306596

A1 1998-12-08

BRPI9306596

CA2138668

C 2001-09-04

CA2138668

BRPI9306596

B1 2001-09-04

BR9306596



EP0647144	B1	2002-03-13	EP-647144
DE69331698	D1	2002-04-18	DE69331698
EP1201209	A2	2002-05-02	EP1201209
DK0647144	T3	2002-05-21	DK-647144T
DE69331698	T2	2002-09-12	DE69331698
EP1201209	A3	2004-02-04	EP1201209
EP1201209	B1	2010-08-11	EP1201209
DE69334341	D1	2010-09-23	DE69334341

**Abstract**

(EP1201209)

A vaginal discharge collection (250) device is formed of an elastomeric trim (252) and a flexible film reservoir (254). The rim (252) may have a generally rectangular cross section and forms a collection space for collecting vaginal discharge. The reservoir (254) may be collapsible so as to be substantially enclosed within the rim (252) when the device is being used. Advantageously, the rim (252) and the reservoir (254) are arranged such that compressing diametrically opposed portions of the rim (252), toward each other causes a leading portion of the rim (252) to dip downwardly to facilitate insertion of the device. The device ergonomically constructed so as to be convenient to use, comfortable to wear internally, and reliable. A system for reliably, comfortably and conveniently introducing agents, including drugs and other substances, into the vaginal canal is also disclosed.

Inventors

CONTENTE AUDREY

POTTER RICHARD C

ROSE BRUCE F

Latest standardized assignees - inventors removed

ULTRAFEM


Family 176/200 - FAMPAT - ©Questel

Title

(EP1159965)

Use of a progesterone receptor antagonist for preventing or inhibiting fertilization

Images



	A1	1994-09-01	CA2156493				
AU6299294	A	1994-09-14	AU9462992				
NO953242	A	1995-08-17	NO9503242				
NO953242	D0	1995-08-17	NO9503242				
NO953242	L	1995-08-17	NO-953242				
FI953878	A	1995-08-17	FI9503878				
FI953878	A0	1995-08-17	FI9503878				
EP0684825	A1	1995-12-06	EP-684825				
PL310357	A1	1995-12-11	PL94310357				
CZ205095	A3	1996-01-17	CZ9502050				
BR9406666	A	1996-01-23	BR9406666				
BRPI9406666	A1	1996-01-23	BRPI9406666				
KR19960700726	A	1996-02-24	KR19967000726				
HUT72079	A	1996-03-28	HU-T72079				
BG99867	A	1996-04-30	BG--99867				
US5516769	A	1996-05-14	US5516769				
JPH08510992	A	1996-11-19	JP08510992				
SK101395	A3	1997-04-09	SK9501013				
NZ262998	A	1997-06-24	NZ-262998				
EP0684825	A4	1998-01-14	EP-684825				
AU692150	B2	1998-06-04	AU-692150				
PL175440	B1	1998-12-31	PL-175440				
RU2139055	C1	1999-10-10	RU2139055				
BG62431	B1	1999-11-30	BG--62431				
KR100232833	B1	1999-12-01	KR100232833				
NO307916	B1	2000-06-19	NO-307916				
JP3054780	B2	2000-06-19	JP3054780				
SK282068	B6	2001-10-08	SK-282068				
EP1159965	A2	2001-12-05	EP1159965				
EP1159965	A3	2002-05-22	EP1159965				
EP0684825	B1	2002-06-05	EP-684825				
AT218347	T	2002-06-15	ATE218347				
DE69430732	D1	2002-07-11	DE69430732				
DK684825	T3	2002-07-15	DK-684825T				
HU221162	B1	2002-08-28	HU-221162				
DE69430732	T2	2002-10-24	DE69430732				
CA2156493	C	2002-10-29	CA2156493				
PT684825	E	2002-10-31	PT-684825				
RO118565	B1	2003-07-30	RO-118565				
CZ294325	B6	2004-11-10	CZ-294325				
FI114687	B	2004-12-15	FI-114687				
EP1159965	B1	2005-01-12	EP1159965				
AT286734	T	2005-01-15	ATE286734				
DE69434239	D1	2005-02-17	DE69434239				
PT1159965	E	2005-03-31	PT1159965				
ES2231356	T3	2005-05-16	ES2231356				
DK1159965	T3	2005-05-23	DK1159965T				
DE69434239	T2	2006-03-30	DE69434239				

Abstract

(EP1159965)

The use of a progesterone receptor antagonist for the preparation of a pharmaceutical composition for preventing an oocyte from becoming fertilized without preventing ovulation or interfering with the regularity of the ovarian menstrual cycle of a mammal.

Inventors

HODGEN GARRY D

Latest standardized assignees - inventors removed


EASTERN VIRGINIA MEDICAL SCHOOL

Family 177/200 - FAMPAT - ©Questel

Title

(US4286587)

Vaginal drug delivery system made from polymer

Images**Publication data including kind & date**

US4215691	A	1980-08-05	US4215691
US4286587	A	1981-09-01	US4286587

**Abstract**

(US4286587)

An intravaginal therapeutic system for the pre-programmed, unattended delivery of a drug is disclosed. The system comprises (a) a drug, (b) a delivery module comprising a reservoir for storing the drug in an amount for execution of the program, a rate controller which maintains the rate of drug delivered in a therapeutically effective amount throughout the life of the system, an energy source for transferring drug from the reservoir to the vagina, and a portal for releasing the drug

from the module to the vagina, (c) a platform which integrates the module into a unit sized, shaped and adapted for insertion and retention in a vagina, and (d) therapeutic program which provides for the controlled release of drug to produce a beneficial effect over a prolonged period of time.

Inventors

WONG PATRICK S

Latest standardized assignees - inventors removed

ALZA

Family 178/200 - FAMPAT - ©Questel

Title

(EP2117554)

Progesterone for the prevention of preterm birth

Images

Demographics and Pre-treatment Subject Characteristics

	Descriptive Statistic			Placebo (N = 302)		Prochieve (N = 309)		Total (N = 611)	
	Statistic								
Age (Years)	n			302		308		610	
	Mean			27.3		27.1		27.2	
	Std. Dev.			5.60		5.82		5.71	
	Median			26.5		25.9		26.2	
	Min – Max			17.9 – 40.8		16.1 – 44.2		16.1 – 44.2	
Race	n (%)			99 (32.8%)		111 (35.9%)		210 (34.4%)	
	Caucasian								
	n (%)			85 (28.1%)		76 (24.6%)		161 (26.4%)	
	African-American								
	n (%)			14 (4.6%)		22 (7.1%)		36 (5.9%)	
	Hispanic								
	n (%)			60 (19.9%)		55 (17.8%)		115 (18.8%)	
Asian/Pacific Islander	n (%)			1 (0.3%)		0		1 (0.2%)	
	Native American								
	n (%)			43 (14.2%)		45 (14.6%)		88 (14.4%)	
	Other								
Cervical Length (cm)	n			295		305		600	
	Mean			3.7		3.7		3.7	
	Std. Dev.			0.90		0.72		0.81	
	Median			3.6		3.7		3.6	
	Min – Max			1.1 – 7.9		2.0 – 6.4		1.1 – 7.9	
Gestational Age First Dose (1)	n (%)			21 (7.0%)		25 (8.1%)		46 (7.9%)	
	< 18 0/7 Weeks								
	18 0/7 Weeks to <= 18 6/7 Weeks			85 (28.1%)		85 (27.5%)		170 (27.8%)	
	19 0/7 Weeks to <= 19 6/7 Weeks			66 (21.9%)		56 (18.1%)		122 (20.0%)	
	20 0/7 Weeks to <= 20 6/7 Weeks			39 (12.9%)		53 (17.2%)		92 (15.1%)	
	21 0/7 Weeks to <= 21 6/7 Weeks			34 (11.3%)		41 (13.3%)		75 (12.3%)	
	>= 22 0/7 Weeks			57 (18.9%)		49 (15.9%)		106 (17.3%)	

(1) Gestational age at first dose is calculated based on the accepted estimated data of confinement.

Fig. 1

Publication data including kind & date

CL2008000375	A1	2008-05-30	CL0375200800
US20080188829	A1	2008-08-07	US20080188829
WO2008096122	A2	2008-08-14	WO2008096122
CA2677354	A1	2008-08-14	CA2677354
AU2008212724	A1	2008-08-14	AU2008212724
PE17382008	A1	2008-11-20	PE200801738
TW200902030	A	2009-01-16	TW200902030
WO2008096122	A3	2009-02-26	WO2008096122
AR065179	A1	2009-05-20	AR--65179
MX2009008409	A	2009-09-16	MX2009008409
US20090264395	A1	2009-10-22	US20090264395



CR10985	A	2009-10-23	CR--10985				
EP2117554	A2	2009-11-18	EP2117554				
KR20090123875	A	2009-12-02	KR20090123875				
VN21852	A	2010-01-25	VN--21852				
CN101636166	A	2010-01-27	CN101636166				
MA31200	B1	2010-02-01	MA--31200				
IL200272	A	2010-04-29	IL-200272				
IN5637/DELNP/2009	A	2010-05-07	IN2009DN05637				
ZA200905726	B	2010-05-26	ZA200905726				
JP2010518058	A	2010-05-27	JP2010518058				
CO6220941	A2	2010-11-19	CO6220941				
US7884093	B2	2011-02-08	US7884093				
RU2009133315	A	2011-03-20	RU2009133315				
ME00930	B	2012-03-20	ME----930				
NZ579114	A	2012-07-27	NZ-579114				
GEP20135727	B	2013-01-25	GE201305727				
UA101474	C2	2013-04-10	UA-101474				
CN101636166	B	2013-04-10	CN101636166B				
IL200272	B	2014-02-27	IL-200272				
JP2014058529	A	2014-04-03	JP2014058529				
JP5580601	B2	2014-07-18	JP5580601				
BRPI0807203	A2	2014-07-22	BR200807203				
RU2524617	C2	2014-07-27	RU2524617				
US8828981	B2	2014-09-09	US8828981				
TWI471135	B	2015-02-01	TWI471135				
CA2677354	C	2015-07-07	CA2677354				
KR101546101	B1	2015-08-20	KR101546101				
EP2117554	B1	2016-07-13	EP2117554				
ES2596803	T3	2017-01-12	ES2596803				
HK1136975	A1	2017-04-28	HK1136975				

Abstract

(EP2117554)

A method for treating or preventing spontaneous preterm birth in pregnant women and improving neonatal morbidity and mortality. The method includes administering to a pregnant woman in need thereof an effective amount of a progesterone sufficient to prolong gestation by minimizing the shortening or effacing of her cervix. Treatment and prophylaxis with progesterone in pregnant women having symptoms of short cervix has been clinically shown to increase neonatal health.

Inventors

CREASY GEORGE

Latest standardized assignees - inventors removed

COVENTRY ACQUISITION

JUNIPER PHARMACEUTICALS

WATSON LABORATORIES

ALLERGAN


Family 179/200 - FAMPAT - ©Questel

Title

(EP2275066)

Intravaginal device with fluid transport plates

Images



US20050256511	A1	2005-11-17	US20050256511
AR048790	A1	2006-05-24	AR--48790
WO2006055036	A1	2006-05-26	WO200655036
CA2566796	A1	2006-05-26	CA2566796
AU2005307119	A1	2006-05-26	AU2005307119
NO20065607	L	2007-02-06	NO20065607
IL179272	A	2007-03-08	IL-179272
EP1765243	A1	2007-03-28	EP1765243
CN1968665	A	2007-05-23	CN1968665
BRPI0511113	A	2007-11-27	BR200511113
BRPI0511113	A1	2007-11-27	BRPI0511113
JP2007537023	A	2007-12-20	JP2007537023
US20090177173	A1	2009-07-09	US20090177173
EP2275066	A1	2011-01-19	EP2275066
AU2005307119	B2	2011-06-16	AU2005307119
JP2011255211	A	2011-12-22	JP2011255211
JP4902530	B2	2012-01-13	JP4902530
CN102512291	A	2012-06-27	CN102512291
JP5143936	B2	2012-11-30	JP5143936
CA2566796	C	2013-01-29	CA2566796
CN1968665	B	2013-02-27	CN1968665B
EP2275066	B1	2013-08-14	EP2275066
US8604269	B2	2013-12-10	US8604269
US8653322	B2	2014-02-18	US8653322
CN102512291	B	2014-04-02	CN102512291B
EP1765243	B1	2015-08-19	EP1765243
HUE028042	T2	2016-11-28	HUE028042
BRPI0511113	A8	2017-10-03	BRPI0511113



Abstract

(EP2275066)

An intravaginal device comprising: a. at least one fluid transport element comprising; i. a first plate having an outwardly oriented surface and an inwardly oriented surface; and ii. a second plate coupled to the first plate; 1. that has a first surface disposed and maintained in facing relationship with the inwardly oriented surface of the first plate and an opposite surface; and 2. that is capable of separating from the first plate sufficiently to provide inter-plate capillary action; wherein the fluid

transport element comprises a plurality of spacer elements that are disposed to separate the surfaces of the first and second plates; and b. a fluid storage element having a longitudinal axis, the fluid storage element being in fluid communication with the at least one fluid transport element; wherein the at least one fluid transport element is bendable about an axis substantially parallel to the longitudinal axis of the fluid storage element.

Inventors

CHASE DAVID J

DANYI ERIN

HOU MARI

GLASGOW TARA

KOZOROVITSKY JULIA

STURGEON JENNIFER

Latest standardized assignees - inventors removed

JOHNSON & JOHNSON CONSUMER



Family 180/200 - FAMPAT - ©Questel

Title

(EP1605949)

Mesoproggestins (progesterone receptor modulators) as a component of female contraceptives

Images



Publication data including kind & date

WO200126603	A2	2001-04-19	WO200126603
CA2383650	A1	2001-04-19	CA2383650
AU3215001	A	2001-04-23	AU200132150
PE05792001	A1	2001-06-04	PE200100579
WO200126603	A3	2002-01-17	WO200126603
NO20020998	D0	2002-02-28	NO200200998
NO20020998	A	2002-03-14	NO200200998
NO20020998	L	2002-03-14	NO20020998
BR0013711	A	2002-05-07	BR200013711



BRPI0013711	A1	2002-05-07	BRPI0013711				
KR20020038745	A	2002-05-23	KR20020038745				
SK2982002	A3	2002-07-02	SK200200298				
CO5190694	A1	2002-08-29	CO5190694A1				
MXPA02002186	A	2002-09-02	MX2002PA002186				
IL148415	A	2002-09-12	IL-148415				
BG106441	A	2002-09-30	BG-106441				
LT2002035	A	2002-10-25	LT200200035				
SI20853	A	2002-10-31	SI--20853				
EA200200284	A1	2002-10-31	EA200200284				
CZ2002707	A3	2002-11-13	CZ200200707				
AR025455	A1	2002-11-27	AR--25455				
CN1384748	A	2002-12-11	CN1384748				
HU0202515	A2	2002-12-28	HU200202515				
LT5001	B	2003-03-25	LT---5001				
JP2003511399	A	2003-03-25	JP2003511399				
EE200200103	A	2003-04-15	EE200200103				
LV12940	B	2003-06-20	LV--12940				
PL353994	A1	2003-12-15	PL2000353994				
HRP20020265	A2	2004-02-29	HRP20020265				
NZ517470	A	2004-03-26	NZ-517470				
HU0202515	A3	2004-06-28	HU200202515				
AU781835	B2	2005-06-16	AU-781835				
EP1605949	A2	2005-12-21	EP1605949				
YU13902	A	2006-01-16	YU200200139				
EA006805	B1	2006-04-28	EA---6805				
UA77150	C2	2006-11-15	UA--77150				
IN0247/DELNP/2002	A	2007-05-25	IN2002DN00247				
BRPI0013711	A2	2010-08-24	BR200013711				

Abstract

(EP1605949)

The present invention relates to the use of mesoproggestins for the production of a pharmaceutical for female contraception, to a pharmaceutical preparation for female contraception and to a method of female contraception administering effective amounts of a mesoproggestin in a female desiring contraception. Optionally the mesoproggestin can be used in combination with an estrogen. Mesoproggestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiproggestins. J867, J912, J956 and J1042 are the mesoproggestins preferred according to the invention.

Inventors

CHWALISZ KRISTOF
ELGER WALTER
SCHUBERT GERD

Latest standardized assignees - inventors removed

SCHERING

Family 181/200 - FAMPAT - ©Questel

Title

(EP1239829)

Devices for the delivery of drugs having antiprogesterinic properties

UA70401	C2	2004-10-15	UA--70401				
AU781555	B2	2005-06-02	AU-781555				
TW1248367	B	2006-02-01	TW1248367				
IL149663	B	2007-02-11	IL-149663				
CN100346772	C	2007-11-07	CN100346772C				
EP1239829	B1	2008-07-23	EP1239829				
KR100850548	B1	2008-08-06	KR100850548				
AT401859	T	2008-08-15	ATE401859				
DE60039626	D1	2008-09-04	DE60039626				
PT1239829	E	2008-10-09	PT1239829				
DK1239829	T3	2008-11-24	DK1239829T				
ES2310526	T3	2009-01-16	ES2310526				
CA2395226	C	2009-01-27	CA2395226				
EE05123	B1	2009-02-16	EE---5123				
PL201216	B1	2009-03-31	PL-201216				
HK1047235	A1	2009-04-24	HK1047235				
SK287229	B6	2010-03-08	SK-287229				
BRPI0016697	A2	2010-03-23	BR200016697				
CZ301865	B6	2010-07-14	CZ-301865				
JP4895150	B2	2012-01-06	JP4895150				
NO332261	B1	2012-08-13	NO-332261				
HU229438	B1	2013-12-30	HU-229438				

Abstract

(EP1239829)

This invention relates to a device for the controlled release over a prolonged period of time of a drug having antiprogesteric properties, said device comprising - a core comprising said drug,- optionally a membrane encasing said core, wherein said core and/or membrane is made of a siloxane-based elastomer composition comprising at least one elastomer and possibly a non-crosslinked polymer. The device is characterized in that - the elastomer composition comprises poly(alkylene oxide) groups and that the poly(alkylene oxide) groups are present in the elastomer or polymer as alkoxy-terminated grafts of polysiloxane units, or as blocks, the said grafts or blocks being linked to the polysiloxane units by silicon-carbon bonds, or as a mixture of these forms.

Inventors

JUKARAINEN HARRI

MARKKULA TOMMI

ALA-SORVARI JUHA

LEHTINEN MATTI

RUOHONEN JARKKO

HAAPAKUMPU TIMO

Latest standardized assignees - inventors removed

BAYER SCHERING PHARMA


Family 182/200 - FAMPAT - ©Questel

Title

(EP3174542)

Transdermal cream

Images

Figure 1**Publication data including kind & date**

CA2951284	A1	2016-02-04	CA2951284
US20160030449	A1	2016-02-04	US20160030449
WO2016018993	A1	2016-02-04	WO201618993
AU2015296609	A1	2016-12-22	AU2015296609
BR112016029338	A1	2017-01-10	BR112016029338
IL248984	A	2017-01-31	IL-248984
KR20170040209	A	2017-04-12	KR20170040209
EP3174542	A1	2017-06-07	EP3174542
JP2017523138	A	2017-08-17	JP2017523138
BR112016029338	A2	2017-08-22	BR112016029338



MX2016013693	A	2017-10-31	MX2016013693				
EP3174542	A4	2018-01-03	EP3174542				
RU2016141135	A	2018-08-28	RU2016141135				
US10098894	B2	2018-10-16	US10098894				
US20190070197	A1	2019-03-07	US20190070197				

Abstract

(EP3174542)

This disclosure relates to transdermal pharmaceutical compositions containing progesterone in combination with one or more solubilizing agents and penetration enhancers, wherein the pharmaceutical compositions are formulated as creams for topical administration. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, and d-limonene. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, a penetration enhancer (e.g., propylene glycol, a fatty acid ester of propylene glycol, a glycol ether), and optionally d-limonene. In certain embodiments, the pharmaceutical compositions further include estradiol. Methods for treating conditions associated with hormone deficiency in a subject are also described.

Inventors

PERSICANER PETER

GHANTA AJAY

AMADIO JULIA

LEGASSIE JASON

THORSTEINSSON THORSTEINN

SHADIACK ANNETTE

WINNEKER RICHARD

Latest standardized assignees - inventors removed

THERAPEUTICSMD

Family 183/200 - FAMPAT - ©Questel


Title

(US8252532)

Regulators of the non-genomic action of progesterone and methods of use

Images

Figure 1

**Publication data including kind & date**

US20070238645	A1	2007-10-11	US20070238645
US20090226917	A1	2009-09-10	US20090226917
US7723300	B2	2010-05-25	US7723300
US8252532	B2	2012-08-28	US8252532

**Abstract**

(US8252532)

A progesterone regulator capable of modulating the non-genomic action of progesterone and methods of using the progesterone regulator are described. The progesterone regulator is useful for attenuating progesterone's inhibition of apoptosis and for the treatment of patients having a progesterone-responsive tissue disease such as endometriosis or cancer, particularly ovarian cancer, as well as for diagnosis, prognosis, and/or staging of ovarian cancers.

Inventors

PELUSO JOHN J

Latest standardized assignees - inventors removed

UNIVERSITY OF CONNECTICUT


Family 184/200 - FAMPAT - ©Questel

Title

(EP1624848)

Methods of hormonal treatment utilizing extended cycle contraceptive regimens

Images


Publication data including kind & date

US20040220152	A1	2004-11-04	US20040220152
WO2004098517	A2	2004-11-18	WO2004098517
CA2524474	A1	2004-11-18	CA2524474
WO2004098517	A8	2005-04-21	WO2004098517
WO2004098517	A8	2005-08-18	WO2004098517
EP1624848	A2	2006-02-15	EP1624848
WO2004098517	A3	2006-04-27	WO2004098517
JP2006525358	A	2006-11-09	JP2006525358
EP1624848	A4	2009-02-25	EP1624848
US7772219	B2	2010-08-10	US7772219


Abstract

(EP1624848)

The present invention provides extended cycle contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin. The disclosed extended cycle contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.

Inventors

BEN-MAIMON CAROLE S

HAIT HOWARD

REAPE KATHLEEN Z

BRONNENKANT LANCE J

Latest standardized assignees - inventors removed


TEVA WOMENS HEALTH

Family 185/200 - FAMPAT - ©Questel

Title

(EP1427366)

Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy

Images**Publication data including kind & date**

WO03020210	A2	2003-03-13	WO200320210				
US20030049302	A1	2003-03-13	US20030049302				
CA2457526	A1	2003-03-13	CA2457526				
WO03020210	A3	2003-11-20	WO200320210				
EP1427366	A2	2004-06-16	EP1427366				
JP2005507874	A	2005-03-24	JP2005507874				
US6982091	B2	2006-01-03	US6982091				
US20060002966	A1	2006-01-05	US20060002966				
AU2002329842	B2	2006-09-14	AU2002329842				

Abstract

(EP1427366)

Devices, methods, and compositions for cancer therapy by administration of chemotherapeutic agents and/or inhibitors of membrane efflux systems to the vagina for topical and systemic tumor targets.

Inventors

PAULETTI GIOVANNI M

LIU JAMES H

BENET LESLIE Z

RITSCHER WOLFGANG A

Latest standardized assignees - inventors removed

FEMINA PHARMA

Family 186/200 - FAMPAT - ©Questel

Title

(DE19915073)

Monitoring the fertility and pregnancy of cows in a herd including a bull comprises performing an enzyme-linked immunosorbent assay for progesterone in milk, urine or blood 60-100 days after calving

Publication data including kind & date

[DE19915073](#)

A1 2000-10-05

DE19915073



Abstract

(DE19915073)

Method for monitoring the fertility and pregnancy of cows in a herd including a bull comprises performing an enzyme-linked immunosorbent assay (ELISA) for progesterone in milk, urine or blood 60-100 days after calving.

Inventors

ARNSTADT INGO

Latest standardized assignees - inventors removed

BIOLAB

Family 187/200 - FAMPAT - ©Questel

Title

(EP-491415)

Low estrogen oral contraceptives

Images

화합물

양 (mg/정제)

에티닐 에스트라디올

0.025

데소제스트렐

0.100

감자 전분

8.000

폴리비닐 피롤리돈

2.400

스테아르산

0.800

실리카

0.800

d l - α -토코페롤

0.080

락토오스

qsad 80.000

Publication data including kind & date

[NO914900](#)

D0 1991-12-12

NO9104900

[FI915855](#)

A0 1991-12-12

FI9105855

[FI915855](#)

A 1992-06-14

FI9105855

[CA2057528](#)

A1 1992-06-14

CA2057528

[NO914900](#)

L 1992-06-15

NO-914900

[IE914221](#)

A1 1992-06-17

IE9104221

[AU8964791](#)

A 1992-06-18

AU9189647

[EP0491415](#)

A1 1992-06-24

EP-491415

[CN1062290](#)

A 1992-07-01

CN1062290



KR19920011517	A	1992-07-24	KR19920011517				
ZA9109731	B	1992-09-30	ZA9109731				
JPH04290828	A	1992-10-15	JP04290828				
PT99782	A	1992-12-31	PT--99782				
US5262408	A	1993-11-16	US5262408				
AU645382	B2	1994-01-13	AU-645382				
NZ240944	A	1994-05-26	NZ-240944				
EP0491415	B1	1996-04-03	EP-491415				
AT136218	T	1996-04-15	ATE136218				
DE69118493	D1	1996-05-09	DE69118493				
NO179234	B	1996-05-28	NO-179234				
DK0491415	T3	1996-07-08	DK-491415T				
ES2087964	T3	1996-08-01	ES2087964				
DE69118493	T2	1996-08-22	DE69118493				
NO179234	C	1996-09-04	NO-179234				
GR3020179	T3	1996-09-30	GR3020179				
IE71203	B1	1997-02-12	IE--71203				
FI99083	B	1997-06-30	FI--99083				
FI99083	C	1997-10-10	FI--99083				
CN1036835	C	1997-12-31	CN1036835C				
KR187316	B1	1999-05-01	KR100187316				
PT99782	B	2001-05-31	PT--99782				
CA2057528	C	2003-02-04	CA2057528				

Abstract

(EP-491415)

Disclosed is a contraceptive regimen, and method of using the regimen, comprising 24 daily sequential dosage units of: a first phase comprising about 7 to 9 separate first dosage units containing a progestogen at a daily dosage equivalent in progestogenic activity to 100 mu g desogestrel and an estrogen at a daily dosage equivalent in estrogenic activity to 25 mu g ethinyl estradiol ("EE"). A second phase of 7 to 9 second dosage units, each of the second dosage units containing a progestogen equivalent to 125 mu g desogestrel and an estrogen equivalent to 20 mu g EE. A third phase of 7 to 9 third dosage units, each unit containing a progestogen equivalent to 150 mu g desogestrel and an estrogen equivalent to 20 mu g EE. The kit generally has 28 daily dosage units wherein four of the daily dosage units contain no contraceptive steroid, or, alternatively, have only 24 dosage units with a four day "pill-free" period. The fourth phase may also be four dosage units containing a progestogen equivalent to 25 - 35 mu g desogestrel.

Inventors

BERGINK ENGELBERT WILHELM

Latest standardized assignees - inventors removed

ORGANON


Family 188/200 - FAMPAT - ©Questel

Title

(US4927816)

Formulae and methods for sublingual ingestion of natural progesterone


Images



7-Hydroxy-6 α -methylpregn-4-ene-3,20-dione
acetate [71-58-9] $C_{24}H_{34}O_4$ (386.53)

FIG_1

Pregn-4-ene-3,20-dione;
Progesterone USP



Progesterone [57-83-0] $C_{21}H_{30}O_2$ (314.47)

FIG_2

Publication data including kind & date

US4927816 A 1990-05-22 US4927816

**Abstract**

(US4927816)

Formulae, means, and methods for the sublingual ingestion of natural Progesterone comprising milling and blending natural Progesterone such that it can be absorbed by the sublingual mucosae of a patient and applying it to said sublingual mucosae in a form which permits such absorption.

Inventors

ESTER GEORGE C

Family 189/200 - FAMPAT - ©Questel

Title

(US4756907)

Active/passive immunization of the internal female reproductive organs

Images




FIG. 1




FIG. 2




FIG. 3




FIG. 4





FIG 5

Publication data including kind & date

BE879442	A	1980-04-16	BE-879442
JPS5555114	A	1980-04-22	JP55055114
ZA7905549	B	1980-11-26	ZA7905549
US4585651	A	1986-04-29	US4585651
US4732763	A	1988-03-22	US4732763
US4756907	A	1988-07-12	US4756907
JPH024576	B2	1990-01-29	JP90004576

Abstract

(US4756907)

Antibody or antigen containing microparticles for the active or passive immunization of the internal female reproductive organs, comprising: microparticles of an antigen or antibody incorporated in a matrix material which is biocompatible and biologically degradable, said microparticles capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.

Inventors

BECK LEE R

FLOWERS JR CHARLES F

COWSAR DONALD R

TANQUARY ALBERT C

Latest standardized assignees - inventors removed

ALKERMES CONTROLLED THERAPEUTICS

Family 190/200 - FAMPAT - ©Questel

Title

(US20130337054)

Treatment of excessive menstrual blood loss by intravaginal administration of low doses of antifibrinolytic or hemostatic agent

Publication data including kind & date[US20130337054](#)

A1 2013-12-19

US20130337054

**Abstract**

(US20130337054)

A method and drug delivery device for reducing menstrual blood loss in a female are provided. The method comprises administering intravaginally to the female a therapeutically effective amount of an active agent on a delivery device directly to uterine cavity during a menstrual period, wherein the active agent is any one of an antifibrinolytic agent and a hemostatic agent.

Inventors

RUBIN ARKADY

Latest standardized assignees - inventors removed

ARSTAT


Family 191/200 - FAMPAT - ©Questel

Title

(US20120097171)

Inhibitor of pathogens

Images

**Publication data including kind & date**

US20120097171	A1	2012-04-26	US20120097171
AU2011239297	A1	2012-05-10	AU2011239297
ZA201107786	B	2012-07-25	ZA201107786

**Abstract**

(US20120097171)

An intravaginal device for use in combating pathogens includes a ring of flexible material shaped to be received and retained in the vaginal cavity and includes at least one strand of copper wire.

Inventors

POPE MAURICE ROGER

Family 192/200 - FAMPAT - ©Questel


Title

(US9427400)

Platinum-catalyzed intravaginal rings

Images

Comparative *In Vivo* Data



Publication data including kind & date

US20120093911	A1	2012-04-19	US20120093911
US8580294	B2	2013-11-12	US8580294
US20140056961	A1	2014-02-27	US20140056961
US9427400	B2	2016-08-30	US9427400



Abstract

(US9427400)

The present invention provides improved intravaginal drug delivery devices, i.e., intravaginal rings, useful for the prophylactic administration of an antimicrobial compound, e.g., Dapivirine, to a human. The intravaginal rings of the invention address previous stability issues by utilizing a platinum catalyst (e.g., in the form of a platinum-siloxane complex) for the cross-linking reaction. The vaginal rings surprisingly achieve relatively high and steady release rates in vivo with a matrix ring containing a relatively small loading dose. While the matrix rings of the present invention have in vivo the steady release rates associated with reservoir rings, they are easier and less expensive to manufacture. The present invention also provides methods of blocking DNA polymerization by an HIV reverse transcriptase enzyme, methods of preventing HIV infection in a female human, methods of treating HIV infection in a female human, and methods of preparing platinum-catalyzed intravaginal rings.

Inventors

MALCOLM KARL
WOOLFSON DAVID
ROMANO JOSEPH

Latest standardized assignees - inventors removed

INTERNATIONAL PARTNERSHIP FOR MICROBICIDES

Family 193/200 - FAMPAT - ©Questel

Title


(EP2392333)

Images

	炔诺酮			EE 当量		
	剂量	当量		剂量	剂量	
孕激素	(mg)	剂 量 (mg)	雌激素	(mg)	(mg)	P/E 比
异炔诺酮	9.85	9.85	美雌醇	0.150	0.105	93.810
	5.00	5.00		0.075	0.053	95.238
	2.50	2.50		0.036	0.025	99.206
	2.50	2.50		0.100	0.070	35.714
炔诺酮	10.00	10.00	美雌醇	0.060	0.042	238.095
	2.00	2.00		0.100	0.070	28.571
	1.00	1.00		0.050	0.035	28.571
	1.00	1.00		0.080	0.056	17.857
炔诺酮	1.00	1.00	乙炔雌二 醇(EE)	0.050	0.050	20.000
	1.00	1.00		0.035	0.035	28.571
	0.50	0.50		0.035	0.035	14.286
	0.40	0.40		0.035	0.035	11.429
醋酸炔诺酮	2.50	2.50	EE	0.050	0.050	50.000
	1.00	1.00		0.050	0.050	20.000
	0.60	0.60		0.030	0.030	20.000
	1.50	1.50		0.030	0.030	50.000
	1.00	1.00		0.020	0.020	50.000
双醋炔诺醇	1.00	1.00	美雌醇	0.100	0.070	14.286
双醋炔诺醇	1.00	1.00	EE	0.050	0.050	20.000
	1.00	1.00		0.035	0.035	28.571
dl-炔诺孕酮	0.50	0.75	EE	0.050	0.050	10.000
	0.30	0.45		0.030	0.030	10.000
左炔诺孕酮	0.10	0.35	EE	0.020	0.020	5.000
	0.15	0.52		0.030	0.030	5.000

Publication data including kind & date

WO2006042021	A2	2006-04-20	WO200642021
CA2582530	A1	2006-04-20	CA2582530
AU2005294269	A1	2006-04-20	AU2005294269
WO2006042021	A3	2006-06-08	WO200642021
US20060135496	A1	2006-06-22	US20060135496
TW200626161	A	2006-08-01	TW200626161
WO2006042021	B1	2006-08-03	WO200642021
AR051931	A1	2007-02-21	AR--51931
US20070111975	A1	2007-05-17	US20070111975
MX2007004120	A	2007-06-15	MX2007004120
IN1499/KOLNP/2007	A	2007-07-20	IN2007KN01499
EP1814556	A2	2007-08-08	EP1814556
CN101068552	A	2007-11-07	CN101068552
IL182287	A	2008-04-13	IL-182287
JP2008515909	A	2008-05-15	JP2008515909
US20080125402	A1	2008-05-29	US20080125402
TW200831107	A	2008-08-01	TW200831107
BRPI0516247	A	2008-08-26	BR200516247



BRPI0516247	A1	2008-08-26	BRPI0516247				
WO2008127303	A1	2008-10-23	WO2008127303				
CA2668211	A1	2008-10-23	CA2668211				
MX2009004616	A	2009-05-22	MX2009004616				
IN1794/KOLNP/2009	A	2009-06-12	IN2009KN01794				
EP2079461	A1	2009-07-22	EP2079461				
KR20090094437	A	2009-09-07	KR20090094437				
CN101626760	A	2010-01-13	CN101626760				
IL198441	A	2010-02-17	IL-198441				
JP2010508275	A	2010-03-18	JP2010508275				
RU2009120528	A	2010-12-10	RU2009120528				
EP2079461	A4	2011-07-20	EP2079461				
AU2005294269	B2	2011-07-28	AU2005294269				
BRPI0516247	A2	2011-11-22	BR200516247				
EP2392333	A1	2011-12-07	EP2392333				
EP2392332	A1	2011-12-07	EP2392332				
US20120252767	A1	2012-10-04	US20120252767				
US8415332	B2	2013-04-09	US8415332				
US8450299	B2	2013-05-28	US8450299				
BRPI0716291	A2	2013-12-24	BR200716291				
IL198441	B	2014-07-31	IL-198441				
BRPI0516247	A8	2016-09-20	BR200516247				

Abstract

(EP2392333)

The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.

Inventors

DILIBERTI CHARLES E

REAPE KATHLEEN Z

BRONNENKANT LANCE J

Latest standardized assignees - inventors removed

TEVA WOMENS HEALTH

Family 194/200 - FAMPAT - ©Questel

Title

(EP-911029)

Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy

Publication data including kind & date

NO982815	D0	1998-06-18	NO9802815				
NO982815	L	1998-12-28	NO-982815				
JP11029481	A	1999-02-02	JP11029481				
US5898032	A	1999-04-27	US5898032				
EP0911029	A2	1999-04-28	EP-911029				
EP0911029	A3	2000-03-29	EP-911029				
CA2256977	A1	2000-06-23	CA2256977				
EP0911029	B1	2002-04-17	EP-911029				
AT216241	T	2002-05-15	ATE216241				

DE69804918	D1	2002-05-23	DE69804918			
DK0911029	T3	2002-06-17	DK-911029T			
PT911029	E	2002-09-30	PT-911029			
DE69804918	T2	2002-11-07	DE69804918			
ES2175650	T3	2002-11-16	ES2175650			
JP2007197459	A	2007-08-09	JP2007197459			
USRE39861	E1	2007-09-25	USRE39861			
CA2256977	C	2008-11-25	CA2256977			

Abstract

(EP-911029)

A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.

Inventors

HODGEN GARY D

Latest standardized assignees - inventors removed

BARR LABORATORIES

TEVA WOMENS HEALTH

Family 195/200 - FAMPAT - ©Questel


Title

(EP-730644)

Methods for screening for regulators of intracellular receptor transcription using progesterone receptor a subtype

Images

Adapter Limiting



Publication data including kind & date

WO9511973	A1	1995-05-04	WO9511973
CA2174416	A1	1995-05-04	CA2174416
AU7847994	A	1995-05-22	AU9478479
US5506102	A	1996-04-09	US5506102
EP0730644	A1	1996-09-11	EP-730644
MX9408266	A	1997-02-28	MX9408266
JPH09504691	A	1997-05-13	JP09504691



Abstract

(EP-730644)

Methods to screen for antagonists of steroid IR transcription as mediated by the PR-A isoform of the progesterone receptor are provided. Such cell-based methods include a cell in which PR-A is transcriptionally inactive containing a steroid IR other than PR, PR-A and a reporter vector that includes a promoter which is transcriptionally active in the presence of the steroid IR and an activator of said steroid IR, but is substantially transcriptionally inactive in the presence of PR-A. This cell is contacted with the activator of the steroid IR and a compound to be assayed, and the level of reporter product produced in the cell is measured and compared to the level of reporter product expressed in a similar cellular system absent PR-A as

an indication of the potential antagonist activity of the compound being assayed. Also provided are an assay kit, a method of screening PR active compounds as ER antagonists and compounds that inhibit the transcriptional activity of a steroid IR in the presence of PR-A in a cellular context where PR-A is substantially transcriptionally inactive.

Inventors

MCDONNELL DONALD

Latest standardized assignees - inventors removed

LIGAND PHARMACEUTICALS

Family 196/200 - FAMPAT - ©Questel

Title

(EP-639970)

Contraception method using competitive progesterone antagonists and novel compounds useful therein

Images




FIG.1A

FIG.1B

FIG.1C

Publication data including kind & date

IL105684	A	1993-09-22	IL-105684				
WO9323020	A1	1993-11-25	WO9323020				
CA2135608	A1	1993-11-25	CA2135608				
AU4067393	A	1993-12-13	AU9340673				
MX9302748	A	1994-02-28	MX9302748				
CN1087643	A	1994-06-08	CN1087643				
FI945289	A	1994-11-10	FI9405289				
FI945289	A0	1994-11-10	FI9405289				
NO944308	D0	1994-11-11	NO9404308				
NO944308	A	1995-01-11	NO9404308				
NO944308	L	1995-01-11	NO-944308				
CZ278094	A3	1995-02-15	CZ9402780				
EP0639970	A1	1995-03-01	EP-639970				
KR19957001526	A	1995-04-28	KR19957001526				
HUT68061	A	1995-05-29	HU-T68061				
BG99178	A	1995-05-31	BG--99178				
JPH07506582	A	1995-07-20	JP07506582				
US5439913	A	1995-08-08	US5439913				
NZ252154	A	1996-04-26	NZ-252154				
PH29913	A	1996-09-16	PH--29913				
RU94046068	A	1996-10-20	RU94046068				
RU94046068	A1	1996-10-20	RU94046068				
EP0639970	B1	1998-01-28	EP-639970				
AT162712	T	1998-02-15	ATE162712				
AU687000	B2	1998-02-19	AU-687000				
PL173337	B1	1998-02-27	PL-173337				
DE69316747	D1	1998-03-05	DE69316747				
SK134794	A3	1998-05-06	SK9401347				
ES2114605	T3	1998-06-01	ES2114605				
GR3026316	T3	1998-06-30	GR3026316				
BR9306354	A	1998-06-30	BR9306354				
BRPI9306354	A1	1998-06-30	BRPI9306354				
IL105684	B	1998-08-16	IL-105684				
DK0639970	T3	1998-09-21	DK-639970T				
DE69316747	T2	1998-09-24	DE69316747				
BG61965	B1	1998-11-30	BG--61965				
RU2137476	C1	1999-09-20	RU2137476				
NO307691	B1	2000-05-15	NO-307691				
KR100253922	B1	2000-09-01	KR100253922				
CN1059446	C	2000-12-13	CN1059446C				
RO116769	B1	2001-06-29	RO-116769				
US6340688	B1	2002-01-22	US6340688				
CZ290612	B6	2002-09-11	CZ-290612				
SK282531	B6	2002-10-08	SK-282531				
EP0639970	B2	2002-11-06	EP-639970				
DK0639970	T4	2003-02-10	DK-639970T				
DE69316747	T3	2003-04-10	DE69316747				

ES2114605	T5	2003-04-16	ES2114605				
FI112167	B	2003-11-14	FI-112167				
US20050026885	A1	2005-02-03	US20050026885				
CA2135608	C	2007-04-10	CA2135608				
US7297702	B2	2007-11-20	US7297702				

Abstract

(EP-639970)

Competitive progesterone antagonists, including two novel steroids, viz., 11 beta ,19-[4-(cyanophenyl)-o-phenylene]-17 beta -hydroxy-17 alpha -(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11 beta ,19-[4-(3-pyridinyl)-o-phenylene]-17 beta -hydroxy-17 alpha -(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.

Inventors

CHWALISZ KRZYSZTOF

SCHMIDT-GOLLWITZER KARIN

OTTOW ECKHARD

KLAR ULRICH

MICHNA HORST

ELGER WALTER

Latest standardized assignees - inventors removed

BAYER SCHERING PHARMA


Family 197/200 - FAMPAT - ©Questel

Title

(US4900734)

Novel pharmaceutical composition containing estradiol and progesterone for oral administration

Images

**FIG 1****Publication data including kind & date**[US4900734](#)

A 1990-02-13 US4900734

**Abstract**

(US4900734)

A pharmaceutical composition is provided for oral administration. The composition comprises estradiol dissolved in an oil vehicle containing a suspension of micronized progesterone. The oil vehicle is high in glycerides of polyunsaturated fatty acids. The estradiol and micronized progesterone contained in the oil are more readily absorbable in the blood stream and achieve enhanced estradiol and progesterone blood serum levels. The pharmaceutical composition according to the invention can be readily formulated into capsules and administered for the treatment of menopausal symptoms.

Inventors

MAXSON WAYNE S

HARGROVE JOEL T

DELK JOE H


Family 198/200 - FAMPAT - ©Questel

Title

(EP2790637)

Vaginal drug delivery devices and manufacturing methods

Images



Publication data including kind & date

WO2013090871	A1	2013-06-20	WO201390871
AU2012351886	A1	2014-07-31	AU2012351886
BR112014014600	A1	2014-08-19	BR112014014600
EP2790637	A1	2014-10-22	EP2790637
US20150004213	A1	2015-01-01	US20150004213
CN104379111	A	2015-02-25	CN104379111
JP2015505707	A	2015-02-26	JP2015505707
EP2790637	A4	2015-04-29	EP2790637
BR112014014600	A2	2017-06-13	BR112014014600
BR112014014600	A8	2017-06-13	BR112014014600
BR112014014600	A8	2017-06-27	BR112014014600
BR112014014600	A8	2018-10-23	BR112014014600
BR112014014600	A8	2019-02-12	BR112014014600



Abstract

(EP2790637)

Drug delivery devices (e.g., polymeric vaginal rings) and related methods of manufacture and treatment are disclosed herein. In some embodiments, a manufacturing process for drug delivery devices is disclosed that includes a compounding extrusion process and an injection molding process. The various manufacturing parameters associated with these processes can be optimized to produce a drug delivery device with a favorable release profile and other characteristics. In particular, reducing the energy introduced into the system during manufacture can unexpectedly result in drug delivery devices with improved release profiles, especially in the case of large molecule drugs or in devices with a relatively low drug loading or drug particle size.

Inventors

RON EYAL S

Latest standardized assignees - inventors removed

VIMAC VENTURES


Family 199/200 - FAMPAT - ©Questel

Title

(EP2773333)

Dermal delivery compositions and methods

Images



Publication data including kind & date

US20130116222	A1	2013-05-09	US20130116222
CA2854164	A1	2013-05-10	CA2854164
WO2013/067346	A1	2013-05-10	WO201367346
AU2012332254	A1	2014-05-15	AU2012332254
IL232258	A	2014-06-30	IL-232258
KR20140088199	A	2014-07-09	KR20140088199
CN103957899	A	2014-07-30	CN103957899
EP2773333	A1	2014-09-10	EP2773333
MX2014005294	A	2014-09-22	MX2014005294
EA201400543	A1	2014-09-30	EA201400543
BR112014010670	A1	2014-10-21	BR112014010670



JP2014532719	A	2014-12-08	JP2014532719				
IN3247DEN2014	A	2015-05-22	IN2014DN03247				
HK1200317	A1	2015-08-07	HK1200317				
HK1201152	A1	2015-08-28	HK1201152				
ZA201402988	B	2015-11-25	ZA201402988				
NZ624117	A	2016-02-26	NZ-624117				
US9364487	B2	2016-06-14	US9364487				
US20160250226	A1	2016-09-01	US20160250226				
BR112014010670	A2	2017-05-09	BR112014010670				
EA026664	B1	2017-05-31	EA--26664				
AU2012332254	B2	2017-06-22	AU2012332254				
MX353713	B	2018-01-24	MX-353713				
JP6316749	B2	2018-04-25	JP6316749				
US20180325916	A1	2018-11-15	US20180325916				

Abstract

(EP2773333)

A composition for transdermal delivery of a progestin for progestin hormone therapy is disclosed. Also disclosed is a transdermal delivery device comprising the composition. For progestin-only hormone therapy, the composition contains an anti-oxidant and does not contain an estrogen. For therapy involving a progestin and an estrogen, the composition contains the progestin, the estrogen and an additional anti-oxidant. Methods of improving the stability of progestin-containing compositions comprising oxidative agents are also disclosed. The methods comprise including one or more anti-oxidants in the compositions.

Inventors

ARNOLD CHARLES G

KYDONIEUS AGIS

ROSSI THOMAS M

ALTOMARI ALFRED F

Latest standardized assignees - inventors removed

AGILE THERAPEUTICS


Family 200/200 - FAMPAT - ©Questel

Title

(EP2520301)

Parenteral pharmaceutical formulation in suspension, having sustained release, in low and ultralow dosage, in hormonal therapy in the climacteric syndrome

Images



A= 0.5 mg E2 + 15 mg P4

B= 1.0 mg E2 + 20 mg P4

C= 1.0 mg E2 + 30 mg P4

FIGURE 1

Publication data including kind & date

WO2011074931	A2	2011-06-23	WO201174931
CA2781999	A1	2011-06-23	CA2781999
UY33103	A	2011-07-29	UY--33103
WO2011074931	A3	2011-09-22	WO201174931
AR079453	A1	2012-01-25	AR--79453
AU2010330982	A1	2012-07-05	AU2010330982
SG181723	A1	2012-07-30	SG-181723
ECSP12011934	A	2012-07-31	EC201211934
MX2012006604	A	2012-08-17	MX2012006604
IL220422	A	2012-08-30	IL-220422
CN102655867	A	2012-09-05	CN102655867
KR20120114269	A	2012-10-16	KR20120114269
VN31305	A	2012-10-25	VN--31305
CO6551723	A2	2012-10-31	CO6551723
EP2520301	A2	2012-11-07	EP2520301
MA33808	B1	2012-12-03	MA--33808
BR112012013823	A1	2012-12-11	BR112012013823
PE00152013	A1	2013-01-30	PE201300015
ZA201203992	B	2013-02-27	ZA201203992
JP2013513658	A	2013-04-22	JP2013513658
EP2520301	A4	2013-10-23	EP2520301
IN5115/CHENP/2012	A	2013-10-25	IN2012CN05115
TH129001	A	2013-11-14	TH-129001



RU2012126501	A	2014-01-27	RU2012126501				
NZ600539	A	2014-10-31	NZ-600539				
AU2010330982	B2	2015-05-21	AU2010330982				
CN102655867	B	2015-05-27	CN102655867B				
UA108865	C2	2015-06-25	UA-108865				
JP5900925	B2	2016-03-18	JP5900925				
HK1170431	A1	2016-04-15	HK1170431				
RU2582272	C2	2016-04-20	RU2582272				
IL220422	B	2017-01-31	IL-220422				
EP2520301	B1	2017-05-10	EP2520301				
PT2520301	T	2017-06-30	PT2520301T				
KR101758407	B1	2017-07-14	KR101758407				
DK2520301	T3	2017-07-17	DK2520301T				
LT2520301	T	2017-07-25	LT2520301				
SI2520301	T1	2017-07-31	SI2520301T				
ES2629204	T3	2017-08-07	ES2629204				
HRP20170962	T1	2017-09-22	HRP20170962				
MY163619	A	2017-10-13	MY-163619				
RS56142	B1	2017-10-31	RS--56142				
CY1119169	T1	2018-02-14	CY1119169				
HUE035223	T2	2018-05-02	HUE035223				
BR112012013823	A2	2018-07-31	BR112012013823				
CA2781999	C	2018-10-23	CA2781999				

Abstract

(EP2520301)

Parenteral pharmaceutical formulation or composition, in suspension, having sustained release, containing suspended particles of estradiol and progesterone for hormonal replacement in female mammals in low and ultralow dosage; the formulation consists of an injectable suspension comprising particles of estradiol, particles of progesterone, a surfactant agent, an isosmotic agent, a thickening agent, and one or more preservation agents, wherein the estradiol is in particles having a size between 1 and 100 microns and the progesterone is in particles having a size between 1 and 100 microns, for application thereof in parenteral, intramuscular, subcutaneous or intradermal pharmaceutical form.

Inventors

ÁNGELES URIBE JUAN

SAVOIR VILBOEUF JOHN CLAUDE

Latest standardized assignees - inventors removed

TECHSPHERE